

1. Cheng KW, Lu Y, Mills GB. *Assay of Rab25 function in ovarian and breast cancers*. **Methods Enzymol**, 2005. 403: p. 202-215. PMID: 16473588 PMCID:
2. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. *Exploiting the PI3K/AKT pathway for cancer drug discovery*. **Nat Rev Drug Discov**, 2005. 4(12): p. 988-1004. PMID: 16341064 PMCID:
3. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF, 3rd, Wulfkuhle JD. *Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma*. **Mol Cell Proteomics**, 2005. 4(4): p. 346-355. PMID: 15671044 PMCID:
4. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, Kornblau SM. *Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells*. **Mol Cancer Ther**, 2006. 5(10): p. 2512-2521. PMID: 17041095 PMCID:
5. Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, Tarcic G, Siwak D, Lahad J, Jacob-Hirsch J, Amariglio N, Vaisman N, Segal E, Rechavi G, Alon U, Mills GB, Domany E, Yarden Y. *A module of negative feedback regulators defines growth factor signaling*. **Nat Genet**, 2007. 39(4): p. 503-512. PMID: 17322878 PMCID:
6. Gajewiak J, Tsukahara R, Tsukahara T, Fujiwara Y, Yu S, Lu Y, Murph M, Mills GB, Tigyi G, Prestwich GD. *Alkoxy-methylenephosphonate analogues of (Lyso) phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor*. **ChemMedChem**, 2007. 2(12): p. 1789-1798. PMID: 17952880 PMCID:
7. Hennessy BT, Lu Y, Poradosu E, Yu Q, Yu S, Hall H, Carey MS, Ravoori M, Gonzalez-Angulo AM, Birch R, Henderson IC, Kundra V, Mills GB. *Pharmacodynamic markers of perifosine efficacy*. **Clin Cancer Res**, 2007. 13(24): p. 7421-7431. PMID: 18094426 PMCID:
8. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng Q, Durden DL. *A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity*. **Cancer Res**, 2008. 68(1): p. 206-215. PMID: 18172313 PMCID:
9. Grote T, Siwak DR, Fritsche HA, Joy C, Mills GB, Simeone D, Whitcomb DC, Logsdon CD. *Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer*. **Proteomics**, 2008. 8(15): p. 3051-3060. PMID: 18615426 PMCID: 2992687
10. Ji Y, Lu Y, Mills GB. *Bayesian models based on test statistics for multiple hypothesis testing problems*. **Bioinformatics**, 2008. 24(7): p. 943-949. PMID: 18245123 PMCID:
11. Kim WY, Chang DJ, Hennessy B, Kang HJ, Yoo J, Han SH, Kim YS, Park HJ, Seo SY, Mills G, Kim KW, Hong WK, Suh YG, Lee HY. *A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy*. **Cancer Prev Res (Phila)**, 2008. 1(7): p. 577-587. PMID: 19139008 PMCID: 2738643
12. Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, Liao WS, Bast RC, Jr. *The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells*. **J Clin Invest**, 2008. 118(12): p. 3917-3929. PMID: 19033662 PMCID: 2582930
13. Muller M, Obeyesekere M, Mills GB, Ram PT. *Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R*. **FASEB J**, 2008. 22(5): p. 1393-1403. PMID: 18171696 PMCID:
14. Murph MM, Smith DL, Hennessy B, Lu Y, Joy C, Coombes KR, Mills GB. *Individualized molecular medicine: linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients*. **Adv Exp Med Biol**, 2008. 622: p. 183-195. PMID: 18546628 PMCID:
15. Stanislaus R, Carey M, Deus HF, Coombes K, Hennessy BT, Mills GB, Almeida JS. *RPPAML/RIMS: a metadata format and an information management system for reverse phase protein arrays*. **BMC Bioinformatics**, 2008. 9: p. 555. PMID: 19102773 PMCID: 2639439
16. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernardis R, Mills GB, Hennessy BT. *An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer*. **Cancer Res**, 2008. 68(15): p. 6084-6091. PMID: 18676830 PMCID: 2680495
17. Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB, Hennessy BT. *Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer*. **Clin Cancer Res**, 2009. 15(11): p. 3654-3662. PMID: 19470724 PMCID: 2887710
18. Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV, Johnson FM. *Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer*. **Clin Cancer Res**, 2009. 15(22): p. 6852-6861. PMID: 19861436 PMCID: 2935176

19. Chen Y, Guggisberg N, Jorda M, Gonzalez-Angulo A, Hennessy B, Mills GB, Tan CK, Slingerland JM. *Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.* **Clin Cancer Res**, 2009. 15(10): p. 3396-3405. PMID: 19451593 PMCID:
20. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. *Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.* **Clin Cancer Res**, 2009. 15(24): p. 7538-7546. PMID: 19996208 PMCID: 2805170
21. Dillon RL, Marcotte R, Hennessy BT, Woodgett JR, Mills GB, Muller WJ. *Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression.* **Cancer Res**, 2009. 69(12): p. 5057-5064. PMID: 19491266 PMCID: 4151524
22. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT. *Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.* **Clin Cancer Res**, 2009. 15(7): p. 2472-2478. PMID: 19276248 PMCID:
23. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB. *Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.* **Cancer Res**, 2009. 69(10): p. 4116-4124. PMID: 19435916 PMCID: 2737191
24. Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, Coombes KR, Mills GB. *Functional proteomic profiling of AML predicts response and survival.* **Blood**, 2009. 113(1): p. 154-164. PMID: 18840713 PMCID: 2951831
25. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, Coombes K, Muller W, Hung MC, Perou CM, Lee AV, Fang X, Mills GB. *Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases.* **Cancer Cell**, 2009. 15(6): p. 539-550. PMID: 19477432 PMCID: 4157573
26. Miller TW, Perez-Torres M, Narasanna A, Guix M, Stal O, Perez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, Lindsley CW, Arteaga CL. *Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-1 receptor signaling to promote antiestrogen resistance in breast cancer.* **Cancer Res**, 2009. 69(10): p. 4192-4201. PMID: 19435893 PMCID: 2724871
27. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, Korn WM. *Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.* **Cancer Res**, 2009. 69(2): p. 565-572. PMID: 19147570 PMCID: 2737189
28. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JA. *Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.* **Blood**, 2009. 113(22): p. 5549-5557. PMID: 19318683 PMCID: 4580965
29. Nikolova DA, Asangani IA, Nelson LD, Hughes DP, Siwak DR, Mills GB, Harms A, Buchholz E, Pilz LR, Manegold C, Allgayer H. *Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity.* **Cancer Res**, 2009. 69(6): p. 2461-2470. PMID: 19276367 PMCID:
30. O'Reilly KE, Warycha M, Davies MA, Rodrik V, Zhou XK, Yee H, Polsky D, Pavlick AC, Rosen N, Bhardwaj N, Mills G, Osman I. *Phosphorylated 4E-BP1 is associated with poor survival in melanoma.* **Clin Cancer Res**, 2009. 15(8): p. 2872-2878. PMID: 19336517 PMCID: 3995540
31. Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK. *Dual targeting of EphA2 and FAK in ovarian carcinoma.* **Cancer Biol Ther**, 2009. 8(11): p. 1027-1034. PMID: 19395869 PMCID: 2748749
32. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA. *AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.* **Cancer Cell**, 2009. 16(1): p. 21-32. PMID: 19573809 PMCID: 2752826

33. Wei X, Guo W, Wu S, Wang L, Lu Y, Xu B, Liu J, Fang B. *Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells.* **J Biol Chem**, 2009. 284(25): p. 16948-16955. PMID: 19414586 PMCID: 2719332
34. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA. *Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.* **Mol Cancer Ther**, 2009. 8(8): p. 2079-2085. PMID: 19671763 PMCID: 3346953
35. Zhang L, Wei Q, Mao L, Liu W, Mills GB, Coombes K. *Serial dilution curve: a new method for analysis of reverse phase protein array data.* **Bioinformatics**, 2009. 25(5): p. 650-654. PMID: 19176552 PMCID: 2647837
36. Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX, Yamasaki F, Liu S, Hayashi N, Zhang D, Esteva FJ, Hortobagyi GN, Ueno NT. *PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase.* **Clin Cancer Res**, 2010. 16(6): p. 1802-1811. PMID: 20215547 PMCID: 20215547
37. Cai D, Shames DS, Raso MG, Xie Y, Kim YH, Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, Nanjundan M, Byers L, Heymach J, Mills G, Gazdar AF, Wistuba I, Kodadek T, Minna JD. *Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.* **Cancer Res**, 2010. 70(16): p. 6477-6485. PMID: 20663904 PMCID: 2922434
38. Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J, Ju Z, Lu Y, Zhang F, Coombes KR, Miller D, Huntsman D, Mills GB, Hennessy BT. *Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy.* **Clin Cancer Res**, 2010. 16(10): p. 2852-2860. PMID: 20460476 PMCID: 2877659
39. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R. *Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.* **Breast Cancer Res**, 2010. 12(3): p. R40. PMID: 20569503 PMCID: 2917035
40. Ding Z, Liang J, Li J, Lu Y, Ariyaratna V, Lu Z, Davies MA, Westwick JK, Mills GB. *Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase.* **PLoS One**, 2010. 5(3): p. e9910. PMID: 20361045 PMCID: 2845649
41. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA. *Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.* **Cancer Res**, 2010. 70(21): p. 8736-8747. PMID: 20959481 PMCID: 4286702
42. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, Davies MA, Liu W, Coombes K, Meric-Bernstam F, Bedrosian I, McGahren M, Agarwal R, Zhang F, Overgaard J, Alsner J, Neve RM, Kuo WL, Gray JW, Borresen-Dale AL, Mills GB. *A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers.* **Clin Proteomics**, 2010. 6(4): p. 129-151. PMID: 21691416 PMCID: 3116520
43. Hong B, Lui VW, Hui EP, Lu Y, Leung HS, Wong EY, Cheng SH, Ng MH, Mills GB, Chan AT. *Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1.* **Biochem Pharmacol**, 2010. 79(6): p. 842-852. PMID: 19879857 PMCID: 19879857
44. Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT. *Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis.* **Cancer Res**, 2010. 70(17): p. 6704-6714. PMID: 20643779 PMCID: 2932856
45. Irie HY, Shrestha Y, Selfors LM, Frye F, Iida N, Wang Z, Zou L, Yao J, Lu Y, Epstein CB, Natesan S, Richardson AL, Polyak K, Mills GB, Hahn WC, Brugge JS. *PTK6 regulates IGF-1-induced anchorage-independent survival.* **PLoS One**, 2010. 5(7): p. e11729. PMID: 20668531 PMCID: 2909213
46. Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK. *Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.* **Neuro Oncol**, 2010. 12(6): p. 559-569. PMID: 20156803 PMCID: 2940638
47. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiropoulos C. *PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.* **Proc Natl Acad Sci U S A**, 2010. 107(22): p. 10208-10213. PMID: 20479250 PMCID: 2890442

48. Lu ZH, Shvartsman MB, Lee AY, Shao JM, Murray MM, Kladney RD, Fan D, Krajewski S, Chiang GG, Mills GB, Arbeit JM. *Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis.* **Cancer Res**, 2010. 70(8): p. 3287-3298. PMID: 20388784 PMCID: 2855737
49. Luyimbazi D, Akcakanat A, McAuliffe PF, Zhang L, Singh G, Gonzalez-Angulo AM, Chen H, Do KA, Zheng Y, Hung MC, Mills GB, Meric-Bernstam F. *Rapamycin regulates stearyl CoA desaturase 1 expression in breast cancer.* **Mol Cancer Ther**, 2010. 9(10): p. 2770-2784. PMID: 20876744 PMCID: 2965451
50. Mazzone M, Selfors LM, Albeck J, Overholtzer M, Sale S, Carroll DL, Pandya D, Lu Y, Mills GB, Aster JC, Artavanis-Tsakonas S, Brugge JS. *Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells.* **Proc Natl Acad Sci U S A**, 2010. 107(11): p. 5012-5017. PMID: 20194747 PMCID: 2841923
51. Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, Powis G. *Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.* **Mol Cancer Ther**, 2010. 9(3): p. 706-717. PMID: 20197390 PMCID: 2837366
52. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, Garcia-Echeverria C, Shyr Y, Arteaga CL. *Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.* **J Clin Invest**, 2010. 120(7): p. 2406-2413. PMID: 20530877 PMCID: 2898598
53. Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, Wang J, Coombes KR, Roth JA, Mills GB, Wistuba II, Minna JD, Heymach JV. *Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence.* **J Thorac Oncol**, 2010. 5(12): p. 1894-1904. PMID: 21124077 PMCID: 3374718
54. Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, Ju Z, Deng W, Lu Y, Woo HG, Kim SB, Cheong JH, Garraway LA, Weinstein JN, Mills GB, Lee JS, Davies MA. *Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set.* **Mol Cancer Ther**, 2010. 9(2): p. 257-267. PMID: 20124458 PMCID: 4085051
55. Pontier SM, Huck L, White DE, Rayment J, Sanguin-Gendreau V, Hennessy B, Zuo D, St-Arnaud R, Mills GB, Dedhar S, Marshall CJ, Muller WJ. *Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer.* **Oncogene**, 2010. 29(23): p. 3374-3385. PMID: 20305688 PMCID:
56. Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, Davuluri R, Croce CM, Mills G, Negrini M, Calin GA. *miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells.* **Cell Death Differ**, 2010. 17(2): p. 246-254. PMID: 19730444 PMCID: PMC3648637
57. Tsavachidou-Fenner D, Tannir N, Tamboli P, Liu W, Petillo D, Teh B, Mills GB, Jonasch E. *Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma.* **Ann Oncol**, 2010. 21(8): p. 1599-1606. PMID: 20089566 PMCID: 4092253
58. Chen Y, Alvarez EA, Azzam D, Wander SA, Guggisberg N, Jorda M, Ju Z, Hennessy BT, Slingerland JM. *Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.* **Breast Cancer Res Treat**, 2011. 128(1): p. 69-78. PMID: 20669046 PMCID:
59. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, Wa Cheng K, Hall H, Zhang D, Lu Y, Ravoori M, Kundra V, Ajani J, Lee JS, Ki Hong W, Mills GB. *Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models.* **Mol Cancer Ther**, 2011. 10(12): p. 2350-2362. PMID: 21992792 PMCID: 3237863
60. Cheong LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB. *High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.* **Cancer Discov**, 2011. 1(2): p. 170-185. PMID: 21984976 PMCID: 3187555
61. Edelson JR, Brautigan DL. *The Discodermia calyx toxin calyculin A enhances cyclin D1 phosphorylation and degradation, and arrests cell cycle progression in human breast cancer cells.* **Toxins (Basel)**, 2011. 3(1): p. 105-119. PMID: 22069692 PMCID: 3210456
62. Fox EM, Miller TW, Balko JM, Kuba MG, Sanchez V, Smith RA, Liu S, Gonzalez-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL. *A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a*

- mechanism of escape from hormone dependence in breast cancer. Cancer Res*, 2011. 71(21): p. 6773-6784. PMID: 21908557 PMCID: 3206206
63. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, Gonzalez-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthy S, Mukherjee A, Leitzel K, Kostler WJ, Lipton A, Bates M, Arteaga CL. *Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res*, 2011. 71(5): p. 1871-1882. PMID: 21324925 PMCID: 3221734
64. Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch A, Aparicio S, Brown P, Pusztai L, Symmans WF, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GB. *Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics*, 2011. 8(1): p. 11. PMID: 21906370 PMCID: 3170272
65. Hu Q, Gao F, Tian W, Ruteshouser EC, Wang Y, Lazar A, Stewart J, Strong LC, Behringer RR, Huff V. *Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation. J Clin Invest*, 2011. 121(1): p. 174-183. PMID: 21123950 PMCID: 3007149
66. Jilaveanu LB, Zito CR, Aziz SA, Chakraborty A, Davies MA, Camp RL, Rimm DL, Dudek A, Sznol M, Kluger HM. *In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell Melanoma Res*, 2011. 24(2): p. 386-389. PMID: 21320292 PMCID: 4431976
67. Lu Y, Muller M, Smith D, Dutta B, Komurov K, Iadevaia S, Ruths D, Tseng JT, Yu S, Yu Q, Nakhleh L, Balazsi G, Donnelly J, Schurdak M, Morgan-Lappe S, Fesik S, Ram PT, Mills GB. *Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene*, 2011. 30(45): p. 4567-4577. PMID: 21666717 PMCID: 3175328
68. Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, Gonzalez-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL. *ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov*, 2011. 1(4): p. 338-351. PMID: 22049316 PMCID: 3204388
69. Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Gonzalez-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL. *A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Clin Cancer Res*, 2011. 17(7): p. 2024-2034. PMID: 21346144 PMCID: 3221728
70. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E. *Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med*, 2011. 17(11): p. 1498-1503. PMID: 22037646 PMCID: 4157349
71. Park SY, Jeong KJ, Panupinthu N, Yu S, Lee J, Han JW, Kim JM, Lee JS, Kang J, Park CG, Mills GB, Lee HY. *Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene*, 2011. 30(11): p. 1351-1359. PMID: 21102517 PMCID:
72. Ravi D, Chen Y, Karia B, Brown A, Gu TT, Li J, Carey MS, Hennessy BT, Bishop AJ. *14-3-3 sigma expression effects G2/M response to oxygen and correlates with ovarian cancer metastasis. PLoS One*, 2011. 6(1): p. e15864. PMID: 21249227 PMCID: 3018427
73. Rexer BN, Ham AJ, Rinehart C, Hill S, Granja-Ingram Nde M, Gonzalez-Angulo AM, Mills GB, Dave B, Chang JC, Liebler DC, Arteaga CL. *Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene*, 2011. 30(40): p. 4163-4174. PMID: 21499296 PMCID: 3204390
74. Tabchy A, Hennessy BT, Gonzalez-Angulo AM, Bernstam FM, Lu Y, Mills GB. *Quantitative proteomic analysis in breast cancer. Drugs Today (Barc)*, 2011. 47(2): p. 169-182. PMID: 21431104 PMCID:
75. Valero V, 3rd, Wingate H, Chada S, Liu Y, Palalon F, Mills G, Keyomarsi K, Hunt KK. *MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells. Cancer Gene Ther*, 2011. 18(7): p. 510-519. PMID: 21546925 PMCID: 3875403
76. Zwang Y, Sas-Chen A, Drier Y, Shay T, Avraham R, Lauriola M, Shema E, Lidor-Nili E, Jacob-Hirsch J, Amariglio N, Lu Y, Mills GB, Rechavi G, Oren M, Domany E, Yarden Y. *Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Mol Cell*, 2011. 42(4): p. 524-535. PMID: 21596316 PMCID: 3100487

77. Astanehe A, Finkbeiner MR, Krzywinski M, Fotovati A, Dhillon J, Berquin IM, Mills GB, Marra MA, Dunn SE. *MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.* **Oncogene**, 2012. 31(41): p. 4434-4446. PMID: 22249268 PMCID:
78. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, Gonzalez-Angulo AM, Mills GB, Pinto JA, Gomez HL, Arteaga CL. *Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.* **Nat Med**, 2012. 18(7): p. 1052-1059. PMID: 22683778 PMCID: 3693569
79. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrourpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. *Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.* **Cancer Discov**, 2012. 2(9): p. 798-811. PMID: 22961666 PMCID: 3567922
80. Cancer Genome Atlas N. *Comprehensive molecular portraits of human breast tumours.* **Nature**, 2012. 490(7418): p. 61-70. PMID: 23000897 PMCID: PMC3465532
81. Cheng KW, Agarwal R, Mitra S, Lee JS, Carey M, Gray JW, Mills GB. *Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress.* **EMBO Mol Med**, 2012. 4(2): p. 125-141. PMID: 22253197 PMCID: 3306554
82. Claerhout S, Dutta B, Bossuyt W, Zhang F, Nguyen-Charles C, Dennison JB, Yu Q, Yu S, Balazsi G, Lu Y, Mills GB. *Abortive autophagy induces endoplasmic reticulum stress and cell death in cancer cells.* **PLoS One**, 2012. 7(6): p. e39400. PMID: 22745748 PMCID: 3383753
83. Davies MA, Fox PS, Papadopoulos NE, Bedikian AY, Hwu WJ, Lazar AJ, Prieto VG, Culotta KS, Madden TL, Xu Q, Huang S, Deng W, Ng CS, Gupta S, Liu W, Dancey JE, Wright JJ, Bassett RL, Hwu P, Kim KB. *Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.* **Clin Cancer Res**, 2012. 18(4): p. 1120-1128. PMID: 22223528 PMCID: 3906678
84. Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K. *LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.* **PLoS Genet**, 2012. 8(3): p. e1002538. PMID: 22479189 PMCID: PMC3315462
85. Dutta B, Pusztai L, Qi Y, Andre F, Lazar V, Bianchini G, Ueno N, Agarwal R, Wang B, Shiang CY, Hortobagyi GN, Mills GB, Symmans WF, Balazsi G. *A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes.* **Br J Cancer**, 2012. 106(6): p. 1107-1116. PMID: 22343619 PMCID: 3304402
86. Griffioen AW, Mans LA, de Graaf AM, Nowak-Sliwinska P, de Hoog CL, de Jong TA, Vyth-Dreese FA, van Beijnum JR, Bex A, Jonasch E. *Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients.* **Clin Cancer Res**, 2012. 18(14): p. 3961-3971. PMID: 22573349 PMCID: 4015630
87. Guo H, Liu W, Ju Z, Tamboli P, Jonasch E, Mills GB, Lu Y, Hennessy BT, Tsavachidou D. *An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays.* **Proteome Sci**, 2012. 10(1): p. 56. PMID: 23006314 PMCID: PMC3561137
88. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JJ, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT. *Subtype and pathway specific responses to anticancer compounds in breast cancer.* **Proc Natl Acad Sci U S A**, 2012. 109(8): p. 2724-2729. PMID: 22003129 PMCID: 3286973
89. Hill SM, Lu Y, Molina J, Heiser LM, Spellman PT, Speed TP, Gray JW, Mills GB, Mukherjee S. *Bayesian inference of signaling network topology in a cancer cell line.* **Bioinformatics**, 2012. 28(21): p. 2804-2810. PMID: 22923301 PMCID: 3476330
90. Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A. *MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.* **J Exp Med**, 2012. 209(4): p. 679-696. PMID: 22430491 PMCID: 3328367
91. Hoshino D, Jourquin J, Emmons SW, Miller T, Goldgof M, Costello K, Tyson DR, Brown B, Lu Y, Prasad NK, Zhang B, Mills GB, Yarbrough WG, Quaranta V, Seiki M, Weaver AM. *Network analysis of the focal adhesion to*

- invadopodia transition identifies a PI3K-PKCalpha invasive signaling axis.* **Sci Signal**, 2012. 5(241): p. ra66. PMID: 22969158 PMCID: PMC3583194
92. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK. *State of the science: an update on renal cell carcinoma.* **Mol Cancer Res**, 2012. 10(7): p. 859-880. PMID: 22638109 PMCID: 3399969
  93. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SE. *Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.* **Clin Cancer Res**, 2012. 18(16): p. 4345-4355. PMID: 22733540 PMCID: 3935730
  94. Kim N, He N, Kim C, Zhang F, Lu Y, Yu Q, Stemke-Hale K, Greshock J, Wooster R, Yoon S, Mills GB. *Systematic analysis of genotype-specific drug responses in cancer.* **Int J Cancer**, 2012. 131(10): p. 2456-2464. PMID: 22422301 PMCID: PMC4012336
  95. Kim WY, Prudkin L, Feng L, Kim ES, Hennessy B, Lee JS, Lee JJ, Glisson B, Lippman SM, Wistuba II, Hong WK, Lee HY. *Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.* **Cancer**, 2012. 118(16): p. 3993-4003. PMID: 22359227 PMCID: 3674414
  96. Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong JH, Bender RP, Chu GC, Flaherty KT, Wargo JA, Collins JJ, Chin L. *Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.* **Nat Med**, 2012. 18(10): p. 1503-1510. PMID: 22983396 PMCID: 3777533
  97. Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, Guo W, Scherer SE, Carter H, Westin SN, Dyer MD, Verhaak RG, Zhang F, Karchin R, Liu CG, Lu KH, Broaddus RR, Scott KL, Hennessy BT, Mills GB. *Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.* **Genome Res**, 2012. 22(11): p. 2120-2129. PMID: 23028188 PMCID: 3483541
  98. Mitra R, Mueller P, Ji Y, Mills G, Lu Y. *Sparse Bayesian Graphical Models for RPPA Time Course Data.* **IEEE Int Workshop Genomic Signal Process Stat**, 2012. 2012: p. 113-117. PMID: 25859417 PMCID: PMC4387196
  99. Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, Gao S, Mills GB, Brugge JS. *Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.* **Cancer Cell**, 2012. 21(2): p. 227-239. PMID: 22340595 PMCID: 3297962
  100. Nieto-Barajas LE, Muller P, Ji Y, Lu Y, Mills GB. *A time-series DDP for functional proteomics profiles.* **Biometrics**, 2012. 68(3): p. 859-868. PMID: 22221181 PMCID: 4091682
  101. Oates CJ, Hennessy BT, Lu Y, Mills GB, Mukherjee S. *Network inference using steady-state data and Goldbeter-Koshland kinetics. [corrected].* **Bioinformatics**, 2012. 28(18): p. 2342-2348. PMID: 22815361 PMCID: 3436851
  102. Pareja F, Ferraro DA, Rubin C, Cohen-Dvashi H, Zhang F, Aulmann S, Ben-Chetrit N, Pines G, Navon R, Crosetto N, Kostler W, Carvalho S, Lavi S, Schmitt F, Dikic I, Yakhini Z, Sinn P, Mills GB, Yarden Y. *Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression.* **Oncogene**, 2012. 31(43): p. 4599-4608. PMID: 22179831 PMCID: 3326441
  103. Park YY, Kim K, Kim SB, Hennessy BT, Kim SM, Park ES, Lim JY, Li J, Lu Y, Gonzalez-Angulo AM, Jeong W, Mills GB, Safe S, Lee JS. *Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer.* **EMBO Mol Med**, 2012. 4(1): p. 52-67. PMID: 22174013 PMCID: PMC3376834
  104. Peng G, Dai H, Zhang W, Hsieh HJ, Pan MR, Park YY, Tsai RY, Bedrosian I, Lee JS, Ira G, Lin SY. *Human nuclease/helicase DNA2 alleviates replication stress by promoting DNA end resection.* **Cancer Res**, 2012. 72(11): p. 2802-2813. PMID: 22491672 PMCID: PMC3367086
  105. Pradeep CR, Kostler WJ, Lauriola M, Granit RZ, Zhang F, Jacob-Hirsch J, Rechavi G, Nair HB, Hennessy BT, Gonzalez-Angulo AM, Tekmal RR, Ben-Porath I, Mills GB, Domany E, Yarden Y. *Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling.* **Oncogene**, 2012. 31(7): p. 907-917. PMID: 21743488 PMCID: 3193899
  106. Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. *Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.* **Clin Cancer Res**, 2012. 18(20): p. 5816-5828. PMID: 22932669 PMCID: 3772348
  107. Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB, Slingerland JM. *Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.* **Clin Cancer Res**, 2012. 18(21): p. 5911-5923. PMID: 22896656 PMCID: PMC3698880

108. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. *A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma*. **Eur Urol**, 2012. 62(6): p. 1013-1019. PMID: 22771265 PMCID: 3882163
109. Tarcic G, Avraham R, Pines G, Amit I, Shay T, Lu Y, Zwang Y, Katz M, Ben-Chetrit N, Jacob-Hirsch J, Virgilio L, Rechavi G, Mavrothalassitis G, Mills GB, Domany E, Yarden Y. *EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF*. **FASEB J**, 2012. 26(4): p. 1582-1592. PMID: 22198386 PMCID: 3316897
110. Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM. *Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma*. **Clin Cancer Res**, 2012. 18(8): p. 2278-2289. PMID: 22351687 PMCID: 3430124
111. Anakk S, Bhosale M, Schmidt VA, Johnson RL, Finegold MJ, Moore DD. *Bile acids activate YAP to promote liver carcinogenesis*. **Cell Rep**, 2013. 5(4): p. 1060-1069. PMID: 24268772 PMCID: 3961013
112. Brennan CW, Verhaak RG, McKenna A, Campos B, Nounshmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukheim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L. *The somatic genomic landscape of glioblastoma*. **Cell**, 2013. 155(2): p. 462-477. PMID: 24120142 PMCID: 3910500
113. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. *An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance*. **Clin Cancer Res**, 2013. 19(1): p. 279-290. PMID: 23091115 PMCID: 3567921
114. Cancer Genome Atlas Research N. *Comprehensive molecular characterization of clear cell renal cell carcinoma*. **Nature**, 2013. 499(7456): p. 43-49. PMID: 23792563 PMCID: PMC3771322
115. Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. *Integrated genomic characterization of endometrial carcinoma*. **Nature**, 2013. 497(7447): p. 67-73. PMID: 23636398 PMCID: PMC3704730
116. Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. *The Cancer Genome Atlas Pan-Cancer analysis project*. **Nat Genet**, 2013. 45(10): p. 1113-1120. PMID: 24071849 PMCID: PMC3919969
117. Cardnell RJ, Feng Y, Diao L, Fan YH, Masrourpour F, Wang J, Shen Y, Mills GB, Minna JD, Heymach JV, Byers LA. *Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer*. **Clin Cancer Res**, 2013. 19(22): p. 6322-6328. PMID: 24077350 PMCID: 3882158
118. Creighton CJ. *Widespread molecular patterns associated with drug sensitivity in breast cancer cell lines, with implications for human tumors*. **PLoS One**, 2013. 8(12): p. e71158. PMID: 24386073 PMCID: PMC3873899
119. Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, van't Veer LJ, Spellman PT, Gray JW. *Modeling precision treatment of breast cancer*. **Genome Biol**, 2013. 14(10): p. R110. PMID: 24176112 PMCID: 3937590
120. Fabian CJ, Kimler BF, Donnelly JE, Sullivan DK, Klemp JR, Petroff BK, Phillips TA, Metheny T, Aversman S, Yeh HW, Zalles CM, Mills GB, Hursting SD. *Favorable modulation of benign breast tissue and serum risk biomarkers is associated with > 10 % weight loss in postmenopausal women*. **Breast Cancer Res Treat**, 2013. 142(1): p. 119-132. PMID: 24141897 PMCID: 3921968
121. Fong EL, Lamhamedi-Cherradi SE, Burdett E, Ramamoorthy V, Lazar AJ, Kasper FK, Farach-Carson MC, Vishwamitra D, Demicco EG, Menegaz BA, Amin HM, Mikos AG, Ludwig JA. *Modeling Ewing sarcoma tumors in vitro with 3D scaffolds*. **Proc Natl Acad Sci U S A**, 2013. 110(16): p. 6500-6505. PMID: 23576741 PMCID: 3631678



122. Fu J, Koul D, Yao J, Wang S, Yuan Y, Colman H, Sulman EP, Lang FF, Yung WK. *Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.* **Cancer Res**, 2013. 73(10): p. 3062-3074. PMID: 23492364 PMCID: 3655088
123. Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. *Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial.* **Clin Cancer Res**, 2013. 19(19): p. 5474-5484. PMID: 24089446 PMCID: 3935482
124. Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Fraser Symmans W, Pusztai L, Hortobagyi GN, Mills GB, Meric-Bernstam F. *High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients.* **Breast Cancer Res Treat**, 2013. 137(1): p. 319-327. PMID: 23208590 PMCID: 3556743
125. Hurst RE, Hauser PJ, Kyker KD, Heinlen JE, Hodde JP, Hiles MC, Kosanke SD, Dozmorov M, Ihnat MA. *Suppression and activation of the malignant phenotype by extracellular matrix in xenograft models of bladder cancer: a model for tumor cell "dormancy".* **PLoS One**, 2013. 8(5): p. e64181. PMID: 23717563 PMCID: PMC3663841
126. Jia L, Jin H, Zhou J, Chen L, Lu Y, Ming Y, Yu Y. *A potential anti-tumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF-beta signaling pathways.* **BMC Complement Altern Med**, 2013. 13: p. 33. PMID: 23410205 PMCID: PMC3598193
127. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. *Integrated genomic characterization of endometrial carcinoma.* **Nature**, 2013. 497(7447): p. 67-73. PMID: 23636398 PMCID: 3704730
128. Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Liu J, Sood AK. *Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.* **J Natl Cancer Inst**, 2013. 105(19): p. 1485-1495. PMID: 24062525 PMCID: 3787907
129. Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kantarjian H, Shacham S, Kauffman M, Andreeff M. *Prognostic impact and targeting of CRM1 in acute myeloid leukemia.* **Blood**, 2013. 121(20): p. 4166-4174. PMID: 23564911 PMCID: 3656451
130. Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, Liu W, Yang JY, Broom BM, Verhaak RG, Kane DW, Wakefield C, Weinstein JN, Mills GB, Liang H. *TCPA: a resource for cancer functional proteomics data.* **Nat Methods**, 2013. 10(11): p. 1046-1047. PMID: 24037243 PMCID: 4076789
131. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala R, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Kwok-Shing Ng P, Garraway LA, Hammerman PS, Mills GB, Grandis JR. *Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.* **Cancer Discov**, 2013. 3(7): p. 761-769. PMID: 23619167 PMCID: 3710532
132. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Jr., Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. *Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.* **Clin Cancer Res**, 2013. 19(3): p. 657-667. PMID: 23251002 PMCID: 3563727
133. Overman MJ, Zhang J, Kopetz S, Davies M, Jiang ZQ, Stemke-Hale K, Rummele P, Pilarsky C, Grutzmann R, Hamilton S, Hwang R, Abbruzzese JL, Varadhachary G, Broom B, Wang H. *Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome.* **PLoS One**, 2013. 8(6): p. e65144. PMID: 23776447 PMCID: 3679143
134. Pan Y, Zhang Q, Atsaves V, Yang H, Claret FX. *Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways.* **Oncogene**, 2013. 32(22): p. 2756-2766. PMID: 22797071 PMCID: 3566273
135. Rini BI, Melichar B, Ueda T, Grunwald V, Fishman MN, Arranz JA, Bair AH, Pithavala YK, Andrews GI, Pavlov D, Kim S, Jonasch E. *Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.* **Lancet Oncol**, 2013. 14(12): p. 1233-1242. PMID: 24140184 PMCID: 4120767

136. Sohn J, Do KA, Liu S, Chen H, Mills GB, Hortobagyi GN, Meric-Bernstam F, Gonzalez-Angulo AM. *Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy*. **Ann Oncol**, 2013. 24(10): p. 2522-2526. PMID: 23925999 PMCID: 3784335
137. Su SC, Hu X, Kenney PA, Merrill MM, Babaian KN, Zhang XY, Maity T, Yang SF, Lin X, Wood CG. *Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma*. **Clin Cancer Res**, 2013. 19(23): p. 6461-6472. PMID: 24122794 PMCID: 4191899
138. Taube JH, Malouf GG, Lu E, Sphyris N, Vijay V, Ramachandran PP, Ueno KR, Gaur S, Nicoloso MS, Rossi S, Herschkowitz JI, Rosen JM, Issa JP, Calin GA, Chang JT, Mani SA. *Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties*. **Sci Rep**, 2013. 3: p. 2687. PMID: 24045437 PMCID: 3776231
139. Wei C, Chen J, Pande M, Lynch PM, Frazier ML. *A pilot study comparing protein expression in different segments of the normal colon and rectum and in normal colon versus adenoma in patients with Lynch syndrome*. **J Cancer Res Clin Oncol**, 2013. 139(7): p. 1241-1250. PMID: 23604467 PMCID: 3708474
140. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. *The Cancer Genome Atlas Pan-Cancer analysis project*. **Nat Genet**, 2013. 45(10): p. 1113-1120. PMID: 24071849 PMCID: 3919969
141. Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM. *Poor survival with wild-type TP53 ovarian cancer?* **Gynecol Oncol**, 2013. 130(3): p. 565-569. PMID: 23800698 PMCID: 4059202
142. Yan X, Lyu T, Jia N, Yu Y, Hua K, Feng W. *Huaier aqueous extract inhibits ovarian cancer cell motility via the AKT/GSK3beta/beta-catenin pathway*. **PLoS One**, 2013. 8(5): p. e63731. PMID: 23667667 PMCID: PMC3648479
143. Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H, Takano M, Ushijima K, Tanyi JL, Coukos G, Lu Y, Mills GB, Verhaak RG. *Predicting time to ovarian carcinoma recurrence using protein markers*. **J Clin Invest**, 2013. 123(9): p. 3740-3750. PMID: 23945238 PMCID: 3754259
144. Yang Y, Mallampati S, Sun B, Zhang J, Kim SB, Lee JS, Gong Y, Cai Z, Sun X. *Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target*. **Cancer Lett**, 2013. 333(1): p. 9-17. PMID: 23333798 PMCID: 3880833
145. Zhang S, Huang WC, Zhang L, Zhang C, Lowery FJ, Ding Z, Guo H, Wang H, Huang S, Sahin AA, Aldape KD, Steeg PS, Yu D. *SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases*. **Cancer Res**, 2013. 73(18): p. 5764-5774. PMID: 23913825 PMCID: 3781592
146. Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, Mao S, Pavlick AC, Froehlich AM, Wu MF, Tsimelzon A, Hilsenbeck SG, Chen ES, Zuloaga P, Shaw CA, Rimawi MF, Perou CM, Mills GB, Chang JC, Lewis MT. *A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models*. **Cancer Res**, 2013. 73(15): p. 4885-4897. PMID: 23737486 PMCID: 3732575
147. Akbani R, Becker KF, Carragher N, Goldstein T, de Koning L, Korf U, Liotta L, Mills GB, Nishizuka SS, Pawlak M, Petricoin EF, 3rd, Pollard HB, Serrels B, Zhu J. *Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society*. **Mol Cell Proteomics**, 2014. 13(7): p. 1625-1643. PMID: 24777629 PMCID: 4083105
148. Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, Ling S, Seviour EG, Ram PT, Minna JD, Diao L, Tong P, Heymach JV, Hill SM, Dondelinger F, Stadler N, Byers LA, Meric-Bernstam F, Weinstein JN, Broom BM, Verhaak RG, Liang H, Mukherjee S, Lu Y, Mills GB. *A pan-cancer proteomic perspective on The Cancer Genome Atlas*. **Nat Commun**, 2014. 5: p. 3887. PMID: 24871328 PMCID: 4109726
149. Ambati SR, Lopes EC, Kosugi K, Mony U, Zehir A, Shah SK, Taldone T, Moreira AL, Meyers PA, Chiosis G, Moore MA. *Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma*. **Mol Oncol**, 2014. 8(2): p. 323-336. PMID: 24388362 PMCID: PMC3982393
150. Ashour AA, Abdel-Aziz AA, Mansour AM, Alpay SN, Huo L, Ozpolat B. *Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells*. **Apoptosis**, 2014. 19(1): p. 241-258. PMID: 24193916 PMCID:
151. Baladandayuthapani V, Talluri R, Ji Y, Coombes KR, Lu Y, Hennessy BT, Davies MA, Mallick BK. *Bayesian Sparse Graphical Models for Classification with Application to Protein Expression Data*. **Ann Appl Stat**, 2014. 8(3): p. 1443-1468. PMID: 26246866 PMCID: PMC4523298

152. Blanco E, Sangai T, Wu S, Hsiao A, Ruiz-Esparza GU, Gonzalez-Delgado CA, Cara FE, Granados-Principal S, Evans KW, Akcakanat A, Wang Y, Do KA, Meric-Bernstam F, Ferrari M. *Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway*. **Mol Ther**, 2014. 22(7): p. 1310-1319. PMID: 24569835 PMCID: 4088997
153. Bucheit AD, Chen G, Siroy A, Tetzlaff M, Broaddus R, Milton D, Fox P, Bassett R, Hwu P, Gershenwald JE, Lazar AJ, Davies MA. *Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations*. **Clin Cancer Res**, 2014. 20(21): p. 5527-5536. PMID: 25165098 PMCID: 4216767
154. Cancer Genome Atlas Research N. *Integrated genomic characterization of papillary thyroid carcinoma*. **Cell**, 2014. 159(3): p. 676-690. PMID: 25417114 PMCID: PMC4243044
155. Cancer Genome Atlas Research N. *Comprehensive molecular profiling of lung adenocarcinoma*. **Nature**, 2014. 511(7511): p. 543-550. PMID: 25079552 PMCID: PMC4231481
156. Cancer Genome Atlas Research N. *Comprehensive molecular characterization of gastric adenocarcinoma*. **Nature**, 2014. 513(7517): p. 202-209. PMID: 25079317 PMCID: PMC4170219
157. Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Bogenberger JM, Mu H, Tibes R, Yao H, Coombes KR, Jacamo RO, McQueen T, Kornblau SM, Andreeff M. *Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents*. **J Natl Cancer Inst**, 2014. 106(2): p. djt440. PMID: 24526787 PMCID: 3952202
158. Cerne JZ, Hartig SM, Hamilton MP, Chew SA, Mitsiades N, Poulaki V, McGuire SE. *Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation*. **Invest Ophthalmol Vis Sci**, 2014. 55(4): p. 2130-2139. PMID: 24595385 PMCID: PMC3979518
159. Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peugot S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Borresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB. *Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers*. **Cancer Cell**, 2014. 26(6): p. 863-879. PMID: 25490449 PMCID: 4261159
160. Chavez-Macgregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Puztai L, Fraser Symmans W, Nair L, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. *Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes*. **Cancer Epidemiol Biomarkers Prev**, 2014. 23(2): p. 316-323. PMID: 24296856 PMCID: 3946290
161. Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, Kim SB, Kopetz S, Ledoux AA, Gopal YN, Pereira CG, Deng W, Lee JS, Nathanson KL, Aldape KD, Prieto VG, Stuart D, Davies MA. *Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target*. **Clin Cancer Res**, 2014. 20(21): p. 5537-5546. PMID: 24803579 PMCID: 4216765
162. Chen H, Fu T, Suh WK, Tsavachidou D, Wen S, Gao J, Ng Tang D, He Q, Sun J, Sharma P. *CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy*. **Cancer Immunol Res**, 2014. 2(2): p. 167-176. PMID: 24778280 PMCID: 4004958
163. Cheung LW, Yu S, Zhang D, Li J, Ng PK, Panupinthu N, Mitra S, Ju Z, Yu Q, Liang H, Hawke DH, Lu Y, Broaddus RR, Mills GB. *Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors*. **Cancer Cell**, 2014. 26(4): p. 479-494. PMID: 25284480 PMCID: 4198486
164. Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. *Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance*. **J Clin Invest**, 2014. 124(6): p. 2611-2625. PMID: 24762435 PMCID: 4038562
165. Gao M, Liang J, Lu Y, Guo H, German P, Bai S, Jonasch E, Yang X, Mills GB, Ding Z. *Site-specific activation of AKT protects cells from death induced by glucose deprivation*. **Oncogene**, 2014. 33(6): p. 745-755. PMID: 23396361 PMCID: 3874430
166. Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD, Wargo JA, Long GV, Davies MA. *Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1alpha and oxidative phosphorylation in melanoma*. **Cancer Res**, 2014. 74(23): p. 7037-7047. PMID: 25297634 PMCID: 4347853
167. Gu D, Wang S, Kuitatse I, Wang H, He J, Dai Y, Jones RJ, Bjorklund CC, Yang J, Grant S, Orlowski RZ. *Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple*

- myeloma, and acts synergistically with ABT-737. PLoS One*, 2014. 9(9): p. e103015. PMID: 25181509 PMCID: 4151993
168. Hayashi N, Manyam GC, Gonzalez-Angulo AM, Niikura N, Yamauchi H, Nakamura S, Hortobagyi GN, Baggerly KA, Ueno NT. *Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer. Oncologist*, 2014. 19(9): p. 909-914. PMID: 25117064 PMCID: 4153464
169. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA, Benz CC, Perou CM, Stuart JM. *Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell*, 2014. 158(4): p. 929-944. PMID: 25109877 PMCID: 4152462
170. Honjo S, Ajani JA, Scott AW, Chen Q, Skinner HD, Stroehlein J, Johnson RL, Song S. *Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol*, 2014. 45(2): p. 567-574. PMID: 24859412 PMCID: 4091970
171. Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, Sahin AA, Sood A, Mills GB, Yu D, Hortobagyi GN, Hung MC. *Definition of PKC-alpha, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res*, 2014. 74(17): p. 4822-4835. PMID: 24970481 PMCID: 4154991
172. Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, Zhang Y, Yang L, Zhong X, Wang LP, Jean S, Li C, Huang Q, Katsaros D, Montone KT, Tanyi JL, Lu Y, Boyd J, Nathanson KL, Li H, Mills GB, Zhang L. *A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell*, 2014. 26(3): p. 344-357. PMID: 25203321 PMCID: 4159613
173. Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapparas D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Jennings NB, Huang L, Deavers MT, Broaddus R, Coleman RL, Sood AK. *Cross-talk between EphA2 and BRAF/CRaf is a key determinant of response to Dasatinib. Clin Cancer Res*, 2014. 20(7): p. 1846-1855. PMID: 24486585 PMCID: 3975695
174. Huang YJ, Frazier ML, Zhang N, Liu Q, Wei C. *Reverse-phase protein array analysis to identify biomarker proteins in human pancreatic cancer. Dig Dis Sci*, 2014. 59(5): p. 968-975. PMID: 24248418 PMCID: PMC3995856
175. Joy A, Ramesh A, Smirnov I, Reiser M, Misra A, Shapiro WR, Mills GB, Kim S, Feuerstein BG. *AKT pathway genes define 5 prognostic subgroups in glioblastoma. PLoS One*, 2014. 9(7): p. e100827. PMID: 24984002 PMCID: 4077731
176. Jung Y, Park H, Zhao HY, Jeon R, Ryu JH, Kim WY. *Systemic approaches identify a garlic-derived chemical, Z-ajoene, as a glioblastoma multiforme cancer stem cell-specific targeting agent. Mol Cells*, 2014. 37(7): p. 547-553. PMID: 25078449 PMCID: PMC4132307
177. Kaddi CD, Wang MD. *Models for predicting stage in head and neck squamous cell carcinoma using proteomic data. Conf Proc IEEE Eng Med Biol Soc*, 2014. 2014: p. 5216-5219. PMID: 25571169 PMCID:
178. Kaushik P, Molinelli EJ, Miller ML, Wang W, Korkut A, Liu W, Ju Z, Lu Y, Mills G, Sander C. *Spatial normalization of reverse phase protein array data. PLoS One*, 2014. 9(12): p. e97213. PMID: 25501559 PMCID: PMC4264691
179. Kim TH, Yoo JY, Kim HI, Gilbert J, Ku BJ, Li J, Mills GB, Broaddus RR, Lydon JP, Lim JM, Yoon HG, Jeong JW. *Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activation. Cancer Res*, 2014. 74(24): p. 7371-7382. PMID: 25377472 PMCID: 4268053
180. Klinke DJ, 2nd. *Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective study. PLoS Comput Biol*, 2014. 10(1): p. e1003409. PMID: 24426833 PMCID: PMC3890420
181. Kugel CH, 3rd, Hartsough EJ, Davies MA, Setiady YY, Aplin AE. *Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor. Cancer Res*, 2014. 74(15): p. 4122-4132. PMID: 25035390 PMCID: 4120074
182. Lee J, Tiwari A, Shum V, Mills GB, Mancini MA, Igoshin OA, Balazsi G. *Unraveling the regulatory connections between two controllers of breast cancer cell fate. Nucleic Acids Res*, 2014. 42(11): p. 6839-6849. PMID: 24792166 PMCID: 4066784
183. Lin SH, Wang J, Saintigny P, Wu CC, Giri U, Zhang J, Menju T, Diao L, Byers L, Weinstein JN, Coombes KR, Girard L, Komaki R, Wistuba II, Date H, Minna JD, Heymach JV. *Genes suppressed by DNA methylation in non-*

- small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.* **BMC Genomics**, 2014. 15: p. 1079. PMID: 25486910 PMCID: 4298954
184. Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Maelandsmo GM, Engebraaten O. *Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations.* **Clin Cancer Res**, 2014. 20(2): p. 404-412. PMID: 24192926 PMCID: PMC4326070
185. Liu S, Meng X, Chen H, Liu W, Miller T, Murph M, Lu Y, Zhang F, Gagea M, Arteaga CL, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. *Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.* **Oncotarget**, 2014. 5(19): p. 9049-9064. PMID: 24979294 PMCID: PMC4253418
186. Liu W, Ju Z, Lu Y, Mills GB, Akbani R. *A comprehensive comparison of normalization methods for loading control and variance stabilization of reverse-phase protein array data.* **Cancer Inform**, 2014. 13: p. 109-117. PMID: 25374453 PMCID: 4213190
187. Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, Broaddus RR, Zhang W. *Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.* **J Natl Cancer Inst**, 2014. 106(9). PMID: 25214561 PMCID: 4200060
188. Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ, Bahar I, Ju Z, Wang Z, Pendleton KP, Xiao X, Du Y, Vries JK, Hammerman PS, Garraway LA, Mills GB, Johnson DE, Grandis JR. *Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.* **Proc Natl Acad Sci U S A**, 2014. 111(3): p. 1114-1119. PMID: 24395800 PMCID: 3903220
189. Luo Z, Zhao Y, Azencott R. *Impact of miRNA sequence on miRNA expression and correlation between miRNA expression and cell cycle regulation in breast cancer cells.* **PLoS One**, 2014. 9(4): p. e95205. PMID: 24748078 PMCID: PMC3991594
190. Mak PY, Mak DH, Ruvolo V, Jacamo R, Kornblau SM, Kantarjian H, Andreeff M, Carter BZ. *Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.* **Br J Haematol**, 2014. 167(3): p. 376-384. PMID: 25079338 PMCID: 4357400
191. Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK. *Platelet-derived growth factor receptor alpha (PDGFRalpha) targeting and relevant biomarkers in ovarian carcinoma.* **Gynecol Oncol**, 2014. 132(1): p. 166-175. PMID: 24183729 PMCID: 3946949
192. Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, Fan YH, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM. *A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.* **Mol Cancer Ther**, 2014. 13(11): p. 2738-2750. PMID: 25193510 PMCID: 4221385
193. McGuire MJ, Gray BP, Li S, Cupka D, Byers LA, Wu L, Rezaie S, Liu YH, Pattisapu N, Issac J, Oyama T, Diao L, Heymach JV, Xie XJ, Minna JD, Brown KC. *Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer.* **Sci Rep**, 2014. 4: p. 4480. PMID: 24670678 PMCID: 3967199
194. Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, Lucci A, Ivan C, Calin GA, Kalluri R. *Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis.* **Cancer Cell**, 2014. 26(5): p. 707-721. PMID: 25446899 PMCID: 4254633
195. Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada BE, Singh G, Do KA, Garces ZM, Mittendorf E, Babiera G, Bedrosian I, Hwang R, Krishnamurthy S, Symmans WF, Gonzalez-Angulo AM, Mills GB. *Influence of biospecimen variables on proteomic biomarkers in breast cancer.* **Clin Cancer Res**, 2014. 20(14): p. 3870-3883. PMID: 24895461 PMCID: PMC4112583
196. Mitra R, Muller P, Ji Y, Zhu Y, Mills G, Lu Y. *A Bayesian hierarchical model for inference across related reverse phase protein arrays experiments.* **J Appl Stat**, 2014. 41(11): p. 2483-2492. PMID: 26246652 PMCID: PMC4523276
197. Mokkaapati S, Niopek K, Huang L, Cunniff KJ, Ruteshouser EC, deCaestecker M, Finegold MJ, Huff V. *beta-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma.* **Cancer Res**, 2014. 74(16): p. 4515-4525. PMID: 24848510 PMCID: 4134699
198. Osmanbeyoglu HU, Pelossof R, Bromberg JF, Leslie CS. *Linking signaling pathways to transcriptional programs in breast cancer.* **Genome Res**, 2014. 24(11): p. 1869-1880. PMID: 25183703 PMCID: PMC4216927

199. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R. *Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.* **Cancer Cell**, 2014. 25(6): p. 719-734. PMID: 24856586 PMCID: 4180632
200. Panupinthu N, Yu S, Zhang D, Zhang F, Gagea M, Lu Y, Grandis JR, Dunn SE, Lee HY, Mills GB. *Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer.* **Oncogene**, 2014. 33(22): p. 2846-2856. PMID: 23851501 PMCID: 4115609
201. Parfenov M, Peadarallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, Xu AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Issaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS, Kucherlapati R, Cancer Genome Atlas N. *Characterization of HPV and host genome interactions in primary head and neck cancers.* **Proc Natl Acad Sci U S A**, 2014. 111(43): p. 15544-15549. PMID: 25313082 PMCID: PMC4217452
202. Peng H, Peng T, Wen J, Engler DA, Matsunami RK, Su J, Zhang L, Chang CC, Zhou X. *Characterization of p38 MAPK isoforms for drug resistance study using systems biology approach.* **Bioinformatics**, 2014. 30(13): p. 1899-1907. PMID: 24618474 PMCID: PMC4071201
203. Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, Gonzalez-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL. *LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.* **J Clin Invest**, 2014. 124(12): p. 5490-5502. PMID: 25401474 PMCID: 4348968
204. Sewell A, Brown B, Biktasova A, Mills GB, Lu Y, Tyson DR, Issaeva N, Yarbrough WG. *Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.* **Clin Cancer Res**, 2014. 20(9): p. 2300-2311. PMID: 24599934 PMCID: 4027970
205. Tangen IL, Werner HM, Berg A, Halle MK, Kusonmano K, Trovik J, Hoivik EA, Mills GB, Krakstad C, Salvesen HB. *Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions.* **Eur J Cancer**, 2014. 50(17): p. 3003-3010. PMID: 25281525 PMCID:
206. Tell RW, Horvath CM. *Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumors.* **Proc Natl Acad Sci U S A**, 2014. 111(35): p. 12787-12792. PMID: 25139989 PMCID: PMC4156751
207. Umesh V, Rape AD, Ulrich TA, Kumar S. *Microenvironmental stiffness enhances glioma cell proliferation by stimulating epidermal growth factor receptor signaling.* **PLoS One**, 2014. 9(7): p. e101771. PMID: 25000176 PMCID: PMC4084995
208. Wallez Y, Riedl SJ, Pasquale EB. *Association of the breast cancer antiestrogen resistance protein 1 (BCAR1) and BCAR3 scaffolding proteins in cell signaling and antiestrogen resistance.* **J Biol Chem**, 2014. 289(15): p. 10431-10444. PMID: 24584939 PMCID: PMC4036165
209. Weinstein JN, Akbani R, Broom BM, Wang WY, Verhaak RGW, McConkey D, Lerner S, Morgan M, Creighton CJ, Smith C, Kwiatkowski DJ, Cherniack AD, Kim J, Peadarallu CS, Noble MS, Al-Ahmadie HA, Reuter VE, Rosenberg JE, Bajorin DF, Bochner BH, Solit DB, Koppie T, Robinson B, Gordenin DA, Fargo D, Klimczak LJ, Roberts SA, Au J, Laird PW, Hinoue T, Schultz N, Ramirez R, Hansel D, Hoadley KA, Kim WY, Damrauer JS, Baylin SB, Mungall AJ, Robertson AG, Chu A, Kwiatkowski DJ, Sougnez C, Cibulskis K, Lichtenstein L, Sivachenko A, Stewart C, Lawrence MS, Getz G, Lander E, Gabriel SB, Creighton CJ, Donehower L, Cherniack AD, Kim J, Carter SL, Saksena G, Schumacher SE, Sougnez C, Freeman SS, Jung J, Peadarallu CS, Bhatt AS, Pugh T, Getz G, Beroukhi R, Gabriel SB, Meyerson M, Mungall AJ, Robertson AG, Chu A, Ally A, Balasundaram M, Butterfield YSN, Dhalla N, Hirst C, Holt RA, Jones SJM, Lee D, Li HYI, Marra MA, Mayo M, Moore RA, Schein JE, Sipahimalani P, Tam A, Thiessen N, Wong T, Wye N, Bowlby R, Chuah E, Guin R, Jones SJM, Marra MA, Hinoue T, Shen H, Bootwalla MS, Triche T, Lai PH, Van den Berg DJ, Weisenberger DJ, Laird PW, Hansel D, Hoadley KA, Balu S, Bodenheimer T, Damrauer JS, Hoyle AP, Jefferys SR, Meng SW, Mose LE, Simons JV, Soloway MG, Wu JY, Kim WY, Parker JS, Hayes DN, Roach J, Buda E, Jones CD, Mieczkowski PA, Tan DH, Veluvolu U, Waring S, Auman JT, Perou CM, Wilkerson MD, Santoso N, Parfenov M, Ren XJ, Pantazi A, Hadjipanayis A, Seidman J, Kucherlapati R, Lee S, Yang LX, Park PJ, Baylin SB, Xu AW, Protopopov A, Zhang JH, Bristow C, Mahadeshwar HS, Seth S, Song XZ, Tang JB, Zeng D, Chin LD, Guo C, Weinstein JN, Akbani R, Broom BM, McConkey D, Casasent TD, Liu WB, Ju ZL, Motter T, Peng B, Ryan M, Wang WY, Verhaak RGW, Su XP, Yang JY, Lorenzi PL, Yao H, Zhang NX, Zhang JX, Mills GB, Kim J, Noble MS, Cho J, DiCara D, Frazer S,

- Gehlenborg N, Heiman DI, Lin P, Liu YC, Stojanov P, Voet D, Zhang HL, Zou LH, Chin LD, Getz G, Bernard B, Kreisberg D, Reynolds S, Rovira H, Shmulevich I, Ramirez R, Schultz N, Gao JJ, Jacobsen A, Aksoy BA, Antipin Y, Ciriello G, Dresdner G, Gross B, Lee W, Reva B, Shen RL, Sinha R, Sumer SO, Weinhold N, Ladanyi M, Sander C, Benz C, Carlin D, Haussler D, Ng S, Paull EO, Stuart J, Zhu J, Liu YX, Zhang W, Taylor BS, Lichtenberg TM, Zmuda E, Barr T, Black AD, George M, Hanf B, Helsel C, McAllister C, Ramirez NC, Tabler TR, Weaver S, Wise L, Bowen J, Gastier-Foster JM, Weinstein JN, Lerner S, Jian WG, Tello S, Ittman M, Castro P, McClenden WD, Morgan M, Gibbs R, Liu YC, Saller C, Tarvin K, DiPiero JM, Owens J, Bollag R, Li Q, Weinberger P, Czerwinski C, Huelsenbeck-Dill L, Iacocca M, Petrelli N, Rabeno B, Swanson P, Shelton T, Curley E, Gardner J, Mallery D, Penny R, Bang NV, Hanh PT, Kohl B, Le XV, Phu BD, Thorp R, Tien NV, Vinh LQ, Sandusky G, Burks E, Christ K, Gee J, Holway A, Moizadeh A, Sorcini A, Sullivan T, Al-Ahmadie HA, Bajorin DF, Bochner BH, Garcia-Grossman IR, Regazzi AM, Solit DB, Rosenberg JE, Reuter VE, Koppie T, Boice L, Rathmell WK, Thorne L, Bastacky S, Davies B, Dhir R, Gingrich J, Hrebinko R, Maranchie J, Nelson J, Parwani A, Bshara W, Gaudioso C, Morrison C, Alexopoulou V, Bartlett J, Engel J, Kodeeswaran S, Antic T, O'Donnell PH, Smith ND, Steinberg GD, Egea S, Gomez-Fernandez C, Herbert L, Jorda M, Soloway M, Beaver A, Carter S, Kapur P, Lewis C, Lotan Y, Robinson B, Hansel D, Guo C, Bondaruk J, Czerniak B, Akbani R, Broom BM, Liu YX, Zhang W, Weinstein JN, Lerner S, Morgan M, Kim J, Cherniack AD, Freeman SS, Peadarallu CS, Noble MS, Kwiatkowski DJ, Al-Ahmadie HA, Bajorin DF, Bochner BH, Solit DB, Rosenberg JE, Reuter VE, Koppie T, Robinson B, Skinner E, Ramirez R, Schultz N, Hansel D, Kim WY, Guo C, Bondaruk J, Aldape K, Czerniak B, Jensen MA, Kahn AB, Pihl TD, Pot DA, Srinivasan D, Wan YH, Ferguson ML, Zenklusen JC, Davidsen T, Demchok JA, Shaw KRM, Sheth M, Tarnuzzer R, Wang ZN, Yang LM, Hutter C, Ozenberger BA, Sofia HJ, Eley G, Network CGAR. *Comprehensive molecular characterization of urothelial bladder carcinoma*. **Nature**, 2014. 507(7492): p. 315-322. PMID: ISI:000333029000025 PMCID:
210. Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS. *A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation*. **BMC Cancer**, 2014. 14: p. 120. PMID: 24559118 PMCID: 3941949
211. Yuan Y, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, Han L, Huang X, Lawrence MS, Weinstein JN, Stuart JM, Mills GB, Garraway LA, Margolin AA, Getz G, Liang H. *Assessing the clinical utility of cancer genomic and proteomic data across tumor types*. **Nat Biotechnol**, 2014. 32(7): p. 644-652. PMID: 24952901 PMCID: 4102885
212. Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, Ling S, Seviour EG, Ram PT, Minna JD, Diao L, Tong P, Heymach JV, Hill SM, Dondelinger F, Stadler N, Byers LA, Meric-Bernstam F, Weinstein JN, Broom BM, Verhaak RG, Liang H, Mukherjee S, Lu Y, Mills GB. *Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas*. **Nat Commun**, 2015. 6: p. 4852. PMID: 25629879 PMCID:
213. Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, Wang H, Gol-Chambers A, Ozkayar O, Kanlikilicer P, Fuentes-Mattei E, Kahraman N, Pradeep S, Ozpolat B, Tucker S, Hung MC, Baggerly K, Bartholomeusz G, Calin G, Sood AK, Lopez-Berestein G. *The ZNF304-integrin axis protects against anoikis in cancer*. **Nat Commun**, 2015. 6: p. 7351. PMID: 26081979 PMCID: 4830335
214. Atsaves V, Zhang R, Ruder D, Pan Y, Leventaki V, Rassidakis GZ, Claret FX. *Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism*. **Leukemia**, 2015. 29(11): p. 2162-2172. PMID: 25987255 PMCID: PMC4633353
215. Aure MR, Jernstrom S, Krohn M, Vollan HK, Due EU, Rodland E, Karesen R, Ram P, Lu Y, Mills GB, Sahlberg KK, Borresen-Dale AL, Lingjaerde OC, Kristensen VN. *Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer*. **Genome Med**, 2015. 7(1): p. 21. PMID: 25873999 PMCID: 4396592
216. Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Levenson JD, Kornblau SM, Andreeff M, Muschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M. *MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199*. **Cell Rep**, 2015. 13(12): p. 2715-2727. PMID: 26711339 PMCID: PMC4700051

217. Berg A, Hoivik EA, Mjos S, Holst F, Werner HM, Tangen IL, Taylor-Weiner A, Gibson WJ, Kusonmano K, Wik E, Trovik J, Halle MK, Oyan AM, Kalland KH, Cherniack AD, Beroukhir R, Stefansson I, Mills GB, Krakstad C, Salvesen HB. *Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.* **Oncotarget**, 2015. 6(2): p. 1327-1339. PMID: 25415225 PMCID: 4359236
218. Boggs AE, Vitolo MI, Whipple RA, Charpentier MS, Goloubeva OG, Ioffe OB, Tuttle KC, Slovic J, Lu Y, Mills GB, Martin SS. *alpha-Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration.* **Cancer Res**, 2015. 75(1): p. 203-215. PMID: 25503560 PMCID: 4350791
219. Brown KE, Chagoya G, Kwatra SG, Yen T, Keir ST, Cooter M, Hoadley KA, Rasheed A, Lipp ES, McLendon R, Ali-Osman F, Bigner DD, Sampson JH, Kwatra MM. *Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.* **J Neurochem**, 2015. 133(5): p. 730-738. PMID: 25598002 PMCID: PMC4514443
220. Cancer Genome Atlas N. *Genomic Classification of Cutaneous Melanoma.* **Cell**, 2015. 161(7): p. 1681-1696. PMID: 26091043 PMCID: PMC4580370
221. Cancer Genome Atlas N. *Comprehensive genomic characterization of head and neck squamous cell carcinomas.* **Nature**, 2015. 517(7536): p. 576-582. PMID: 25631445 PMCID: PMC4311405
222. Cancer Genome Atlas Research N. *The Molecular Taxonomy of Primary Prostate Cancer.* **Cell**, 2015. 163(4): p. 1011-1025. PMID: 26544944 PMCID: PMC4695400
223. Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhir R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T, Jr., Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatuzzolo C, Campos B, Carlotti CG, Jr., Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, McLendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J. *Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.* **N Engl J Med**, 2015. 372(26): p. 2481-2498. PMID: 26061751 PMCID: PMC4530011



224. Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE. *ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas*. **Cancer Res**, 2015. 75(17): p. 3554-3567. PMID: 26206558 PMCID: 4558382
225. Cardnell RJ, Behrens C, Diao L, Fan Y, Tang X, Tong P, Minna JD, Mills GB, Heymach JV, Wistuba II, Wang J, Byers LA. *An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2*. **Clin Cancer Res**, 2015. 21(15): p. 3480-3491. PMID: 25878335 PMCID: 4526428
226. Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, Gandhi V. *Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia*. **Clin Cancer Res**, 2015. 21(16): p. 3705-3715. PMID: 25829398 PMCID: 4537801
227. Chen Q, Song S, Wei S, Liu B, Honjo S, Scott A, Jin J, Ma L, Zhu H, Skinner HD, Johnson RL, Ajani JA. *ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer*. **Oncotarget**, 2015. 6(28): p. 25883-25896. PMID: 26317542 PMCID: PMC4694873
228. Cheng H, Fertig EJ, Ozawa H, Hatakeyama H, Howard JD, Perez J, Considine M, Thakar M, Ranaweera R, Krigsfeld G, Chung CH. *Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma*. **Cancer Biol Ther**, 2015. 16(8): p. 1252-1258. PMID: 26046389 PMCID: PMC4623002
229. Cheng PF, Dummer R, Levesque MP. *Data mining The Cancer Genome Atlas in the era of precision cancer medicine*. **Swiss Med Wkly**, 2015. 145: p. w14183. PMID: 26375999 PMCID:
230. Cheraghchi-Bashi A, Parker CA, Curry E, Salazar JF, Gungor H, Saleem A, Cunnea P, Rama N, Salinas C, Mills GB, Morris SR, Kumar R, Gabra H, Stronach EA. *A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway*. **Oncotarget**, 2015. 6(39): p. 41736-41749. PMID: 26497682 PMCID: 4747185
231. Chiu HS, Llobet-Navas D, Yang X, Chung WJ, Ambesi-Impiombato A, Iyer A, Kim HR, Seviour EG, Luo Z, Sehgal V, Moss T, Lu Y, Ram P, Silva J, Mills GB, Califano A, Sumazin P. *Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks*. **Genome Res**, 2015. 25(2): p. 257-267. PMID: 25378249 PMCID: 4315299
232. Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW, McMahon M, Holmen SL. *AKT1 Activation Promotes Development of Melanoma Metastases*. **Cell Rep**, 2015. 13(5): p. 898-905. PMID: 26565903 PMCID: 4646731
233. Cierlitz M, Chauvistre H, Bogeski I, Zhang X, Hauschild A, Herlyn M, Schadendorf D, Vogt T, Roesch A. *Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations*. **Exp Dermatol**, 2015. 24(2): p. 155-157. PMID: 25453510 PMCID: 4335723
234. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, Perou CM. *Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer*. **Cell**, 2015. 163(2): p. 506-519. PMID: 26451490 PMCID: 4603750
235. Creighton CJ, Huang S. *Reverse phase protein arrays in signaling pathways: a data integration perspective*. **Drug Des Devel Ther**, 2015. 9: p. 3519-3527. PMID: 26185419 PMCID: PMC4500628
236. Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, Van't Veer LJ, Spellman PT, Gray JW. *Erratum to: Modeling precision treatment of breast cancer*. **Genome Biol**, 2015. 16: p. 95. PMID: 25962591 PMCID: 4426644
237. Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M. *mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation*. **Cancer Cell**, 2015. 27(1): p. 41-56. PMID: 25584893 PMCID: 4295062
238. Daver N, Bumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, Kawedia JD, Basnett J, Culotta KS, Zeng Z, Lu H, Richie MA, Garris R, Xiao L, Liu W, Baggerly KA, Jabbour E, O'Brien S, Burger J, Bendall LJ, Thomas D, Konopleva M. *A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD*

- Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res*, 2015. 21(12): p. 2704-2714. PMID: 25724525 PMCID: 4470787
239. Do K, Speranza G, Chang LC, Polley EC, Bishop R, Zhu W, Trepel JB, Lee S, Lee MJ, Kinders RJ, Phillips L, Collins J, Lyons J, Jeong W, Antony R, Chen AP, Neckers L, Doroshow JH, Kummar S. *Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors. Invest New Drugs*, 2015. 33(4): p. 921-930. PMID: 26082332 PMCID:
240. Dogruluk T, Tsang YH, Espitia M, Chen F, Chen T, Chong Z, Appadurai V, Dogruluk A, Eterovic AK, Bonnen PE, Creighton CJ, Chen K, Mills GB, Scott KL. *Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. Cancer Res*, 2015. 75(24): p. 5341-5354. PMID: 26627007 PMCID: 4681596
241. Eedunuri VK, Rajapakshe K, Fiskus W, Geng C, Chew SA, Foley C, Shah SS, Shou J, Mohamed JS, Coarfa C, O'Malley BW, Mitsiades N. *miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation. Mol Endocrinol*, 2015. 29(8): p. 1170-1183. PMID: 26066330 PMCID: PMC4518002
242. Engebraaten O, Silwal-Pandit L, Krohn M, Moller EK, Nord S, Fleischer T, Gythfelt HV, Borgen E, Garred O, Fangberget A, Holmen MM, Schlichting E, Skjerven H, Lundgren S, Kristensen VN, Lingjaerde OC, Wist E, Naume B, Borresen-Dale AL. *Molecular response in breast cancer treated with neoadjuvant chemotherapy with and without bevacizumab: Results from NeoAva - a randomized phase II study. Cancer Research*, 2015. 75. PMID: ISI:000356730202237 PMCID:
243. French CL, Ye F, Revetta F, Zhang B, Coffey RJ, Washington MK, Deane NG, Beauchamp RD, Weaver AM. *Linking patient outcome to high throughput protein expression data identifies novel regulators of colorectal adenocarcinoma aggressiveness. F1000Res*, 2015. 4: p. 99. PMID: 26097693 PMCID: PMC4457132
244. Fukunaga-Kalabis M, Hristova DM, Wang JX, Li L, Heppt MV, Wei Z, Gyurdieva A, Webster MR, Oka M, Weeraratna AT, Herlyn M. *UV-Induced Wnt7a in the Human Skin Microenvironment Specifies the Fate of Neural Crest-Like Cells via Suppression of Notch. J Invest Dermatol*, 2015. 135(6): p. 1521-1532. PMID: 25705850 PMCID: 4430391
245. Garnier A, Vykoukal J, Hubertus J, Alt E, von Schweinitz D, Kappler R, Berger M, Ilmer M. *Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells. Int J Oncol*, 2015. 47(1): p. 151-160. PMID: 25998227 PMCID:
246. Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriguez-Aguayo C, Fernandez-de Thomas RJ, Aslan B, Del CMP, Velazquez-Torres G, Previs RA, Pradeep S, Kahraman N, Wang H, Kanlikilicer P, Ozpolat B, Calin G, Sood AK, Lopez-Berestein G. *Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clin Cancer Res*, 2015. 21(9): p. 2127-2137. PMID: 25595279 PMCID: 4417466
247. Grubbs EG, Ng PK, Bui J, Busaidy NL, Chen K, Lee JE, Lu X, Lu H, Meric-Bernstam F, Mills GB, Palmer G, Perrier ND, Scott KL, Shaw KR, Waguespack SG, Williams MD, Yelensky R, Cote GJ. *RET fusion as a novel driver of medullary thyroid carcinoma. J Clin Endocrinol Metab*, 2015. 100(3): p. 788-793. PMID: 25546157 PMCID: 4333032
248. Guo C, Hao C, Shao R, Fang B, Correa AM, Hofstetter WL, Roth JA, Behrens C, Kalhor N, Wistuba II, Swisher SG, Pataer A. *RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer. Oncotarget*, 2015. 6(13): p. 11114-11124. PMID: 25798539 PMCID: 4484443
249. Guo L, Wang J, Yang P, Lu Q, Zhang T, Yang Y. *MicroRNA-200 promotes lung cancer cell growth through FOG2-independent AKT activation. IUBMB Life*, 2015. 67(9): p. 720-725. PMID: 26314828 PMCID: PMC4659740
250. Han L, Diao L, Yu S, Xu X, Li J, Zhang R, Yang Y, Werner HM, Eterovic AK, Yuan Y, Nair N, Minelli R, Tsang YH, Cheung LW, Jeong KJ, Roszik J, Ju Z, Woodman SE, Lu Y, Scott KL, Li JB, Mills GB, Liang H. *The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell*, 2015. 28(4): p. 515-528. PMID: 26439496 PMCID: 4605878
251. Ilmer M, Boiles AR, Regel I, Yokoi K, Michalski CW, Wistuba II, Rodriguez J, Alt E, Vykoukal J. *RSPO2 Enhances Canonical Wnt Signaling to Confer Stemness-Associated Traits to Susceptible Pancreatic Cancer Cells. Cancer Res*, 2015. 75(9): p. 1883-1896. PMID: 25769727 PMCID:
252. Ilmer M, Garnier A, Vykoukal J, Alt E, von Schweinitz D, Kappler R, Berger M. *Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma. Mol Cancer Ther*, 2015. 14(12): p. 2712-2721. PMID: 26516161 PMCID:
253. Ince TA, Sousa AD, Jones MA, Harrell JC, Agoston ES, Krohn M, Selfors LM, Liu W, Chen K, Yong M, Buchwald P, Wang B, Hale KS, Cohick E, Sergeant P, Witt A, Kozhekbaeva Z, Gao S, Agoston AT, Merritt MA, Foster R,

- Rueda BR, Crum CP, Brugge JS, Mills GB. *Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours*. **Nat Commun**, 2015. 6: p. 7419. PMID: 26080861 PMCID: 4473807
254. Jeon YJ, Khelifa S, Ratnikov B, Scott DA, Feng Y, Parisi F, Ruller C, Lau E, Kim H, Brill LM, Jiang T, Rimm DL, Cardiff RD, Mills GB, Smith JW, Osterman AL, Kluger Y, Ronai ZA. *Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies*. **Cancer Cell**, 2015. 27(3): p. 354-369. PMID: 25759021 PMCID: 4356903
255. Ji Z, Wu D, Zhao W, Peng H, Zhao S, Huang D, Zhou X. *Systemic modeling myeloma-osteoclast interactions under normoxic/hypoxic condition using a novel computational approach*. **Sci Rep**, 2015. 5: p. 13291. PMID: 26282073 PMCID: PMC4539608
256. Joe AK, Schnoll-Sussman F, Bresalier RS, Abrams JA, Hibshoosh H, Cheung K, Friedman RA, Yang CS, Milne GL, Liu DD, Lee JJ, Abdul K, Bigg M, Foreman J, Su T, Wang X, Ahmed A, Neugut AI, Akpa E, Lippman SM, Perloff M, Brown PH, Lightdale CJ. *Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus*. **Cancer Prev Res (Phila)**, 2015. 8(12): p. 1131-1137. PMID: 26471236 PMCID: PMC4670789
257. Ju Z, Liu W, Roebuck PL, Siwak DR, Zhang N, Lu Y, Davies MA, Akbani R, Weinstein JN, Mills GB, Coombes KR. *Development of a robust classifier for quality control of reverse-phase protein arrays*. **Bioinformatics**, 2015. 31(6): p. 912-918. PMID: 25380958 PMCID: 4375399
258. Kang Y, Zhang R, Suzuki R, Li SQ, Roife D, Truty MJ, Chatterjee D, Thomas RM, Cardwell J, Wang Y, Wang H, Katz MH, Fleming JB. *Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype*. **Lab Invest**, 2015. 95(2): p. 207-222. PMID: 25485535 PMCID: 4670045
259. Korkola JE, Collisson EA, Heiser L, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, Jakkula L, Feiler H, Lu Y, Mills GB, Spellman PT, Tomlin C, Mukherjee S, Gray JW. *Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer*. **PLoS One**, 2015. 10(7): p. e0133219. PMID: 26181325 PMCID: 4504492
260. Kwong LN, Boland GM, Frederick DT, Helms TL, Akid AT, Miller JP, Jiang S, Cooper ZA, Song X, Seth S, Kamara J, Protopopov A, Mills GB, Flaherty KT, Wargo JA, Chin L. *Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma*. **J Clin Invest**, 2015. 125(4): p. 1459-1470. PMID: 25705882 PMCID: 4396463
261. Labidi-Galy SI, Clauss A, Ng V, Duraisamy S, Elias KM, Piao HY, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Gyorffy B, Kang UB, Ficarro S, Ganesan S, Mills GB, Marto JA, Drapkin R. *Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors*. **Oncogene**, 2015. 34(3): p. 373-383. PMID: 24469047 PMCID: 4112176
262. Liang J, Xu ZX, Ding Z, Lu Y, Yu Q, Werle KD, Zhou G, Park YY, Peng G, Gambello MJ, Mills GB. *Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance*. **Nat Commun**, 2015. 6: p. 7926. PMID: 26272043 PMCID:
263. Liao S, Hartmaier RJ, McGuire KP, Puhalla SL, Luthra S, Chandran UR, Ma T, Bhargava R, Modugno F, Davidson NE, Benz S, Lee AV, Tseng GC, Oesterreich S. *The molecular landscape of premenopausal breast cancer*. **Breast Cancer Res**, 2015. 17: p. 104. PMID: 26251034 PMCID: PMC4531812
264. McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. *Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes*. **PLoS One**, 2015. 10(9): p. e0136851. PMID: 26325287 PMCID: 4556673
265. Meyer K, Albaugh B, Schoenike B, Roopra A. *Type 1 Insulin-Like Growth Factor Receptor/Insulin Receptor Substrate 1 Signaling Confers Pathogenic Activity on Breast Tumor Cells Lacking REST*. **Mol Cell Biol**, 2015. 35(17): p. 2991-3004. PMID: 26100015 PMCID: PMC4525306
266. Mishra S, Kaddi CD, Wang MD. *Pan-cancer analysis for studying cancer stage using protein expression data*. **Conf Proc IEEE Eng Med Biol Soc**, 2015. 2015: p. 8189-8192. PMID: 26738195 PMCID: PMC4983429
267. Mitra R, Lin CC, Eischen CM, Bandyopadhyay S, Zhao Z. *Concordant dysregulation of miR-5p and miR-3p arms of the same precursor microRNA may be a mechanism in inducing cell proliferation and tumorigenesis: a lung cancer study*. **RNA**, 2015. 21(6): p. 1055-1065. PMID: 25852169 PMCID: PMC4436660
268. Moss TJ, Luo Z, Seviour EG, Sehgal V, Lu Y, Hill SM, Rupaimoole R, Lee JS, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Azencott R, Gray JW, Mukherjee S, Mills GB, Ram PT. *Genome-wide perturbations by*

- miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers.* **NPJ Syst Biol Appl**, 2015. 1: p. 15001. PMID: 28725457 PMCID: PMC5516802
269. Nishida Y, Maeda A, Chachad D, Ishizawa J, Qiu YH, Kornblau SM, Kimura S, Andreeff M, Kojima K. *Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapy.* **Cancer Sci**, 2015. 106(12): p. 1705-1713. PMID: 26450753 PMCID: PMC4714665
270. Pettazoni P, Viale A, Shah P, Carugo A, Ying H, Wang H, Genovese G, Seth S, Minelli R, Green T, Huang-Hobbs E, Corti D, Sanchez N, Nezi L, Marchesini M, Kapoor A, Yao W, Francesco ME, Petrocchi A, Deem AK, Scott K, Colla S, Mills GB, Fleming JB, Heffernan TP, Jones P, Toniatti C, DePinho RA, Draetta GF. *Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.* **Cancer Res**, 2015. 75(6): p. 1091-1101. PMID: 25736685 PMCID: 4446709
271. Pham LV, Lu G, Tamayo AT, Chen J, Challagundla P, Jorgensen JL, Medeiros LJ, Ford RJ. *Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RC.* **J Hematol Oncol**, 2015. 8: p. 121. PMID: 26515759 PMCID: PMC4627381
272. Roy A, Skibo J, Kalume F, Ni J, Rankin S, Lu Y, Dobyns WB, Mills GB, Zhao JJ, Baker SJ, Millen KJ. *Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy.* **Elife**, 2015. 4. PMID: 26633882 PMCID: 4744197
273. Ruvolo PP, Qiu Y, Coombes KR, Zhang N, Neeley ES, Ruvolo VR, Hail N, Jr., Borthakur G, Konopleva M, Andreeff M, Kornblau SM. *Phosphorylation of GSK3alpha/beta correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients.* **BBA Clin**, 2015. 4: p. 59-68. PMID: 26674329 PMCID: PMC4661707
274. Scortegagna M, Lau E, Zhang T, Feng Y, Sereduk C, Yin H, De SK, Meeth K, Platt JT, Langdon CG, Halaban R, Pellecchia M, Davies MA, Brown K, Stern DF, Bosenberg M, Ronai ZA. *PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.* **Cancer Res**, 2015. 75(7): p. 1399-1412. PMID: 25712345 PMCID: PMC4383687
275. Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, Kapoor P, Ju Z, Mo Q, Shih Ie M, Uray IP, Wu X, Brown PH, Shen X, Mills GB, Peng G. *ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.* **Cancer Discov**, 2015. 5(7): p. 752-767. PMID: 26069190 PMCID: 4497871
276. Sonnenblick A, Brohee S, Fumagalli D, Rothe F, Vincent D, Ignatiadis M, Desmedt C, Salgado R, Sirtaine N, Loi S, Neven P, Loibl S, Denkert C, Joensuu H, Piccart M, Sotiriou C. *Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.* **Oncotarget**, 2015. 6(30): p. 30306-30316. PMID: 26358523 PMCID: PMC4745800
277. Sonnenblick A, Brohee S, Fumagalli D, Vincent D, Venet D, Ignatiadis M, Salgado R, Van den Eynden G, Rothe F, Desmedt C, Neven P, Loibl S, Denkert C, Joensuu H, Loi S, Sirtaine N, Kellokumpu-Lehtinen PL, Piccart M, Sotiriou C. *Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.* **BMC Med**, 2015. 13: p. 177. PMID: 26234940 PMCID: PMC4522972
278. Sun M, Lai D, Zhang L, Huang X. *Modified SuperCurve Method for Analysis of Reverse-Phase Protein Array Data.* **J Comput Biol**, 2015. 22(8): p. 765-769. PMID: 26052632 PMCID: 4523010
279. Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA. *Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-gamma.* **J Invest Dermatol**, 2015. 135(11): p. 2775-2784. PMID: 26039541 PMCID: 4640965
280. Turley RS, Tokuhiya Y, Toshimitsu H, Lidsky ME, Padussis JC, Fontanella A, Deng W, Augustine CK, Beasley GM, Davies MA, Dewhirst MW, Tyler DS. *Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.* **Ann Surg**, 2015. 261(2): p. 368-377. PMID: 24646553 PMCID: 4431893
281. Vu HL, Rosenbaum S, Purwin TJ, Davies MA, Aplin AE. *RAC1 P29S regulates PD-L1 expression in melanoma.* **Pigment Cell Melanoma Res**, 2015. 28(5): p. 590-598. PMID: 26176707 PMCID: 4675336
282. Wen W, Chen WS, Xiao N, Bender R, Ghazalpour A, Tan Z, Swensen J, Millis SZ, Basu G, Gatalica Z, Press MF. *Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.* **J Mol Diagn**, 2015. 17(5): p. 487-495. PMID: 26320869 PMCID:
283. Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK. *Immunotherapy targeting folate receptor induces cell*

- death associated with autophagy in ovarian cancer.* **Clin Cancer Res**, 2015. 21(2): p. 448-459. PMID: 25416196  
PMCID: 4297546
284. Westin SN, Ju Z, Broaddus RR, Krakstad C, Li J, Pal N, Lu KH, Coleman RL, Hennessy BT, Klempner SJ, Werner HM, Salvesen HB, Cantley LC, Mills GB, Myers AP. *PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.* **Mol Oncol**, 2015. 9(8): p. 1694-1703. PMID: 26045339 PMCID: 4584169
285. Wolfe AR, Debeb BG, Lacerda L, Larson R, Bambhroliya A, Huang X, Bertucci F, Finetti P, Birnbaum D, Van Laere S, Diagaradjan P, Ruffell B, Trenton NJ, Chu K, Hittelman W, Diehl M, Levental I, Ueno NT, Woodward WA. *Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a.* **Breast Cancer Res Treat**, 2015. 154(3): p. 495-508. PMID: 26590814 PMCID: PMC5901982
286. Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, Fan L, Kandalaft LE, Tanyi JL, Li C, Yuan CX, Zhang D, Yuan H, Hua K, Lu Y, Katsaros D, Huang Q, Montone K, Fan Y, Coukos G, Boyd J, Sood AK, Rebbeck T, Mills GB, Dang CV, Zhang L. *Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers.* **Cancer Cell**, 2015. 28(4): p. 529-540. PMID: 26461095 PMCID: 4777353
287. Zhang PW, Chen L, Huang T, Zhang N, Kong XY, Cai YD. *Classifying ten types of major cancers based on reverse phase protein array profiles.* **PLoS One**, 2015. 10(3): p. e0123147. PMID: 25822500 PMCID: PMC4378934
288. Zhao J, Zhao D, Poage GM, Mazumdar A, Zhang Y, Hill JL, Hartman ZC, Savage MI, Mills GB, Brown PH. *Death-associated protein kinase 1 promotes growth of p53-mutant cancers.* **J Clin Invest**, 2015. 125(7): p. 2707-2720. PMID: 26075823 PMCID: 4563671
289. Acharya S, Xu J, Wang X, Jain S, Wang H, Zhang Q, Chang CC, Bower J, Arun B, Seewaldt V, Yu D. *Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib.* **Am J Cancer Res**, 2016. 6(5): p. 981-995. PMID: 27293993 PMCID: 4889714
290. Bastos EP, Brentani H, Pereira CA, Polpo A, Lima L, Puga RD, Pasini FS, Osorio CA, Roela RA, Achatz MI, Trape AP, Gonzalez-Angulo AM, Brentani MM. *A Set of miRNAs, Their Gene and Protein Targets and Stromal Genes Distinguish Early from Late Onset ER Positive Breast Cancer.* **PLoS One**, 2016. 11(5): p. e0154325. PMID: 27152840 PMCID: 4859528
291. Bhattacharya R, Ye XC, Wang R, Ling X, McManus M, Fan F, Boulbes D, Ellis LM. *Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells.* **Cancer Res**, 2016. 76(10): p. 3014-3024. PMID: 26988990 PMCID: PMC4873444
292. Bissig-Choisat B, Kettlun-Leyton C, Legras XD, Zorman B, Barzi M, Chen LL, Amin MD, Huang YH, Pautler RG, Hampton OA, Prakash MM, Yang D, Borowiak M, Muzny D, Doddapaneni HV, Hu J, Shi Y, Gaber MW, Hicks MJ, Thompson PA, Lu Y, Mills GB, Finegold M, Goss JA, Parsons DW, Vasudevan SA, Sumazin P, Lopez-Terrada D, Bissig KD. *Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer.* **J Hepatol**, 2016. 65(2): p. 325-333. PMID: 27117591 PMCID:
293. Budina-Kolomets A, Webster MR, Leu JI, Jennis M, Krepler C, Guerrini A, Kossenkov AV, Xu W, Karakousis G, Schuchter L, Amaravadi RK, Wu H, Yin X, Liu Q, Lu Y, Mills GB, Xu X, George DL, Weeraratna AT, Murphy ME. *HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors.* **Cancer Res**, 2016. 76(9): p. 2720-2730. PMID: 26984758 PMCID: 4939897
294. Cancer Genome Atlas Research N, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhi R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra

- D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Chevillie JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R. *Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma*. **N Engl J Med**, 2016. 374(2): p. 135-145. PMID: 26536169 PMCID: PMC4775252
295. Cardnell RJ, Feng Y, Mukherjee S, Diao L, Tong P, Stewart CA, Masrourpour F, Fan Y, Nilsson M, Shen Y, Heymach JV, Wang J, Byers LA. *Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer*. **PLoS One**, 2016. 11(4): p. e0152584. PMID: 27055253 PMCID: PMC4824499
296. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG, Jr., Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukheim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, Nounshmehr H, Iavarone A, Verhaak RG. *Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma*. **Cell**, 2016. 164(3): p. 550-563. PMID: 26824661 PMCID: 4754110
297. Chae YK, Gagliato Dde M, Pai SG, Carneiro B, Mohindra N, Giles FJ, Ramakrishnan-Geethakumari P, Sohn J, Liu S, Chen H, Ueno N, Hortobagyi G, Gonzalez-Angulo AM. *The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer*. **PLoS One**, 2016. 11(4): p. e0152585. PMID: 27055285 PMCID: 4824503
298. Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, Mills GB. *Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer*. **Cell Rep**, 2016. 15(7): p. 1493-1504. PMID: 27160903 PMCID: 4914391
299. Chen F, Zhang Y, Parra E, Rodriguez J, Behrens C, Akbani R, Lu Y, Kurie JM, Gibbons DL, Mills GB, Wistuba II, Creighton CJ. *Multiplatform-based molecular subtypes of non-small-cell lung cancer*. **Oncogene**, 2016. PMID: 27775076 PMCID:
300. Chen F, Zhang Y, Senbabaoglu Y, Ciriello G, Yang L, Reznik E, Shuch B, Micevic G, De Velasco G, Shinbrot E, Noble MS, Lu Y, Covington KR, Xi L, Drummond JA, Muzny D, Kang H, Lee J, Tamboli P, Reuter V, Shelley CS, Kaiparettu BA, Bottaro DP, Godwin AK, Gibbs RA, Getz G, Kucherlapati R, Park PJ, Sander C, Henske EP, Zhou JH, Kwiatkowski DJ, Ho TH, Choueiri TK, Hsieh JJ, Akbani R, Mills GB, Hakimi AA, Wheeler DA, Creighton CJ. *Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma*. **Cell Rep**, 2016. 14(10): p. 2476-2489. PMID: 26947078 PMCID: 4794376
301. Chen T, Wang Z, Zhou W, Chong Z, Meric-Bernstam F, Mills GB, Chen K. *Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types*. **BMC Genomics**, 2016. 17 Suppl 2: p. 394. PMID: 27356755 PMCID: 4928158
302. Choi JI, Park SH, Lee HJ, Lee DW, Lee HN. *Inhibition of Phospho-S6 Kinase, a Protein Involved in the Compensatory Adaptive Response, Increases the Efficacy of Paclitaxel in Reducing the Viability of Matrix-Attached Ovarian Cancer Cells*. **PLoS One**, 2016. 11(5): p. e0155052. PMID: 27148873 PMCID: PMC4858236
303. Coloff JL, Murphy JP, Braun CR, Harris IS, Shelton LM, Kami K, Gygi SP, Selfors LM, Brugge JS. *Differential Glutamate Metabolism in Proliferating and Quiescent Mammary Epithelial Cells*. **Cell Metab**, 2016. 23(5): p. 867-880. PMID: 27133130 PMCID:
304. den Hollander P, Rawls K, Tsimelzon A, Shepherd J, Mazumdar A, Hill J, Fuqua SA, Chang JC, Osborne CK, Hilsenbeck SG, Mills GB, Brown PH. *Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival*. **Cancer Res**, 2016. 76(7): p. 1942-1953. PMID: 26921331 PMCID: 4873402
305. Dennison JB, Shahmoradgoli M, Liu W, Ju Z, Meric-Bernstam F, Perou CM, Sahin AA, Welm A, Oesterreich S, Sikora MJ, Brown RE, Mills GB. *High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype*. **Clin Cancer Res**, 2016. 22(20): p. 5068-5078. PMID: 27172895 PMCID:

306. Erdem C, Nagle AM, Casa AJ, Litzenburger BC, Wang YF, Taylor DL, Lee AV, Lezon TR. *Proteomic Screening and Lasso Regression Reveal Differential Signaling in Insulin and Insulin-like Growth Factor I (IGF1) Pathways.* **Mol Cell Proteomics**, 2016. 15(9): p. 3045-3057. PMID: 27364358 PMCID: PMC5013316
307. Fatkhutdinov N, Sproesser K, Krepler C, Liu Q, Brafford PA, Herlyn M, Aird KM, Zhang R. *Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma.* **Mol Cancer Res**, 2016. 14(9): p. 767-775. PMID: 27297629 PMCID: 5025362
308. Ferrarotto R, Goonatilake R, Yoo SY, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM. *Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.* **Clin Cancer Res**, 2016. 22(7): p. 1674-1686. PMID: 26597303 PMCID: PMC4818738
309. Goedert L, Pereira CG, Roszik J, Placa JR, Cardoso C, Chen G, Deng W, Yennu-Nanda VG, Silva WA, Jr., Davies MA, Espreafico EM. *RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma.* **Oncotarget**, 2016. 7(24): p. 36711-36718. PMID: 27167340 PMCID: 5095033
310. Haukaas TH, Euceda LR, Giskeodegard GF, Lamichhane S, Krohn M, Jernstrom S, Aure MR, Lingjaerde OC, Schlichting E, Garred O, Due EU, Mills GB, Sahlberg KK, Borresen-Dale AL, Bathen TF. *Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes.* **Cancer Metab**, 2016. 4: p. 12. PMID: 27350877 PMCID: 4922058
311. Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Xu M, Wang-Gillam A, Samatar AA, Maitra A, Wennerberg K, Petricoin EF, 3rd, Yin HH, Nelkin B, Cox AD, Yeh JJ, Der CJ. *Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.* **Cancer Cell**, 2016. 29(1): p. 75-89. PMID: 26725216 PMCID: PMC4816652
312. He N, Kim N, Jeong E, Lu Y, Mills GB, Yoon S. *Glucose starvation induces mutation and lineage-dependent adaptive responses in a large collection of cancer cell lines.* **Int J Oncol**, 2016. 48(1): p. 67-72. PMID: 26573869 PMCID: 4734611
313. Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford P, Gao W, Lu Y, Mills GB, Slingerland JM, Simpkins F. *MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.* **Clin Cancer Res**, 2016. 22(4): p. 935-947. PMID: 26482043 PMCID: 4755805
314. Hill SM, Heiser LM, Cokelaer T, Unger M, Nesser NK, Carlin DE, Zhang Y, Sokolov A, Paull EO, Wong CK, Graim K, Bivol A, Wang H, Zhu F, Afsari B, Danilova LV, Favorov AV, Lee WS, Taylor D, Hu CW, Long BL, Noren DP, Bisberg AJ, Mills GB, Gray JW, Kellen M, Norman T, Friend S, Qutub AA, Fertig EJ, Guan Y, Song M, Stuart JM, Spellman PT, Koepl H, Stolovitzky G, Saez-Rodriguez J, Mukherjee S. *Inferring causal molecular networks: empirical assessment through a community-based effort.* **Nat Methods**, 2016. 13(4): p. 310-318. PMID: 26901648 PMCID: 4854847
315. Iwanicki MP, Chen HY, Iavarone C, Zervantonakis IK, Muranen T, Novak M, Ince TA, Drapkin R, Brugge JS. *Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.* **JCI Insight**, 2016. 1(10). PMID: 27482544 PMCID: 4963159
316. Jeong AL, Han S, Lee S, Su Park J, Lu Y, Yu S, Li J, Chun KH, Mills GB, Yang Y. *Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway.* **Sci Rep**, 2016. 6: p. 27391. PMID: 27272709 PMCID: 4895347
317. Jiang G, Zhang S, Yazdanparast A, Li M, Pawar AV, Liu Y, Inavolu SM, Cheng L. *Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer.* **BMC Genomics**, 2016. 17 Suppl 7: p. 525. PMID: 27556158 PMCID: PMC5001206
318. Jing Y, Zhang Z, Ma P, An S, Shen Y, Zhu L, Zhuang G. *Concomitant BET and MAPK blockade for effective treatment of ovarian cancer.* **Oncotarget**, 2016. 7(3): p. 2545-2554. PMID: 26575423 PMCID: 4823054
319. Kalinsky K, Zheng T, Hibshoosh H, Du X, Mundi P, Yang J, Refice S, Feldman SM, Taback B, Connolly E, Crew KD, Maurer MA, Hershman DL. *Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial.* **Clin Transl Oncol**, 2016. PMID: 27305912 PMCID:
320. Kim JA, Tan Y, Wang X, Cao X, Veeraraghavan J, Liang Y, Edwards DP, Huang S, Pan X, Li K, Schiff R, Wang XS. *Comprehensive functional analysis of the tousel-like kinase 2 frequently amplified in aggressive luminal breast cancers.* **Nat Commun**, 2016. 7: p. 12991. PMID: 27694828 PMCID: PMC5064015
321. Kim N, Song M, Kim S, Seo Y, Kim Y, Yoon S. *Differential regulation and synthetic lethality of exclusive RB1 and CDKN2A mutations in lung cancer.* **Int J Oncol**, 2016. 48(1): p. 367-375. PMID: 26647789 PMCID:

322. Kim N, Yim HY, He N, Lee CJ, Kim JH, Choi JS, Lee HS, Kim S, Jeong E, Song M, Jeon SM, Kim WY, Mills GB, Cho YY, Yoon S. *Cardiac glycosides display selective efficacy for STK11 mutant lung cancer*. **Sci Rep**, 2016. 6: p. 29721. PMID: 27431571 PMCID: 4949473
323. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhietty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airolidi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algul H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auburger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantiaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Banhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolome A, Bassham DC, Bassi MT, Bast RC, Jr., Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Jr., Becker C, Beckham JD, Bedard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, Benard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Bockler S, Boes M, Boesze-Battaglia K, Boise LH, Bolino A, Boman A, Bonaldo P, Bordi M, Bosch J, Botana LM, Botti J, Bou G, Bouche M, Bouchecareilh M, Boucher MJ, Boulton ME, Bouret SG, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady N, Braga VM, Brancolini C, Braus GH, Bravo-San Pedro JM, Brennan LA, Bresnick EH, Brest P, Bridges D, Bringer MA, Brini M, Brito GC, Brodin B, Brookes PS, Brown EJ, Brown K, Broxmeyer HE, Bruhat A, Brum PC, Brumell JH, Brunetti-Pierri N, Bryson-Richardson RJ, Buch S, Buchan AM, Budak H, Bulavin DV, Bultman SJ, Bultynck G, Bumbasirevic V, Burelle Y, Burke RE, Burmeister M, Butikofer P, Caberlotto L, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calatayud S, Camougrand N, Campanella M, Campbell GR, Campbell M, Campello S, Candau R, Caniggia I, Cantoni L, Cao L, Caplan AB, Caraglia M, Cardinali C, Cardoso SM, Carew JS, Carleton LA, Carlin CR, Carloni S, Carlsson SR, Carmona-Gutierrez D, Carneiro LA, Carnevali O, Carra S, Carrier A, Carroll B, Casas C, Casas J, Cassinelli G, Castets P, Castro-Obregon S, Cavallini G, Ceccherini I, Cecconi F, Cederbaum AI, Cena V, Cenci S, Cerella C, Cervia D, Cetrullo S, Chaachouay H, Chae HJ, Chagin AS, Chai CY, Chakrabarti G, Chamilos G, Chan EY, Chan MT, Chandra D, Chandra P, Chang CP, Chang RC, Chang TY, Chatham JC, Chatterjee S, Chauhan S, Che Y, Cheetham ME, Cheluvappa R, Chen CJ, Chen G, Chen GC, Chen H, Chen JW, Chen JK, Chen M, Chen P, Chen Q, Chen SD, Chen S, Chen SS, Chen W, Chen WJ, Chen WQ, Chen X, Chen YH, Chen YG, Chen Y, Chen YJ, Chen YQ, Chen Z, Cheng A, Cheng CH, Cheng H, Cheong H, Cherry S, Chesney J, Cheung CH, Chevet E, Chi HC, Chi SG, Chiacchiera F, Chiang HL, Chiarelli R, Chiariello M, Chieppa M, Chin LS, Chiong M, Chiu GN, Cho DH, Cho SG, Cho WC, Cho YY, Cho YS, Choi AM, Choi EJ, Choi EK, Choi J, Choi ME, Choi SI, Chou TF, Chouaib S, Choubey D, Choubey V, Chow KC, Chowdhury K, Chu CT, Chuang TH, Chun T, Chung H, Chung T, Chung YL, Chwae YJ, Cianfanelli V, Ciarcia R, Ciecchomska IA, Ciriolo MR, Cirone M, Claerhout S, Clague MJ, Claria J, Clarke PG, Clarke R, Clementi E, Cleyrat C, Cnop M, Coccia EM, Cocco T, Codogno P, Coers J, Cohen EE, Colecchia D, Coletto L, Coll NS, Colucci-Guyon E, Comincini S, Condello M, Cook KL, Coombs GH, Cooper CD, Cooper JM, Coppens I, Corasaniti MT, Corazzari M, Corbalan R, Corcelle-Termeau E, Cordero MD, Corral-Ramos C, Corti O, Cossarizza A, Costelli P, Costes S, Cotman SL, Coto-Montes A, Cottet S, Couve E, Covey LR, Cowart LA, Cox JS, Coxon FP, Coyne CB, Cragg MS, Craven RJ, Crepaldi T, Crespo JL, Criollo A, Crippa V, Cruz MT, Cuervo AM, Cuezva JM, Cui T, Cutillas PR, Czaja MJ, Czyzyk-Krzeska MF, Dagda RK, Dahmen U, Dai C, Dai W, Dai Y, Dalby KN, Dalla Valle L, Dalmasso G, D'Amelio M, Damme M, Darfeuille-Michaud A, Dargemont C, Darley-Usmar VM, Dasarathy S, Dasgupta B, Dash S, Dass CR, Davey HM, Davids LM, Davila D, Davis RJ, Dawson TM, Dawson VL, Daza P, de Belleruche J, de Figueiredo P, de Figueiredo RC, de la Fuente J, De Martino L, De Matteis A, De Meyer GR, De Milito A, De Santi M, de Souza W, De Tata V, De Zio D, Debnath J, Dechant R, Decuypere JP, Deegan S, Dehay B, Del Bello B, Del Re DP, Delage-Mourroux R, Delbridge LM, Deldicque L, Delorme-Axford E, Deng Y, Dengjel J, Denizot M, Dent P, Der CJ, Deretic V, Derrien B, Deutsch E, Devarenne TP, Devenish RJ, Di Bartolomeo S, Di Daniele N, Di



Domenico F, Di Nardo A, Di Paola S, Di Pietro A, Di Renzo L, DiAntonio A, Diaz-Araya G, Diaz-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dickey CA, Dickson RC, Diederich M, Digard P, Dikic I, Dinesh-Kumar SP, Ding C, Ding WX, Ding Z, Dini L, Distler JH, Diwan A, Djavaheri-Mergny M, Dmytruk K, Dobson RC, Doetsch V, Dokladny K, Dokudovskaya S, Donadelli M, Dong XC, Dong X, Dong Z, Donohue TM, Jr., Doran KS, D'Orazi G, Dorn GW, 2nd, Dosenko V, Dridi S, Drucker L, Du J, Du LL, Du L, du Toit A, Dua P, Duan L, Duann P, Dubey VK, Duchon MR, Duchosal MA, Duez H, Dugail I, Dumit VI, Duncan MC, Dunlop EA, Dunn WA, Jr., Dupont N, Dupuis L, Duran RV, Durcan TM, Duvezin-Caubet S, Duvvuri U, Eapen V, Ebrahimi-Fakhari D, Echard A, Eckhart L, Edelstein CL, Edinger AL, Eichinger L, Eisenberg T, Eisenberg-Lerner A, Eissa NT, El-Deiry WS, El-Khoury V, Elazar Z, Eldar-Finkelman H, Elliott CJ, Emanuele E, Emmenegger U, Engedal N, Engelbrecht AM, Engelender S, Enserink JM, Erdmann R, Erenpreisa J, Eri R, Eriksen JL, Erman A, Escalante R, Eskelinen EL, Espert L, Esteban-Martinez L, Evans TJ, Fabri M, Fabrias G, Fabrizi C, Facchiano A, Faergeman NJ, Faggioni A, Fairlie WD, Fan C, Fan D, Fan J, Fang S, Fanto M, Fanzani A, Farkas T, Faure M, Favier FB, Fearnhead H, Federici M, Fei E, Felizardo TC, Feng H, Feng Y, Ferguson TA, Fernandez AF, Fernandez-Barrena MG, Fernandez-Checa JC, Fernandez-Lopez A, Fernandez-Zapico ME, Feron O, Ferraro E, Ferreira-Halder CV, Fesus L, Feuer R, Fiesel FC, Filippi-Chiela EC, Filomeni G, Fimia GM, Fingert JH, Finkbeiner S, Finkel T, Fiorito F, Fisher PB, Flajolet M, Flamigni F, Florey O, Florio S, Floto RA, Folini M, Follo C, Fon EA, Fornai F, Fortunato F, Fraldi A, Franco R, Francois A, Frankel LB, Fraser ID, Frey N, Freyssenet DG, Frezza C, Friedman SL, Frigo DE, Fu D, Fuentes JM, Fueyo J, Fujitani Y, Fujiwara Y, Fujiya M, Fukuda M, Fulda S, Fusco C, Gabryel B, Gaestel M, Gailly P, Gajewska M, Galadari S, Galili G, Galindo I, Galindo MF, Galliciotti G, Galluzzi L, Galy V, Gammoh N, Gandy S, Ganesan AK, Ganesan S, Ganley IG, Gannage M, Gao FB, Gao F, Gao JX, Garcia Nannig L, Garcia Vescovi E, Garcia-Macia M, Garcia-Ruiz C, Garg AD, Garg PK, Gargini R, Gassen NC, Gatica D, Gatti E, Gavard J, Gavathiotis E, Ge L, Ge P, Ge S, Gean PW, Gelmetti V, Genazzani AA, Geng J, Genschik P, Gerner L, Gestwicki JE, Gewirtz DA, Ghavami S, Ghigo E, Ghosh D, Giammarioli AM, Giampieri F, Giampietri C, Giatromanolaki A, Gibbings DJ, Gibellini L, Gibson SB, Ginet V, Giordano A, Giorgini F, Giovannetti E, Girardin SE, Gispert S, Giuliano S, Gladson CL, Glavic A, Gleave M, Godefroy N, Gogal RM, Jr., Gokulan K, Goldman GH, Goletti D, Goligorsky MS, Gomes AV, Gomes LC, Gomez H, Gomez-Manzano C, Gomez-Sanchez R, Goncalves DA, Goncu E, Gong Q, Gongora C, Gonzalez CB, Gonzalez-Alegre P, Gonzalez-Cabo P, Gonzalez-Polo RA, Goping IS, Gorbea C, Gorbunov NV, Goring DR, Gorman AM, Gorski SM, Goruppi S, Goto-Yamada S, Gotor C, Gottlieb RA, Gozes I, Gozuacik D, Graba Y, Graef M, Granato GE, Grant GD, Grant S, Gravina GL, Green DR, Greenhough A, Greenwood MT, Grimaldi B, Gros F, Grose C, Groulx JF, Gruber F, Grumati P, Grune T, Guan JL, Guan KL, Guerra B, Guillen C, Gulshan K, Gunst J, Guo C, Guo L, Guo M, Guo W, Guo XG, Gust AA, Gustafsson AB, Gutierrez E, Gutierrez MG, Gwak HS, Haas A, Haber JE, Hadano S, Hagedorn M, Hahn DR, Halayko AJ, Hamacher-Brady A, Hamada K, Hamai A, Hamann A, Hamasaki M, Hamer I, Hamid Q, Hammond EM, Han F, Han W, Handa JT, Hanover JA, Hansen M, Harada M, Harhaji-Trajkovic L, Harper JW, Harrath AH, Harris AL, Harris J, Hasler U, Hasselblatt P, Hasui K, Hawley RG, Hawley TS, He C, He CY, He F, He G, He RR, He XH, He YW, He YY, Heath JK, Hebert MJ, Heinzen RA, Helgason GV, Hensel M, Henske EP, Her C, Herman PK, Hernandez A, Hernandez C, Hernandez-Tiedra S, Hetz C, Hiesinger PR, Higaki K, Hilfiker S, Hill BG, Hill JA, Hill WD, Hino K, Hofius D, Hofman P, Hoglinger GU, Hohfeld J, Holz MK, Hong Y, Hood DA, Hoozemans JJ, Hoppe T, Hsu C, Hsu CY, Hsu LC, Hu D, Hu G, Hu HM, Hu H, Hu MC, Hu YC, Hu ZW, Hua F, Hua Y, Huang C, Huang HL, Huang KH, Huang KY, Huang S, Huang WP, Huang YR, Huang Y, Huber TB, Huebbe P, Huh WK, Hulmi JJ, Hur GM, Hurley JH, Husak Z, Hussain SN, Hussain S, Hwang JJ, Hwang S, Hwang TI, Ichihara A, Imai Y, Imbriano C, Inomata M, Into T, Iovane V, Iovanna JL, Iozzo RV, Ip NY, Irazoqui JE, Iribarren P, Isaka Y, Isakovic AJ, Ischiropoulos H, Isenberg JS, Ishaq M, Ishida H, Ishii I, Ishmael JE, Isidoro C, Isobe K, Isono E, Issazadeh-Navikas S, Itahana K, Itakura E, Ivanov AI, Iyer AK, Izquierdo JM, Izumi Y, Izzo V, Jaattela M, Jaber N, Jackson DJ, Jackson WT, Jacob TG, Jacques TS, Jagannath C, Jain A, Jana NR, Jang BK, Jani A, Janji B, Jannig PR, Jansson PJ, Jean S, Jendrach M, Jeon JH, Jessen N, Jeung EB, Jia K, Jia L, Jiang H, Jiang L, Jiang T, Jiang X, Jiang Y, Jimenez A, Jin C, Jin H, Jin L, Jin M, Jin S, Jinwal UK, Jo EK, Johansen T, Johnson DE, Johnson GV, Johnson JD, Jonasch E, Jones C, Joosten LA, Jordan J, Joseph AM, Joseph B, Joubert AM, Ju D, Ju J, Juan HF, Juenemann K, Juhasz G, Jung HS, Jung JU, Jung YK, Jungbluth H, Justice MJ, Jutten B, Kaakoush NO, Kaarniranta K, Kaasik A, Kabuta T, Kaeffer B, Kagedal K, Kahana A, Kajimura S, Kakhlon O, Kalia M, Kalvakolanu DV, Kamada Y, Kambas K, Kaminsky VO, Kampinga HH, Kandouz M, Kang C, Kang R, Kang TC, Kanki T, Kanneganti TD, Kanno H, Kanthasamy AG, Kantorow M, Kaparakis-Liaskos M, Kapuy O, Karantza V, Karim MR, Karmakar P, Kaser A, Kaushik S, Kawula T, Kaynar AM, Ke PY, Ke ZJ, Kehrl JH, Keller KE, Kemper JK, Kenworthy AK, Kepp O, Kern A, Kesari S, Kessel D, Ketteler R, Kettelhut Ido C, Khambu B, Khan MM,

Khandelwal VK, Khare S, Kiang JG, Kiger AA, Kihara A, Kim AL, Kim CH, Kim DR, Kim DH, Kim EK, Kim HY, Kim HR, Kim JS, Kim JH, Kim JC, Kim KW, Kim MD, Kim MM, Kim PK, Kim SW, Kim SY, Kim YS, Kim Y, Kimchi A, Kimmelman AC, Kimura T, King JS, Kirkegaard K, Kirkin V, Kirshenbaum LA, Kishi S, Kitajima Y, Kitamoto K, Kitaoka Y, Kitazato K, Kley RA, Klimecki WT, Klinkenberg M, Klucken J, Knaevelsrud H, Knecht E, Knuppertz L, Ko JL, Kobayashi S, Koch JC, Koechlin-Ramonatxo C, Koenig U, Koh YH, Kohler K, Kohlwein SD, Koike M, Komatsu M, Kominami E, Kong D, Kong HJ, Konstantakou EG, Kopp BT, Korcsmaros T, Korhonen L, Korolchuk VI, Koshkina NV, Kou Y, Koukourakis MI, Koumenis C, Kovacs AL, Kovacs T, Kovacs WJ, Koya D, Kraft C, Krainc D, Kramer H, Kravic-Stevovic T, Krek W, Kretz-Remy C, Krick R, Krishnamurthy M, Kriston-Vizi J, Kroemer G, Kruer MC, Kruger R, Ktistakis NT, Kuchitsu K, Kuhn C, Kumar AP, Kumar A, Kumar D, Kumar R, Kumar S, Kundu M, Kung HJ, Kuno A, Kuo SH, Kuret J, Kurz T, Kwok T, Kwon TK, Kwon YT, Kyrmizi I, La Spada AR, Lafont F, Lahm T, Lakkaraju A, Lam T, Lamark T, Lancel S, Landowski TH, Lane DJ, Lane JD, Lanzi C, Lapaquette P, Lapierre LR, Laporte J, Laukkarinen J, Laurie GW, Lavandero S, Lavie L, LaVoie MJ, Law BY, Law HK, Law KB, Layfield R, Lazo PA, Le Cam L, Le Roch KG, Le Stunff H, Leardkamolkarn V, Lecuit M, Lee BH, Lee CH, Lee EF, Lee GM, Lee HJ, Lee H, Lee JK, Lee J, Lee JH, Lee M, Lee MS, Lee PJ, Lee SW, Lee SJ, Lee SY, Lee SH, Lee SS, Lee S, Lee YR, Lee YJ, Lee YH, Leeuwenburgh C, Lefort S, Legouis R, Lei J, Lei QY, Leib DA, Leibowitz G, Lekli I, Lemaire SD, Lemasters JJ, Lemberg MK, Lemoine A, Leng S, Lenz G, Lenzi P, Lerman LO, Lettieri Barbato D, Leu JI, Leung HY, Levine B, Lewis PA, Lezoualc'h F, Li C, Li F, Li FJ, Li J, Li K, Li L, Li M, Li Q, Li R, Li S, Li W, Li X, Li Y, Lian J, Liang C, Liang Q, Liao Y, Liberal J, Liberski PP, Lie P, Lieberman AP, Lim HJ, Lim KL, Lim K, Lima RT, Lin CS, Lin CF, Lin F, Lin FC, Lin K, Lin KH, Lin PH, Lin T, Lin WW, Lin YS, Lin Y, Linden R, Lindholm D, Lindqvist LM, Lingor P, Linkermann A, Liotta LA, Lipinski MM, Lira VA, Lisanti MP, Liton PB, Liu B, Liu C, Liu CF, Liu F, Liu HJ, Liu J, Liu JJ, Liu JL, Liu K, Liu L, Liu Q, Liu RY, Liu S, Liu W, Liu XD, Liu X, Liu XH, Liu Y, Liu Z, Liuzzi JP, Lizard G, Ljujic M, Lodhi IJ, Logue SE, Lokeshwar BL, Long YC, Lonial S, Loos B, Lopez-Otin C, Lopez-Vicario C, Lorente M, Lorenzi PL, Lorincz P, Los M, Lotze MT, Lovat PE, Lu B, Lu J, Lu Q, Lu SM, Lu S, Lu Y, Luciano F, Luckhart S, Lucocq JM, Ludovico P, Lugea A, Lukacs NW, Lum JJ, Lund AH, Luo H, Luo J, Luo S, Luparello C, Lyons T, Ma J, Ma Y, Ma Z, Machado J, Machado-Santelli GM, Macian F, MacIntosh GC, MacKeigan JP, Macleod KF, MacMicking JD, MacMillan-Crow LA, Madeo F, Madesh M, Madrigal-Matute J, Maeda A, Maeda T, Maegawa G, Maellaro E, Maes H, Magarinos M, Maiese K, Maiti TK, Maiuri L, Maiuri MC, Maki CG, Malli R, Malorni W, Maloyan A, Mami-Chouaib F, Man N, Mancias JD, Mandelkow EM, Mandell MA, Manfredi AA, Manie SN, Manzoni C, Mao K, Mao Z, Mao ZW, Marambaud P, Marconi AM, Marelja Z, Marfe G, Margeta M, Margittai E, Mari M, Mariani FV, Marin C, Marinelli S, Marino G, Markovic I, Marquez R, Martelli AM, Martens S, Martin KR, Martin SJ, Martin S, Martin-Acebes MA, Martin-Sanz P, Martinand-Mari C, Martinet W, Martinez J, Martinez-Lopez N, Martinez-Outschoorn U, Martinez-Velazquez M, Martinez-Vicente M, Martins WK, Mashima H, Mastrianni JA, Matarese G, Matarrese P, Mateo R, Matoba S, Matsumoto N, Matsushita T, Matsuura A, Matsuzawa T, Mattson MP, Matus S, Maugeri N, Mauvezin C, Mayer A, Maysinger D, Mazzolini GD, McBrayer MK, McCall K, McCormick C, McInerney GM, McIver SC, McKenna S, McMahon JJ, McNeish IA, Mechta-Grigoriou F, Medema JP, Medina DL, Megyeri K, Mehrpour M, Mehta JL, Mei Y, Meier UC, Meijer AJ, Melendez A, Melino G, Melino S, de Melo EJ, Mena MA, Meneghini MD, Menendez JA, Menezes R, Meng L, Meng LH, Meng S, Menghini R, Menko AS, Menna-Barreto RF, Menon MB, Meraz-Rios MA, Merla G, Merlini L, Merlot AM, Meryk A, Meschini S, Meyer JN, Mi MT, Miao CY, Micale L, Michaeli S, Michiels C, Migliaccio AR, Mihailidou AS, Mijaljica D, Mikoshiba K, Milan E, Miller-Fleming L, Mills GB, Mills IG, Minakaki G, Minassian BA, Ming XF, Minibayeva F, Minina EA, Mintern JD, Minucci S, Miranda-Vizuete A, Mitchell CH, Miyamoto S, Miyazawa K, Mizushima N, Mnich K, Mograbi B, Mohseni S, Moita LF, Molinari M, Moller AB, Mollereau B, Mollinedo F, Mongillo M, Monick MM, Montagnaro S, Montell C, Moore DJ, Moore MN, Mora-Rodriguez R, Moreira PI, Morel E, Morelli MB, Moreno S, Morgan MJ, Moris A, Moriyasu Y, Morrison JL, Morrison LA, Morselli E, Moscat J, Moseley PL, Mostowy S, Motori E, Mottet D, Mottram JC, Moussa CE, Mpakou VE, Mukhtar H, Mulcahy Levy JM, Muller S, Munoz-Moreno R, Munoz-Pinedo C, Munz C, Murphy ME, Murray JT, Murthy A, Mysorekar IU, Nabi IR, Nabissi M, Nader GA, Nagahara Y, Nagai Y, Nagata K, Nagelkerke A, Nagy P, Naidu SR, Nair S, Nakano H, Nakatogawa H, Nanjundan M, Napolitano G, Naqvi NI, Nardacci R, Narendra DP, Narita M, Nascimbeni AC, Natarajan R, Navegantes LC, Nawrocki ST, Nazarko TY, Nazarko VY, Neill T, Neri LM, Netea MG, Netea-Maier RT, Neves BM, Ney PA, Nezis IP, Nguyen HT, Nguyen HP, Nicot AS, Nilsen H, Nilsson P, Nishimura M, Nishino I, Niso-Santano M, Niu H, Nixon RA, Njar VC, Noda T, Noegel AA, Nolte EM, Norberg E, Norga KK, Nourcini SK, Notomi S, Notterpek L, Nowikovsky K, Nukina N, Nurnberger T, O'Donnell VB, O'Donovan T, O'Dwyer PJ, Oehme I, Oeste CL, Ogawa M, Ogretmen B, Ogura Y, Oh YJ, Ohmuraya M, Ohshima T, Ojha R, Okamoto K, Okazaki T, Oliver FJ, Ollinger K, Olsson S, Orban DP,

Ordonez P, Orhon I, Orosz L, O'Rourke EJ, Orozco H, Ortega AL, Ortona E, Osellame LD, Oshima J, Oshima S, Osiewacz HD, Otomo T, Otsu K, Ou JH, Outeiro TF, Ouyang DY, Ouyang H, Overholtzer M, Ozbun MA, Ozdinler PH, Ozpolat B, Pacelli C, Paganetti P, Page G, Pages G, Pagnini U, Pajak B, Pak SC, Pakos-Zebrucka K, Pakpour N, Palkova Z, Palladino F, Pallauf K, Pallet N, Palmieri M, Paludan SR, Palumbo C, Palumbo S, Pampiega O, Pan H, Pan W, Panaretakis T, Pandey A, Pantazopoulou A, Papackova Z, Papademetrio DL, Papassideri I, Papini A, Parajuli N, Pardo J, Parekh VV, Parenti G, Park JI, Park J, Park OK, Parker R, Parlato R, Parys JB, Parzych KR, Pasquet JM, Pasquier B, Pasumarthi KB, Patschan D, Patterson C, Pattingre S, Pattison S, Pause A, Pavenstadt H, Pavone F, Pedrozo Z, Pena FJ, Penalva MA, Pende M, Peng J, Penna F, Penninger JM, Pensalfini A, Pepe S, Pereira GJ, Pereira PC, Perez-de la Cruz V, Perez-Perez ME, Perez-Rodriguez D, Perez-Sala D, Perier C, Perl A, Perlmutter DH, Perrotta I, Pervaiz S, Pesonen M, Pessin JE, Peters GJ, Petersen M, Petrache I, Petrof BJ, Petrovski G, Phang JM, Piacentini M, Pierdominici M, Pierre P, Pierrefite-Carle V, Pietrocola F, Pimentel-Muinos FX, Pinar M, Pineda B, Pinkas-Kramarski R, Pinti M, Pinton P, Piperdi B, Piret JM, Platanias LC, Platta HW, Plowey ED, Poggeler S, Poirot M, Polcic P, Poletti A, Poon AH, Popelka H, Popova B, Poprawa I, Poulouse SM, Poulton J, Powers SK, Powers T, Pozuelo-Rubio M, Prak K, Prange R, Prescott M, Priault M, Prince S, Proia RL, Proikas-Cezanne T, Prokisch H, Promponas VJ, Przyklenk K, Puertollano R, Pugazhenth S, Puglielli L, Pujol A, Puyal J, Pyeon D, Qi X, Qian WB, Qin ZH, Qiu Y, Qu Z, Quadrilatero J, Quinn F, Raben N, Rabinowich H, Radogna F, Ragusa MJ, Rahmani M, Raina K, Ramanadham S, Ramesh R, Rami A, Randall-Demllo S, Randow F, Rao H, Rao VA, Rasmussen BB, Rasse TM, Ratovitski EA, Rautou PE, Ray SK, Razani B, Reed BH, Reggiori F, Rehm M, Reichert AS, Rein T, Reiner DJ, Reits E, Ren J, Ren X, Renna M, Reusch JE, Revuelta JL, Reyes L, Rezaie AR, Richards RI, Richardson DR, Richetta C, Riehle MA, Rihn BH, Rikihisa Y, Riley BE, Rimbach G, Rippo MR, Ritis K, Rizzi F, Rizzo E, Roach PJ, Robbins J, Roberge M, Roca G, Roccheri MC, Rocha S, Rodrigues CM, Rodriguez CI, de Cordoba SR, Rodriguez-Muela N, Roelofs J, Rogov VV, Rohn TT, Rohrer B, Romanelli D, Romani L, Romano PS, Roncero MI, Rosa JL, Rosello A, Rosen KV, Rosenstiel P, Rost-Roszkowska M, Roth KA, Roue G, Rouis M, Rouschop KM, Ruan DT, Ruano D, Rubinsztein DC, Rucker EB, 3rd, Rudich A, Rudolf E, Rudolf R, Ruegg MA, Ruiz-Roldan C, Ruparelia AA, Rusmini P, Russ DW, Russo GL, Russo G, Russo R, Rusten TE, Ryabovol V, Ryan KM, Ryter SW, Sabatini DM, Sacher M, Sachse C, Sack MN, Sadoshima J, Saftig P, Sagi-Eisenberg R, Sahni S, Saikumar P, Saito T, Saitoh T, Sakakura K, Sakoh-Nakatogawa M, Sakuraba Y, Salazar-Roa M, Salomoni P, Saluja AK, Salvaterra PM, Salvioli R, Samali A, Sanchez AM, Sanchez-Alcazar JA, Sanchez-Prieto R, Sandri M, Sanjuan MA, Santaguida S, Santambrogio L, Santoni G, Dos Santos CN, Saran S, Sardiello M, Sargent G, Sarkar P, Sarkar S, Sarrias MR, Sarwal MM, Sasakawa C, Sasaki M, Sass M, Sato K, Sato M, Satriano J, Savaraj N, Saveljeva S, Schaefer L, Schaible UE, Scharl M, Schatzl HM, Schekman R, Scheper W, Schiavi A, Schipper HM, Schmeisser H, Schmidt J, Schmitz I, Schneider BE, Schneider EM, Schneider JL, Schon EA, Schonenberger MJ, Schonthal AH, Schorderet DF, Schroder B, Schuck S, Schulze RJ, Schwarten M, Schwarz TL, Sciarretta S, Scotto K, Scovassi AI, Screatton RA, Screen M, Seca H, Sedej S, Segatori L, Segev N, Seglen PO, Segui-Simarro JM, Segura-Aguilar J, Seki E, Sell C, Seilliez I, Semenkovich CF, Semenza GL, Sen U, Serra AL, Serrano-Puebla A, Sesaki H, Setoguchi T, Settembre C, Shacka JJ, Shajahan-Haq AN, Shapiro IM, Sharma S, She H, Shen CK, Shen CC, Shen HM, Shen S, Shen W, Sheng R, Sheng X, Sheng ZH, Shepherd TG, Shi J, Shi Q, Shi Y, Shibutani S, Shibuya K, Shidoji Y, Shieh JJ, Shih CM, Shimada Y, Shimizu S, Shin DW, Shinohara ML, Shintani M, Shintani T, Shioi T, Shirabe K, Shiri-Sverdlov R, Shirihai O, Shore GC, Shu CW, Shukla D, Sibirny AA, Sica V, Sigurdson CJ, Sigurdsson EM, Sijwali PS, Sikorska B, Silveira WA, Silvente-Poirot S, Silverman GA, Simak J, Simmet T, Simon AK, Simon HU, Simone C, Simons M, Simonsen A, Singh R, Singh SV, Singh SK, Sinha D, Sinha S, Sinicrope FA, Sirko A, Sirohi K, Sishi BJ, Sittler A, Siu PM, Sivridis E, Skwarska A, Slack R, Slaninova I, Slavov N, Smaili SS, Smalley KS, Smith DR, Soenen SJ, Soleimanpour SA, Solhaug A, Somasundaram K, Son JH, Sonawane A, Song C, Song F, Song HK, Song JX, Song W, Soo KY, Sood AK, Soong TW, Soontornniyomkij V, Sorice M, Sotgia F, Soto-Pantoja DR, Sotthibundhu A, Sousa MJ, Spaik HP, Span PN, Spang A, Sparks JD, Speck PG, Spector SA, Spies CD, Springer W, Clair DS, Stacchiotti A, Staels B, Stang MT, Starczynowski DT, Starokadomskyy P, Steegborn C, Steele JW, Stefanis L, Steffan J, Stellrecht CM, Stenmark H, Stepkowski TM, Stern ST, Stevens C, Stockwell BR, Stoka V, Storchova Z, Stork B, Stratoulas V, Stravopodis DJ, Strnad P, Strohecker AM, Strom AL, Stromhaug P, Stulik J, Su YX, Su Z, Subauste CS, Subramaniam S, Sue CM, Suh SW, Sui X, Sukseree S, Sulzer D, Sun FL, Sun J, Sun SY, Sun Y, Sundaramoorthy V, Sung J, Suzuki H, Suzuki K, Suzuki N, Suzuki T, Suzuki YJ, Swanson MS, Swanton C, Sward K, Swarup G, Sweeney ST, Sylvester PW, Szatmari Z, Szegezdi E, Szlosarek PW, Taegtmeier H, Tafani M, Taillebourg E, Tait SW, Takacs-Vellai K, Takahashi Y, Takats S, Takemura G, Takigawa N, Talbot NJ, Tamagno E, Tamburini J, Tan CP, Tan L, Tan ML, Tan M, Tan YJ, Tanaka K, Tanaka M, Tang D,

- Tang G, Tanida I, Tanji K, Tannous BA, Tapia JA, Tasset-Cuevas I, Tatar M, Tavassoly I, Tavernarakis N, Taylor A, Taylor GS, Taylor GA, Taylor JP, Taylor MJ, Tchetina EV, Tee AR, Teixeira-Clerc F, Telang S, Tencomnao T, Teng BB, Teng RJ, Terro F, Tettamanti G, Theiss AL, Theron AE, Thomas KJ, Thome MP, Thomes PG, Thorburn A, Thorner J, Thum T, Thumm M, Thurston TL, Tian L, Till A, Ting JP, Titorenko VI, Toker L, Toldo S, Tooze SA, Topisirovic I, Torgersen ML, Torosantucci L, Torriglia A, Torrisi MR, Tournier C, Towns R, Trajkovic V, Travassos LH, Triola G, Tripathi DN, Trisciuglio D, Troncoso R, Trougakos IP, Truttman AC, Tsai KJ, Tschan MP, Tseng YH, Tsukuba T, Tsung A, Tsvetkov AS, Tu S, Tuan HY, Tucci M, Tumbarello DA, Turk B, Turk V, Turner RF, Tveita AA, Tyagi SC, Ubukata M, Uchiyama Y, Udelnow A, Ueno T, Umekawa M, Umemiya-Shirafuji R, Underwood BR, Ungermann C, Ureshino RP, Ushioda R, Uversky VN, Uzcategui NL, Vaccari T, Vaccaro MI, Vachova L, Vakifahmetoglu-Norberg H, Valdor R, Valente EM, Vallette F, Valverde AM, Van den Berghe G, Van Den Bosch L, van den Brink GR, van der Goot FG, van der Klei IJ, van der Laan LJ, van Doorn WG, van Egmond M, van Golen KL, Van Kaer L, van Lookeren Campagne M, Vandenabeele P, Vandenbergh W, Vanhorebeek I, Varela-Nieto I, Vasconcelos MH, Vasko R, Vavvas DG, Vega-Naredo I, Velasco G, Velentzas AD, Velentzas PD, Vellai T, Vellenga E, Vendelbo MH, Venkatachalam K, Ventura N, Ventura S, Veras PS, Verdier M, Vertessy BG, Viale A, Vidal M, Vieira HL, Vierstra RD, Vigneswaran N, Vij N, Vila M, Villar M, Villar VH, Villarroya J, Vindis C, Viola G, Viscomi MT, Vitale G, Vogl DT, Voitsekhovskaja OV, von Haefen C, von Schwarzenberg K, Voth DE, Vouret-Craviari V, Vuori K, Vyas JM, Waeber C, Walker CL, Walker MJ, Walter J, Wan L, Wan X, Wang B, Wang C, Wang CY, Wang D, Wang F, Wang G, Wang HJ, Wang H, Wang HG, Wang HD, Wang J, Wang M, Wang MQ, Wang PY, Wang P, Wang RC, Wang S, Wang TF, Wang X, Wang XJ, Wang XW, Wang Y, Wang YJ, Wang YT, Wang ZN, Wappner P, Ward C, Ward DM, Warnes G, Watada H, Watanabe Y, Watase K, Weaver TE, Weekes CD, Wei J, Weide T, Wehl CC, Weindl G, Weis SN, Wen L, Wen X, Wen Y, Westermann B, Weyand CM, White AR, White E, Whitton JL, Whitworth AJ, Wiels J, Wild F, Wildenberg ME, Wileman T, Wilkinson DS, Wilkinson S, Willbold D, Williams C, Williams K, Williamson PR, Winklhofer KF, Witkin SS, Wohlgemuth SE, Wollert T, Wolvetang EJ, Wong E, Wong GW, Wong RW, Wong VK, Woodcock EA, Wright KL, Wu C, Wu D, Wu GS, Wu J, Wu M, Wu S, Wu WK, Wu Y, Wu Z, Xavier CP, Xavier RJ, Xia GX, Xia T, Xia W, Xia Y, Xiao H, Xiao J, Xiao S, Xiao W, Xie CM, Xie Z, Xilouri M, Xiong Y, Xu C, Xu F, Xu H, Xu J, Xu L, Xu X, Xu Y, Xu ZX, Xu Z, Xue Y, Yamada T, Yamamoto A, Yamanaka K, Yamashina S, Yamashiro S, Yan B, Yan X, Yan Z, Yanagi Y, Yang DS, Yang JM, Yang L, Yang M, Yang PM, Yang P, Yang Q, Yang W, Yang WY, Yang X, Yang Y, Yang Z, Yao MC, Yao PJ, Yao X, Yao Z, Yasui LS, Ye M, Yedvobnick B, Yeganeh B, Yeh ES, Yeyati PL, Yi F, Yi L, Yin XM, Yip CK, Yoo YM, Yoo YH, Yoon SY, Yoshida K, Yoshimori T, Young KH, Yu H, Yu JJ, Yu JT, Yu J, Yu L, Yu WH, Yu XF, Yu Z, Yuan J, Yuan ZM, Yue BY, Yue J, Yue Z, Zacks DN, Zacksenhaus E, Zaffaroni N, Zaglia T, Zakeri Z, Zecchini V, Zeng J, Zeng M, Zeng Q, Zervos AS, Zhang DD, Zhang F, Zhang G, Zhang GC, Zhang H, Zhang J, Zhang JP, Zhang L, Zhang MY, Zhang X, Zhang XD, Zhang Y, Zhao M, Zhao WL, Zhao X, Zhao YG, Zhao Y, Zhao YX, Zhao Z, Zhao ZJ, Zheng D, Zheng XL, Zheng X, Zhivotovsky B, Zhong Q, Zhou GZ, Zhou G, Zhou H, Zhou SF, Zhou XJ, Zhu H, Zhu WG, Zhu W, Zhu XF, Zhu Y, Zhuang SM, Zhuang X, Ziparo E, Zois CE, Zoladek T, Zong WX, Zorzano A, Zughaier SM. *Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)*. **Autophagy**, 2016. 12(1): p. 1-222. PMID: 26799652 PMCID: 4835977
324. Krepler C, Xiao M, Samanta M, Vultur A, Chen HY, Brafford P, Reyes-Urbe PI, Halloran M, Chen T, He X, Hristova D, Liu Q, Samatar AA, Davies MA, Nathanson KL, Fukunaga-Kalabis M, Herlyn M, Villanueva J. *Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma*. **Oncotarget**, 2016. 7(44): p. 71211-71222. PMID: 27655717 PMCID: 5342073
325. Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M. *Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies*. **Clin Cancer Res**, 2016. 22(7): p. 1592-1602. PMID: 26673799 PMCID: 4818716
326. Kudinov AE, Deneka A, Nikonova AS, Beck TN, Ahn YH, Liu X, Martinez CF, Schultz FA, Reynolds S, Yang DH, Cai KQ, Yaghmour KM, Baker KA, Egleston BL, Nicolas E, Chikwem A, Andrianov G, Singh S, Borghaei H, Serebriiskii IG, Gibbons DL, Kurie JM, Golemis EA, Boumber Y. *Musashi-2 (MSI2) supports TGF-beta signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis*. **Proc Natl Acad Sci U S A**, 2016. 113(25): p. 6955-6960. PMID: 27274057 PMCID: 4922167
327. Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA. *IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic*

- Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst*, 2016. 108(12). PMID: 27576731 PMCID: PMC5241894
328. Lee H, Kim Y, Jeong JH, Ryu JH, Kim WY. *ATM/CHK/p53 Pathway Dependent Chemopreventive and Therapeutic Activity on Lung Cancer by Pterostilbene. PLoS One*, 2016. 11(9): p. e0162335. PMID: 27612029 PMCID: PMC5017581
329. Li H, Hu J, Wu S, Wang L, Cao X, Zhang X, Dai B, Cao M, Shao R, Zhang R, Majidi M, Ji L, Heymach JV, Wang M, Pan S, Minna J, Mehran RJ, Swisher SG, Roth JA, Fang B. *Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget*, 2016. 7(3): p. 3548-3558. PMID: 26657290 PMCID: 4823126
330. Li H, Wheeler S, Park Y, Ju Z, Thomas SM, Fichera M, Egloff AM, Lui VW, Duvvuri U, Bauman JE, Mills GB, Grandis JR. *Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts. Mol Cancer Res*, 2016. 14(3): p. 278-286. PMID: 26685214 PMCID: 4794346
331. Lisanti S, Garlick DS, Bryant KG, Tavecchio M, Mills GB, Lu Y, Kossenkov AV, Showe LC, Languino LR, Altieri DC. *Transgenic Expression of Mitochondrial Chaperone TRAP1 Accelerates Prostate Cancer Development. J Biol Chem*, 2016. PMID: 27754870 PMCID:
332. Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, Fotheringham S, Wulf G, English J, Kirschmeier PT, Velculescu VE, Paweletz CP, Mills GB, Livingston DM, Brugge JS, Matulonis UA, Drapkin R. *Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for pre-clinical evaluation of novel therapeutics. Clin Cancer Res*, 2016. PMID: 27573169 PMCID:
333. Loibl M, Lang S, Hanke A, Herrmann M, Huber M, Brockhoff G, Klein S, Nerlich M, Angele P, Prantl L, Gehmert S. *Leukocyte-Reduced Platelet-Rich Plasma Alters Protein Expression of Adipose Tissue-Derived Mesenchymal Stem Cells. Plast Reconstr Surg*, 2016. 138(2): p. 397-408. PMID: 27064225 PMCID:
334. Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, Rodriguez JC, Hwu P, Wistuba, II, Heymach JV, Gibbons DL. *Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res*, 2016. 22(14): p. 3630-3642. PMID: 26851185 PMCID: PMC4947453
335. Lu H, Liu S, Zhang G, Kwong LN, Zhu Y, Miller JP, Hu Y, Zhong W, Zeng J, Wu L, Krepler C, Sproesser K, Xiao M, Xu W, Karakousis GC, Schuchter LM, Field J, Zhang PJ, Herlyn M, Xu X, Guo W. *Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Rep*, 2016. 15(9): p. 2012-2024. PMID: 27210749 PMCID: 4889462
336. Lu Y, Ling S, Hegde AM, Byers LA, Coombes K, Mills GB, Akbani R. *Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. Semin Oncol*, 2016. 43(4): p. 476-483. PMID: 27663479 PMCID:
337. Maachani UB, Shankavaram U, Kramp T, Tofilon PJ, Camphausen K, Tandle AT. *FOXM1 and STAT3 interaction confers radioresistance in glioblastoma cells. Oncotarget*, 2016. PMID: 27764801 PMCID:
338. Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba, II, Heymach JV, Weinstein JN, Coombes KR, Wang J, Byers LA. *A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res*, 2016. 22(3): p. 609-620. PMID: 26420858 PMCID: PMC4737991
339. Marcotte R, Sayad A, Brown KR, Sanchez-Garcia F, Reimand J, Haider M, Virtanen C, Bradner JE, Bader GD, Mills GB, Pe'er D, Moffat J, Neel BG. *Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. Cell*, 2016. 164(1-2): p. 293-309. PMID: 26771497 PMCID: 4724865
340. Mazumdar A, Poage GM, Shepherd J, Tsimelzon A, Hartman ZC, Den Hollander P, Hill J, Zhang Y, Chang J, Hilsenbeck SG, Fuqua S, Kent Osborne C, Mills GB, Brown PH. *Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat*, 2016. 158(3): p. 441-454. PMID: 27393618 PMCID: 4963453
341. Meric-Bernstam F, Shaw K, Mendelsohn J, Mills GB. *Reply to M.P. Decatris et al. J Clin Oncol*, 2016. 34(8): p. 886. PMID: 26755522 PMCID:
342. Muranen T, Selfors LM, Hwang J, Gallegos LL, Colloff JL, Thoreen CC, Kang SA, Sabatini DM, Mills GB, Brugge JS. *ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP. Cancer Res*, 2016. 76(24): p. 7168-7180. PMID: 27913436 PMCID: 5161652

343. Nanos-Webb A, Bui T, Karakas C, Zhang D, Carey JP, Mills GB, Hunt KK, Keyomarsi K. *PKC $\alpha$  promotes ovarian tumor progression through deregulation of cyclin E*. **Oncogene**, 2016. 35(19): p. 2428-2440. PMID: 26279297 PMCID: 4856585
344. Nilsson MB, Giri U, Gudikote J, Tang X, Lu W, Tran H, Fan Y, Koo A, Diao L, Tong P, Wang J, Herbst R, Johnson BE, Ryan A, Webster A, Rowe P, Wistuba II, Heymach JV. *KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib*. **Clin Cancer Res**, 2016. 22(8): p. 1940-1950. PMID: 26578684 PMCID: PMC4834253
345. Nishizuka SS, Mills GB. *New era of integrated cancer biomarker discovery using reverse-phase protein arrays*. **Drug Metab Pharmacokinet**, 2016. 31(1): p. 35-45. PMID: 26822993 PMCID:
346. Park SY, Piao Y, Jeong KJ, Dong J, de Groot JF. *Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models*. **Mol Cancer Ther**, 2016. 15(9): p. 2187-2197. PMID: 27307601 PMCID: PMC5104278
347. Park SY, Piao Y, Thomas C, Fuller GN, de Groot JF. *Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma*. **Oncotarget**, 2016. 7(18): p. 26793-26805. PMID: 27050366 PMCID: PMC5042015
348. Peng S, Sen B, Mazumdar T, Byers LA, Diao L, Wang J, Tong P, Giri U, Heymach JV, Kadara HN, Johnson FM. *Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations*. **Oncotarget**, 2016. 7(1): p. 565-579. PMID: 26623721 PMCID: PMC4808018
349. Rhyasen GW, Hattersley MM, Yao Y, Dulak A, Wang W, Petteruti P, Dale IL, Boiko S, Cheung T, Zhang J, Wen S, Castriotta L, Lawson D, Collins M, Bao L, Ahdesmaki MJ, Walker G, O'Connor G, Yeh TC, Rabow AA, Dry JR, Reimer C, Lyne P, Mills GB, Fawell SE, Waring MJ, Zinda M, Clark E, Chen H. *AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies*. **Mol Cancer Ther**, 2016. 15(11): p. 2563-2574. PMID: 27573426 PMCID:
350. Riley MF, You MJ, Multani AS, Lozano G. *Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma*. **Oncogene**, 2016. 35(3): p. 358-365. PMID: 25915849 PMCID: PMC4624041
351. Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE. *Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set*. **BMC Med**, 2016. 14(1): p. 168. PMID: 27776519 PMCID: 5078889
352. Saenz DT, Fiskus W, Manshoury T, Rajapakshe K, Krieger S, Sun B, Mill CP, DiNardo C, Pemmaraju N, Kadia T, Parmar S, Sharma S, Coarfa C, Qiu P, Verstovsek S, Bhalla KN. *BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells*. **Leukemia**, 2016. PMID: 27677740 PMCID:
353. Senbabaoglu Y, Sumer SO, Sanchez-Vega F, Bemis D, Ciriello G, Schultz N, Sander C. *A Multi-Method Approach for Proteomic Network Inference in 11 Human Cancers*. **PLoS Comput Biol**, 2016. 12(2): p. e1004765. PMID: 26928298 PMCID: 4771175
354. Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot CV, Sood AK, Mukherjee S, Gray JW, Mills GB, Ram PT. *Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer*. **Oncogene**, 2016. 35(6): p. 691-701. PMID: 25639871 PMCID: 4522411
355. Seviour EG, Sehgal V, Mishra D, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Lee JS, Sood AK, Kim MP, Mills GB, Ram PT. *Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p*. **Oncogene**, 2016. PMID: 27669434 PMCID:
356. Shannan B, Chen Q, Watters A, Perego M, Krepler C, Thombre R, Li L, Rajan G, Peterson S, Gimotty PA, Wilson M, Nathanson KL, Gangadhar TC, Schuchter LM, Weeraratna AT, Herlyn M, Vultur A. *Enhancing the evaluation of PI3K inhibitors through 3D melanoma models*. **Pigment Cell Melanoma Res**, 2016. 29(3): p. 317-328. PMID: 26850518 PMCID: 4840066
357. Shannan B, Perego M, Somasundaram R, Herlyn M. *Heterogeneity in Melanoma*. **Cancer Treat Res**, 2016. 167: p. 1-15. PMID: 26601857 PMCID:

358. Shannan B, Watters A, Chen Q, Mollin S, Dorr M, Meggers E, Xu X, Gimotty PA, Perego M, Li L, Benci J, Krepler C, Brafford P, Zhang J, Wei Z, Zhang G, Liu Q, Yin X, Nathanson KL, Herlyn M, Vultur A. *PIM kinases as therapeutic targets against advanced melanoma*. **Oncotarget**, 2016. 7(34): p. 54897-54912. PMID: 27448973 PMID: 5342389
359. Shingu T, Holmes L, Henry V, Wang Q, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang FF, Rao G, Yuan L, Sulman EP, Farrell NP, Priebe W, Hess KR, Wang YA, Hu J, Bogler O. *Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells*. **J Transl Med**, 2016. 14: p. 46. PMID: 26861698 PMID: 4746796
360. Skinner HD, Giri U, Yang L, Woo SH, Story MD, Pickering CR, Byers LA, Williams MD, El-Naggar A, Wang J, Diao L, Shen L, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV. *Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer*. **Clin Cancer Res**, 2016. 22(18): p. 4643-4650. PMID: 27036135 PMID: PMC5061056
361. Stetson LC, Dazard JE, Barnholtz-Sloan JS. *Protein Markers Predict Survival in Glioma Patients*. **Mol Cell Proteomics**, 2016. 15(7): p. 2356-2365. PMID: 27143410 PMID: 4937509
362. Teh JL, Purwin TJ, Greenawalt EJ, Chervoneva I, Goldberg A, Davies MA, Aplin AE. *An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma*. **Cancer Res**, 2016. 76(18): p. 5455-5466. PMID: 27488531 PMID: 5026598
363. Timsah Z, Ahmed Z, Ivan C, Berrout J, Gagea M, Zhou Y, Pena GN, Hu X, Vallien C, Kingsley CV, Lu Y, Hancock JF, Liu J, Gladden AB, Mills GB, Lopez-Berestein G, Hung MC, Sood AK, Bogdanov M, Ladbury JE. *Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer*. **Oncogene**, 2016. 35(17): p. 2186-2196. PMID: 26212011 PMID: 4792786
364. Tsang YH, Dogruluk T, Tedeschi PM, Wardwell-Ozgo J, Lu H, Espitia M, Nair N, Minelli R, Chong Z, Chen F, Chang QE, Dennison JB, Dogruluk A, Li M, Ying H, Bertino JR, Gingras MC, Ittmann M, Kerrigan J, Chen K, Creighton CJ, Eterovic K, Mills GB, Scott KL. *Functional annotation of rare gene aberration drivers of pancreatic cancer*. **Nat Commun**, 2016. 7: p. 10500. PMID: 26806015 PMID: 4737758
365. Turpin J, Ling C, Crosby EJ, Hartman ZC, Simond AM, Chodosh LA, Rennhack JP, Andrechek ER, Ozelik J, Hallett M, Mills GB, Cardiff RD, Gray JW, Griffith OL, Muller WJ. *The ErbB2DeltaEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment*. **Oncogene**, 2016. PMID: 27157621 PMID:
366. Vermeer DW, Coppock JD, Zeng E, Lee KM, Spanos WC, Onken MD, Uppaluri R, Lee JH, Vermeer PD. *Metastatic model of HPV+ oropharyngeal squamous cell carcinoma demonstrates heterogeneity in tumor metastasis*. **Oncotarget**, 2016. 7(17): p. 24194-24207. PMID: 27013584 PMID: 5029694
367. Vu HL, Rosenbaum S, Capparelli C, Purwin TJ, Davies MA, Berger AC, Aplin AE. *MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma*. **J Invest Dermatol**, 2016. 136(2): p. 453-463. PMID: 26967478 PMID: 4789776
368. Vu TN, Pramana S, Calza S, Suo C, Lee D, Pawitan Y. *Comprehensive landscape of subtype-specific coding and non-coding RNA transcripts in breast cancer*. **Oncotarget**, 2016. PMID: 27634900 PMID:
369. Wang C, Jeong K, Jiang H, Guo W, Gu C, Lu Y, Liang J. *YAP/TAZ regulates the insulin signaling via IRS1/2 in endometrial cancer*. **Am J Cancer Res**, 2016. 6(5): p. 996-1010. PMID: 27293994 PMID: 4889715
370. Wang C, Zhu X, Feng W, Yu Y, Jeong K, Guo W, Lu Y, Mills GB. *Verteporfin inhibits YAP function through up-regulating 14-3-3sigma sequestering YAP in the cytoplasm*. **Am J Cancer Res**, 2016. 6(1): p. 27-37. PMID: 27073720 PMID: 4759394
371. Wang JX, Fukunaga-Kalabis M, Herlyn M. *Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma*. **J Cell Commun Signal**, 2016. 10(3): p. 191-196. PMID: 27553358 PMID: 5055506
372. Witkiewicz AK, Balaji U, Eslinger C, McMillan E, Conway W, Posner B, Mills GB, O'Reilly EM, Knudsen ES. *Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer*. **Cell Rep**, 2016. 16(7): p. 2017-2031. PMID: 27498862 PMID:
373. Yang JY, Werner HM, Li J, Westin SN, Lu Y, Halle MK, Trovik J, Salvesen HB, Mills GB, Liang H. *Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer*. **Clin Cancer Res**, 2016. 22(2): p. 513-523. PMID: 26224872 PMID: 4715969
374. Yuan Y, Liu L, Chen H, Wang Y, Xu Y, Mao H, Li J, Mills GB, Shu Y, Li L, Liang H. *Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients*. **Cancer Cell**, 2016. 29(5): p. 711-722. PMID: 27165743 PMID: 4864951

375. Zhang B, Zhao R, He Y, Fu X, Fu L, Zhu Z, Dong JT. *MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR*. **Oncotarget**, 2016. 7(5): p. 5702-5714. PMID: 26744318 PMID: 4868715
376. Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, Davies MA, Wargo JA, Avadhani NG, Lu Y, Mills GB, Altieri DC, Flaherty KT, Herlyn M. *Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors*. **J Clin Invest**, 2016. 126(5): p. 1834-1856. PMID: 27043285 PMID: 4855947
377. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MC, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA, Hammer GD, Giordano TJ, Verhaak RG. *Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma*. **Cancer Cell**, 2016. 29(5): p. 723-736. PMID: 27165744 PMID: 4864952
378. Zhou J, Alfraidi A, Zhang S, Santiago-O'Farrill J, Yerramreddy V, Alsaadid A, Ahmed AA, Yang H, Liu J, Mao W, Takemori H, Wang Y, Vankayalapati H, Lu Z, Bast RC. *A novel compound ARN-3236 inhibits Salt Inducible Kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel*. **Clin Cancer Res**, 2016. PMID: 27678456 PMID: 27678456
379. Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, Perakis AA, Becker L, Yoo SY, Dwyer KC, Coombes K, Talukder AH, John LSS, Senyukov V, Lee DA, Sergeeva A, He H, Ma Q, Armistead PM, Roszik J, Mittendorf EA, Molldrem JJ, Hawke D, Lizee G, Kornblau SM. *Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target*. **Leukemia**, 2017. 31(1): p. 234-237. PMID: 27573556 PMID: PMC5215491
380. Amith SR, Vincent KM, Wilkinson JM, Postovit LM, Fliegel L. *Defining the Na(+)/H(+) exchanger NHE1 interactome in triple-negative breast cancer cells*. **Cell Signal**, 2017. 29: p. 69-77. PMID: 27751915 PMID: 27751915
381. Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, Kim S, Hirsch FR, Ellison K, Flaherty JT, Mills GB, Grandis JR. *Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer*. **JCI Insight**, 2017. 2(6): p. e90449. PMID: 28352657 PMID: PMC5358497 exists.
382. Behera R, Kaur A, Webster MR, Kim S, Ndoye A, Kugel CH, 3rd, Alicea GM, Wang J, Ghosh K, Cheng P, Lisanti S, Marchbank K, Dang V, Levesque M, Dummer R, Xu X, Herlyn M, Aplin AE, Roesch A, Caino C, Altieri DC, Weeraratna AT. *Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho*. **Clin Cancer Res**, 2017. 23(12): p. 3181-3190. PMID: 28232477 PMID: 5474161
383. Byron A. *Clustering and Network Analysis of Reverse Phase Protein Array Data*. **Methods Mol Biol**, 2017. 1606: p. 171-191. PMID: 28502001 PMID: 28502001
384. Cancer Genome Atlas Research N, Albert Einstein College of M, Analytical Biological S, Barretos Cancer H, Baylor College of M, Beckman Research Institute of City of H, Buck Institute for Research on A, Canada's Michael Smith Genome Sciences C, Harvard Medical S, Helen FGCC, Research Institute at Christiana Care Health S, HudsonAlpha Institute for B, IIsbio LLC, Indiana University School of M, Institute of Human V, Institute for Systems B, International Genomics C, Leidos B, Massachusetts General H, McDonnell Genome Institute at Washington U, Medical College of W, Medical University of South C, Memorial Sloan Kettering Cancer C, Montefiore Medical C, NantOmics, National Cancer I, National Hospital AN, National Human Genome Research I, National Institute of Environmental Health S, National Institute on D, Other Communication D, Ontario Tumour Bank LHSC, Ontario Tumour Bank OlfCR, Ontario Tumour Bank TOH, Oregon H, Science U, Samuel Oschin Comprehensive Cancer Institute C-SMC, International SRA, St Joseph's Candler Health S, Eli, Edythe LBloMioT, Harvard U, Research Institute at Nationwide Children's H, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins U, University of B, University of Texas MDACC, University of Abuja Teaching H, University of Alabama at B, University of California I, University of California Santa C, University of Kansas Medical C, University of L, University of New Mexico Health Sciences C, University of North Carolina at Chapel H, University of Oklahoma Health Sciences C, University of P, University of Sao Paulo RaPMS, University of Southern C, University of W, University of Wisconsin School of M, Public H, Van Andel Research I, Washington University in St L. *Integrated genomic and molecular*



- characterization of cervical cancer. Nature*, 2017. 543(7645): p. 378-384. PMID: 28112728 PMCID: PMC5354998
385. Cancer Genome Atlas Research N, Analysis Working Group: Asan U, Agency BCC, Brigham, Women's H, Broad I, Brown U, Case Western Reserve U, Dana-Farber Cancer I, Duke U, Greater Poland Cancer C, Harvard Medical S, Institute for Systems B, Leuven KU, Mayo C, Memorial Sloan Kettering Cancer C, National Cancer I, Nationwide Children's H, Stanford U, University of A, University of M, University of North C, University of P, University of R, University of Southern C, University of Texas MDACC, University of W, Van Andel Research I, Vanderbilt U, Washington U, Genome Sequencing Center: Broad I, Washington University in St L, Genome Characterization Centers BCCA, Broad I, Harvard Medical S, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins U, University of North C, University of Southern California Epigenome C, University of Texas MDACC, Van Andel Research I, Genome Data Analysis Centers: Broad I, Brown U, Harvard Medical S, Institute for Systems B, Memorial Sloan Kettering Cancer C, University of California Santa C, University of Texas MDACC, Biospecimen Core Resource: International Genomics C, Research Institute at Nationwide Children's H, Tissue Source Sites: Analytic Biologic S, Asan Medical C, Asterand B, Barretos Cancer H, BioreclamationIvt, Botkin Municipal C, Chonnam National University Medical S, Christiana Care Health S, Cureline, Duke U, Emory U, Erasmus U, Indiana University School of M, Institute of Oncology of M, International Genomics C, Invidumed, Israelitisches Krankenhaus H, Keimyung University School of M, Memorial Sloan Kettering Cancer C, National Cancer Center G, Ontario Tumour B, Peter MacCallum Cancer C, Pusan National University Medical S, Ribeirao Preto Medical S, St. Joseph's H, Medical C, St. Petersburg Academic U, Tayside Tissue B, University of D, University of Kansas Medical C, University of M, University of North Carolina at Chapel H, University of Pittsburgh School of M, University of Texas MDACC, Disease Working Group: Duke U, Memorial Sloan Kettering Cancer C, National Cancer I, University of Texas MDACC, Yonsei University College of M, Data Coordination Center CI, Project Team: National Institutes of H. *Integrated genomic characterization of oesophageal carcinoma. Nature*, 2017. 541(7636): p. 169-175. PMID: 28052061 PMCID: PMC5651175
386. Cancer Genome Atlas Research Network. Electronic address aadhe, Cancer Genome Atlas Research N. *Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell*, 2017. 32(2): p. 185-203 e113. PMID: 28810144 PMCID: PMC5964983
387. Cancer Genome Atlas Research Network. Electronic address edsc, Cancer Genome Atlas Research N. *Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell*, 2017. 171(4): p. 950-965 e928. PMID: 29100075 PMCID: PMC5693358
388. Cancer Genome Atlas Research Network. Electronic address wbe, Cancer Genome Atlas Research N. *Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell*, 2017. 169(7): p. 1327-1341 e1323. PMID: 28622513 PMCID: PMC5680778
389. Cheng H, Chua V, Liao C, Purwin TJ, Terai M, Kageyama K, Davies MA, Sato T, Aplin AE. *Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. Mol Cancer Ther*, 2017. 16(3): p. 516-528. PMID: 28138035 PMCID: 5337170
390. Cheng W, Zhang C, Ren X, Jiang Y, Han S, Liu Y, Cai J, Li M, Wang K, Liu Y, Hu H, Li Q, Yang P, Bao Z, Wu A. *Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma. J Neurosurg*, 2017. 126(1): p. 249-259. PMID: 26967788 PMCID:
391. Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, Hu X, Ling S, Soslow RA, Broaddus RR, Zuna RE, Robertson G, Laird PW, Kucherlapati R, Mills GB, Weinstein JN, Zhang J, Akbani R, Levine DA. *Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell*, 2017. 31(3): p. 411-423. PMID: 28292439 PMCID:
392. Clarke CN, Lee MS, Wei W, Manyam G, Jiang ZQ, Lu Y, Morris J, Broom B, Menter D, Vilar-Sanchez E, Raghav K, Eng C, Chang GJ, Simon I, Bernards R, Overman M, Mills GB, Maru D, Kopetz S. *Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Ann Surg Oncol*, 2017. 24(13): p. 4051-4058. PMID: 28936799 PMCID:
393. Datta J, Damodaran S, Parks H, Ocrainiciuc C, Miya J, Yu L, Gardner EP, Samorodnitsky E, Wing MR, Bhatt D, Hays J, Reeser JW, Roychowdhury S. *Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398. Mol Cancer Ther*, 2017. 16(4): p. 614-624. PMID: 28255027 PMCID: PMC5539948
394. Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F. *A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res*, 2017. 23(21): p. 6468-6477. PMID: 29093017 PMCID: PMC5679124

395. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Peadarallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, Cancer Genome Atlas N, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. *Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles*. **Cell Rep**, 2017. 18(11): p. 2780-2794. PMID: 28297679 PMCID: PMC5493145
396. Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, Vellano CP, Ju Z, Gagea M, Liu S, Mitra S, Dennison JB, Lorenzi PL, Cardnell R, Diao L, Wang J, Lu Y, Byers LA, Perou CM, Lin SY, Mills GB. *A murine preclinical syngeneic transplantation model for breast cancer precision medicine*. **Sci Adv**, 2017. 3(4): p. e1600957. PMID: 28439535 PMCID: PMC5397135
397. Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, Jefferys SR, de Cubas AA, Wenz B, Korpershoek E, Amelio AL, Makowski L, Rathmell WK, Gimenez-Roqueplo AP, Giordano TJ, Asa SL, Tischler AS, Pacak K, Nathanson KL, Wilkerson MD. *Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma*. **Cancer Cell**, 2017. 31(2): p. 181-193. PMID: 28162975 PMCID:
398. George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F. *A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers*. **JCI Insight**, 2017. 2(1): p. e89760. PMID: 28097235 PMCID: 5214535
399. Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK. *Platelets reduce anoikis and promote metastasis by activating YAP1 signaling*. **Nat Commun**, 2017. 8(1): p. 310. PMID: 28827520 PMCID: PMC5566477
400. Han G, Zhao W, Song X, Kwok-Shing Ng P, Karam JA, Jonasch E, Mills GB, Zhao Z, Ding Z, Jia P. *Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening*. **BMC Genomics**, 2017. 18(Suppl 6): p. 678. PMID: 28984208 PMCID: PMC5629613
401. Haymaker C, Yang Y, Wang J, Zou Q, Sahoo A, Alekseev A, Singh D, Ritthipichai K, Hailemichael Y, Hoang ON, Qin H, Schluns KS, Wang T, Overwijk WW, Sun SC, Bernatchez C, Kwak LW, Neelapu SS, Nurieva R. *Absence of Grail promotes CD8(+) T cell anti-tumour activity*. **Nat Commun**, 2017. 8(1): p. 239. PMID: 28798332 PMCID: PMC5552797
402. Hill SM, Nesser NK, Johnson-Camacho K, Jeffress M, Johnson A, Boniface C, Spencer SE, Lu Y, Heiser LM, Lawrence Y, Pande NT, Korkola JE, Gray JW, Mills GB, Mukherjee S, Spellman PT. *Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling*. **Cell Syst**, 2017. 4(1): p. 73-83 e10. PMID: 28017544 PMCID: 5279869
403. Huang X, Huang L, Shao M. *Aquaporin 3 facilitates tumor growth in pancreatic cancer by modulating mTOR signaling*. **Biochem Biophys Res Commun**, 2017. 486(4): p. 1097-1102. PMID: 28377226 PMCID:
404. Iida Y, Ciechanover A, Marzese DM, Hata K, Bustos M, Ono S, Wang J, Salomon MP, Tran K, Lam S, Hsu SC, Nelson N, Kravtsova-Ivantsiv Y, Mills GB, Davies MA, Hoon DS. *Epigenetic Regulation of KPC1 Ubiquitin Ligase Effects the NF-kappaB Pathway in Melanoma*. **Clin Cancer Res**, 2017. PMID: 28389511 PMCID:
405. Isik Z, Ercan ME. *Integration of RNA-Seq and RPPA data for survival time prediction in cancer patients*. **Comput Biol Med**, 2017. 89: p. 397-404. PMID: 28869900 PMCID:
406. Jia L, Zhou J, Zhao H, Jin H, Lv M, Zhao N, Zheng Z, Lu Y, Ming Y, Yu Y. *Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snailglycolysis pathways*. **Oncol Rep**, 2017. 38(4): p. 2464-2470. PMID: 28791374 PMCID:
407. Johanning GL, Malouf GG, Zheng X, Esteva FJ, Weinstein JN, Wang-Johanning F, Su X. *Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype*. **Sci Rep**, 2017. 7: p. 41960. PMID: 28165048 PMCID: PMC5292751
408. Johnson MB, Pang B, Gardner DJ, Niknam-Benia S, Soundarajan V, Bramos A, Perrault DP, Banks K, Lee GK, Baker RY, Kim GH, Lee S, Chai Y, Chen M, Li W, Kwong L, Hong YK, Wong AK. *Topical Fibronectin Improves Wound Healing of Irradiated Skin*. **Sci Rep**, 2017. 7(1): p. 3876. PMID: 28634413 PMCID: PMC5478660

409. Joshi S, Yang J, Wang Q, Li P, Wang H, Zhang Q, Xiong Y, Pickering BF, Parker-Thornburg J, Behringer RR, Yu D. *14-3-3zeta loss impedes oncogene-induced mammary tumorigenesis and metastasis by attenuating oncogenic signaling.* **Am J Cancer Res**, 2017. 7(8): p. 1654-1664. PMID: 28861322 PMCID: PMC5574938
410. Kaddi CD, Wang MD. *Models for Predicting Stage in Head and Neck Squamous Cell Carcinoma Using Proteomic and Transcriptomic Data.* **IEEE J Biomed Health Inform**, 2017. 21(1): p. 246-253. PMID: 26462248 PMCID: PMC4983540
411. Kanaya N, Somlo G, Wu J, Frankel P, Kai M, Liu X, Wu SV, Nguyen D, Chan N, Hsieh MY, Kirschenbaum M, Kruper L, Vito C, Badie B, Yim JH, Yuan Y, Hurria A, Peiguo C, Mortimer J, Chen S. *Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers.* **J Steroid Biochem Mol Biol**, 2017. 170: p. 65-74. PMID: 27154416 PMCID: PMC5094906
412. Katerndahl CDS, Heltemes-Harris LM, Willette MJL, Henzler CM, Fietze S, Yang R, Schjerven H, Silverstein KAT, Ramsey LB, Hubbard G, Wells AD, Kuiper RP, Scheijen B, van Leeuwen FN, Muschen M, Kornblau SM, Farrar MA. *Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.* **Nat Immunol**, 2017. 18(6): p. 694-704. PMID: 28369050 PMCID: PMC5540372
413. Kim H, George E, Ragland RL, Rafail S, Zhang R, Krepler C, Morgan MA, Herlyn M, Brown EJ, Simpkins F. *Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models.* **Clin Cancer Res**, 2017. 23(12): p. 3097-3108. PMID: 27993965 PMCID:
414. Klimczak M, Czerwinska P, Mazurek S, Sozanska B, Biecek P, Mackiewicz A, Wiznerowicz M. *TRIM28 epigenetic corepressor is indispensable for stable induced pluripotent stem cell formation.* **Stem Cell Res**, 2017. 23: p. 163-172. PMID: 28759843 PMCID:
415. Korkola JE, Collisson EA, Heiser LM, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, Jakkula L, Feiler H, Lu Y, Mills GB, Spellman PT, Tomlin C, Mukherjee S, Gray JW. *Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.* **PLoS One**, 2017. 12(10): p. e0186551. PMID: 29020035 PMCID: PMC5636161
416. Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuertner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M. *A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.* **Cell Rep**, 2017. 21(7): p. 1953-1967. PMID: 29141225 PMCID: PMC5726788
417. Kwong LN, Zou L, Chagani S, Pedamallu CS, Liu M, Jiang S, Protopopov A, Zhang J, Getz G, Chin L. *Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma.* **Cell Rep**, 2017. 19(7): p. 1304-1312. PMID: 28514651 PMCID: PMC5512587
418. Lee HS, Jang HJ, Shah R, Yoon D, Hamaji M, Wald O, Lee JS, Sugarbaker DJ, Burt BM. *Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features.* **Clin Cancer Res**, 2017. 23(16): p. 4855-4864. PMID: 28400429 PMCID: PMC5559309
419. Lehrer M, Bhadra A, Ravikumar V, Chen JY, Wintermark M, Hwang SN, Holder CA, Huang EP, Fevrier-Sullivan B, Freymann JB, Rao A, Group TGPR. *Multiple-response regression analysis links magnetic resonance imaging features to de-regulated protein expression and pathway activity in lower grade glioma.* **Oncoscience**, 2017. 4(5-6): p. 57-66. PMID: 28781988 PMCID: PMC5538849
420. Leu JI, Barnoud T, Zhang G, Tian T, Wei Z, Herlyn M, Murphy ME, George DL. *Inhibition of stress-inducible HSP70 impairs mitochondrial proteostasis and function.* **Oncotarget**, 2017. PMID: 28484090 PMCID:
421. Li J, Akbani R, Zhao W, Lu Y, Weinstein JN, Mills GB, Liang H. *Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas.* **Cancer Res**, 2017. 77(21): p. e51-e54. PMID: 29092939 PMCID: PMC5679242
422. Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, von Euw EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H. *Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.* **Cancer Cell**, 2017. 31(2): p. 225-239. PMID: 28196595 PMCID: 5501076

423. Lingappan K, Maity S, Jiang W, Wang L, Couroucli X, Veith A, Zhou G, Coarfa C, Moorthy B. *Role of Cytochrome P450 (CYP)1A in Hyperoxic Lung Injury: Analysis of the Transcriptome and Proteome*. **Sci Rep**, 2017. 7(1): p. 642. PMID: 28377578 PMCID: PMC5428698
424. Lu H, Liu S, Zhang G, Bin W, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W. *PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas*. **Nature**, 2017. 550(7674): p. 133-136. PMID: 28953887 PMCID:
425. Mauland KK, Ju Z, Tangen IL, Berg A, Kalland KH, Oyan AM, Bjorge L, Westin SN, Krakstad C, Trovik J, Mills GB, Hoivik EA, Johanna Werner HM. *Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients*. **Oncotarget**, 2017. 8(63): p. 106989-107001. PMID: 29291005 PMCID: PMC5739790
426. McGrail DJ, Lin CC, Garnett J, Liu Q, Mo W, Dai H, Lu Y, Yu Q, Ju Z, Yin J, Vellano CP, Hennessy B, Mills GB, Lin SY. *Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm*. **NPJ Syst Biol Appl**, 2017. 3: p. 8. PMID: 28649435 PMCID: PMC5445594
427. Mustachio LM, Kawakami M, Lu Y, Rodriguez-Canales J, Mino B, Behrens C, Wistuba I, Bota-Rabassedas N, Yu J, Lee JJ, Roszik J, Zheng L, Liu X, Freemantle SJ, Dmitrovsky E. *The ISG15-specific protease USP18 regulates stability of PTEN*. **Oncotarget**, 2017. 8(1): p. 3-14. PMID: 27980214 PMCID: PMC5352120
428. Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer MJ, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AK. *Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis*. **Cell Rep**, 2017. 21(10): p. 2785-2795. PMID: 29212026 PMCID: PMC5749980
429. Patel VM, Balakrishnan K, Douglas M, Tibbitts T, Xu EY, Kutok JL, Ayers M, Sarkar A, Guerrieri R, Wierda WG, O'Brien S, Jain N, Stern HM, Gandhi V. *Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)*. **Leukemia**, 2017. 31(9): p. 1872-1881. PMID: 28017967 PMCID: PMC5540815
430. Pomeroy EJ, Lee LA, Lee RDW, Schirm DK, Temiz NA, Ma J, Gruber TA, Diaz-Flores E, Moriarity BS, Downing JR, Shannon KM, Largaespada DA, Eckfeldt CE. *Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia*. **Oncogene**, 2017. 36(23): p. 3263-3273. PMID: 27991934 PMCID: PMC5464975
431. Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Hansen JM, Lyons Y, Huang J, Haemmerle M, Wagner MJ, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, Dorniak PL, Linesch SL, Mangala LS, Pradeep S, Wu SY, Sood AK. *Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies*. **J Natl Cancer Inst**, 2017. 109(7). PMID: 28376174 PMCID: PMC6059189
432. Ramirez-Ardila D, Timmermans AM, Helmijr JA, Martens JWM, Berns E, Jansen M. *Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis*. **Transl Oncol**, 2017. 10(5): p. 854-866. PMID: 28886403 PMCID: PMC5591392
433. Rebecca VW, Nicastrì MC, McLaughlin N, Fennelly C, McAfee Q, Ronghe A, Nofal M, Lim CY, Witze E, Chude CI, Zhang G, Alicea GM, Piao S, Murugan S, Ojha R, Levi SM, Wei Z, Barber-Rotenberg JS, Murphy ME, Mills GB, Lu Y, Rabinowitz J, Marmorstein R, Liu Q, Liu S, Xu X, Herlyn M, Zoncu R, Brady DC, Speicher DW, Winkler JD, Amaravadi RK. *A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles*. **Cancer Discov**, 2017. 7(11): p. 1266-1283. PMID: 28899863 PMCID: PMC5833978
434. Ring KL, Yates MS, Schmandt R, Onstad M, Zhang Q, Celestino J, Kwan SY, Lu KH. *Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition*. **Int J Gynecol Cancer**, 2017. 27(5): p. 854-862. PMID: 28498246 PMCID: PMC5438270
435. Ritthipichai K, Haymaker CL, Martinez M, Aschenbrenner A, Yi X, Zhang M, Kale C, Vence LM, Roszik J, Hailemichael Y, Overwijk WW, Varadarajan N, Nurieva R, Radvanyi LG, Hwu P, Bernatchez C. *Multifaceted Role of BTLA in the Control of CD8(+) T-cell Fate after Antigen Encounter*. **Clin Cancer Res**, 2017. 23(20): p. 6151-6164. PMID: 28754817 PMCID: PMC5748156
436. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Peadarallu CS, Lu Y, Klimczak LJ,

- Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ, Network TR, Weinstein JN, Kwiatkowski DJ, Lerner SP. *Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer*. **Cell**, 2017. 171(3): p. 540-556 e525. PMID: 28988769 PMID: PMC5687509
437. Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT, Network TR, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfeld L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE. *Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma*. **Cancer Cell**, 2017. 32(2): p. 204-220 e215. PMID: 28810145 PMID: PMC5619925
438. Ross JL, Cooper LAD, Kong J, Gutman D, Williams M, Tucker-Burden C, McCrary MR, Bouras A, Kaluzova M, Dunn WD, Jr., Duong D, Hadjipanayis CG, Brat DJ. *5-Aminolevulinic Acid Guided Sampling of Glioblastoma Microenvironments Identifies Pro-Survival Signaling at Infiltrative Margins*. **Sci Rep**, 2017. 7(1): p. 15593. PMID: 29142297 PMID: PMC5688093
439. Saenz DT, Fiskus W, Qian Y, Manshoury T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, Kim MS, Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. *Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells*. **Leukemia**, 2017. 31(9): p. 1951-1961. PMID: 28042144 PMID: PMC5537055
440. Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, Beqiri M, Sproesser K, Brafford PA, Xiao M, Eggan E, Anastopoulos IN, Vargas-Garcia CA, Singh A, Nathanson KL, Herlyn M, Raj A. *Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance*. **Nature**, 2017. 546(7658): p. 431-435. PMID: 28607484 PMID:
441. Skinner HD, Giri U, Yang LP, Kumar M, Liu Y, Story MD, Pickering CR, Byers LA, Williams MD, Wang J, Shen L, Yoo SY, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV. *Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer*. **Clin Cancer Res**, 2017. 23(11): p. 2713-2722. PMID: 28476872 PMID: PMC5457365
442. Stadler N, Dondelinger F, Hill SM, Akbani R, Lu Y, Mills GB, Mukherjee S. *Molecular heterogeneity at the network level: high-dimensional testing, clustering and a TCGA case study*. **Bioinformatics**, 2017. 33(18): p. 2890-2896. PMID: 28535188 PMID: PMC5590725
443. Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB. *Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers*. **Sci Transl Med**, 2017. 9(392). PMID: 28566428 PMID:
444. Theodosakis N, Micevic G, Langdon CG, Ventura A, Means R, Stern DF, Bosenberg MW. *p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis*. **J Invest Dermatol**, 2017. 137(10): p. 2187-2196. PMID: 28599981 PMID:
445. Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, Tripathy D, Keyomarsi K. *CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers*. **Nat Commun**, 2017. 8: p. 15916. PMID: 28653662 PMID: PMC5490269
446. Vitiello M, Tuccoli A, D'Aurizio R, Sarti S, Giannecchini L, Lubrano S, Marranci A, Evangelista M, Peppicelli S, Ippolito C, Barravecchia I, Guzzolino E, Montagnani V, Gowen M, Mercoledì E, Mercatanti A, Comelli L, Gurrieri S, Wu LW, Ope O, Flaherty K, Boland GM, Hammond MR, Kwong L, Chiariello M, Stecca B, Zhang G, Salvetti A, Angeloni D, Pitto L, Calorini L, Chiorino G, Pellegrini M, Herlyn M, Osman I, Poliseno L. *Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells*. **Oncotarget**, 2017. 8(15): p. 25395-25417. PMID: 28445987 PMID: 5421939
447. Wang C, Gu C, Jeong KJ, Zhang D, Guo W, Lu Y, Ju Z, Panupinthu N, Yang JY, Gagea MM, Ng PK, Zhang F, Mills GB. *YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway*. **Cancer Res**, 2017. 77(7): p. 1637-1648. PMID: 28202507 PMID:
448. Wang J, Xu-Monette ZY, Jabbar KJ, Shen Q, Manyam GC, Tzankov A, Visco C, Wang J, Montes-Moreno S, Dybkaer K, Tam W, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Wang S, Moller MB, Piris MA, Medeiros LJ, Li Y, Pham LV, Young KH. *AKT Hyperactivation and the Potential of AKT-Targeted Therapy in*

- Diffuse Large B-Cell Lymphoma*. **Am J Pathol**, 2017. 187(8): p. 1700-1716. PMID: 28627414 PMCID: PMC5530910
449. Wang X, Yao J, Wang J, Zhang Q, Brady SW, Arun B, Seewaldt VL, Yu D. *Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention*. **Cancer Prev Res (Phila)**, 2017. 10(11): p. 641-650. PMID: 28877935 PMCID: PMC5668174
450. Wang Y, Xu X, Yu S, Jeong KJ, Zhou Z, Han L, Tsang YH, Li J, Chen H, Mangala LS, Yuan Y, Eterovic AK, Lu Y, Sood AK, Scott KL, Mills GB, Liang H. *Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers*. **Genome Res**, 2017. 27(7): p. 1112-1125. PMID: 28411194 PMCID: PMC5495064
451. Xu T, Su B, Huang P, Wei W, Deng Y, Sehgal V, Wang D, Jiang J, Zhang G, Li A, Yang H, Claret FX. *Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load*. **Proteomics Clin Appl**, 2017. 11(5-6). PMID: 27883284 PMCID:
452. Zhang D, Zhang G, Hu X, Wu L, Feng Y, He S, Zhang Y, Hu Z, Yang L, Tian T, Xu W, Wei Z, Lu Y, Flaherty KT, Zhong X, Mills GB, Gimotty PA, Xu X, Herlyn M, Zhang L. *Oncogenic RAS Regulates Long Noncoding RNA *Orilnc1* in Human Cancer*. **Cancer Res**, 2017. 77(14): p. 3745-3757. PMID: 28473531 PMCID: PMC5511552
453. Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R, Hadjipanayis A, Pantazi A, Bristow CA, Lee E, Mahadeshwar HS, Tang J, Zhang J, Yang L, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Westbrook TF, Shelley CS, Choueiri TK, Ittmann M, Van Waes C, Weinstein JN, Liang H, Henske EP, Godwin AK, Park PJ, Kucherlapati R, Scott KL, Mills GB, Kwiatkowski DJ, Creighton CJ. *A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations*. **Cancer Cell**, 2017. 31(6): p. 820-832 e823. PMID: 28528867 PMCID: PMC5502825
454. Zhao W, Li J, Mills GB. *Functional proteomic characterization of cancer cell lines*. **Oncoscience**, 2017. 4(5-6): p. 41-42. PMID: 28781984 PMCID: PMC5538845
455. Al Emran A, Marzese DM, Menon DR, Stark MS, Torrano J, Hammerlindl H, Zhang G, Brafford P, Salomon MP, Nelson N, Hammerlindl S, Gupta D, Mills GB, Lu Y, Sturm RA, Flaherty K, Hoon DSB, Gabrielli B, Herlyn M, Schaider H. *Distinct histone modifications denote early stress-induced drug tolerance in cancer*. **Oncotarget**, 2018. 9(9): p. 8206-8222. PMID: 29492189 PMCID: PMC5823586
456. Ali M, Khan SA, Wennerberg K, Aittokallio T. *Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach*. **Bioinformatics**, 2018. 34(8): p. 1353-1362. PMID: 29186355 PMCID: PMC5905617
457. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Ng PK, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortes-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavitai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H, Group MCW, Cancer Genome Atlas Research N, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. *Comprehensive Characterization of Cancer Driver Genes and Mutations*. **Cell**, 2018. 173(2): p. 371-385 e318. PMID: 29625053 PMCID:
458. Barbhuiya MA, Kashyap MK, Puttamallesh VN, Kumar RV, Wu X, Pandey A, Gowda H. *Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays*. **Oncotarget**, 2018. 9(26): p. 18422-18434. PMID: 29719615 PMCID: PMC5915082
459. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N, Cancer Genome Atlas Research N, Weinstein JN, Mills GB, Levine DA, Akbani R. *A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers*. **Cancer Cell**, 2018. 33(4): p. 690-705 e699. PMID: 29622464 PMCID: PMC5959730
460. Borchering N, Bormann NL, Voigt AP, Zhang W. *TRGAted: A web tool for survival analysis using protein data in the Cancer Genome Atlas*. **F1000Res**, 2018. 7: p. 1235. PMID: 30345029 PMCID: PMC6173115.2
461. Bortolozzi R, Mattiuzzo E, Trentin L, Accordi B, Basso G, Viola G. *Ribociclib, a *Cdk4/Cdk6* kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-ALL)*. **Biochem Pharmacol**, 2018. 153: p. 230-241. PMID: 29408328 PMCID:
462. Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes

- DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK, Cancer Genome Atlas Research N, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C. *Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas*. **Cell Rep**, 2018. 23(1): p. 194-212 e196. PMID: 29617660 PMCID:
463. Chen H, Li C, Peng X, Zhou Z, Weinstein JN, Cancer Genome Atlas Research N, Liang H. *A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples*. **Cell**, 2018. 173(2): p. 386-399 e312. PMID: 29625054 PMCID: PMC5890960
464. Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS, Cancer Genome Atlas Research N, Sood AK, Gunaratne PH, Sumazin P. *Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context*. **Cell Rep**, 2018. 23(1): p. 297-312 e212. PMID: 29617668 PMCID: PMC5906131
465. Cuello MA, Kato S, Liberona F. *The impact on high-grade serous ovarian cancer of obesity and lipid metabolism-related gene expression patterns: the underestimated driving force affecting prognosis*. **J Cell Mol Med**, 2018. 22(3): p. 1805-1815. PMID: 29266765 PMCID: PMC5824367
466. Davenport AJ, Cross RS, Watson KA, Liao Y, Shi W, Prince HM, Beavis PA, Trapani JA, Kershaw MH, Ritchie DS, Darcy PK, Neeson PJ, Jenkins MR. *Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity*. **Proc Natl Acad Sci U S A**, 2018. 115(9): p. E2068-E2076. PMID: 29440406 PMCID: PMC5834689
467. Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang KL, Tokheim C, Cortes-Ciriano I, Jayasinghe R, Chen F, Yu L, Sun S, Olsen C, Kim J, Taylor AM, Cherniack AD, Akbani R, Suphavilai C, Nagarajan N, Stuart JM, Mills GB, Wyczalkowski MA, Vincent BG, Hutter CM, Zenklusen JC, Hoadley KA, Wendl MC, Shmulevich L, Lazar AJ, Wheeler DA, Getz G, Cancer Genome Atlas Research N. *Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics*. **Cell**, 2018. 173(2): p. 305-320 e310. PMID: 29625049 PMCID: PMC5916814
468. Du D, Ma W, Yates MS, Chen T, Lu KH, Lu Y, Weinstein JN, Broaddus RR, Mills GB, Liu Y. *Predicting high-risk endometrioid carcinomas using proteins*. **Oncotarget**, 2018. 9(28): p. 19704-19715. PMID: 29731976 PMCID: PMC5929419
469. Echevarria-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrisette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J. *Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma*. **EMBO Mol Med**, 2018. 10(5). PMID: 29650805 PMCID: PMC5938620
470. Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, Hess J, Ma S, Chiotti KE, McLellan M, Sofia HJ, Hutter C, Getz G, Wheeler D, Ding L, Group MCW, Cancer Genome Atlas Research N. *Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines*. **Cell Syst**, 2018. 6(3): p. 271-281 e277. PMID: 29596782 PMCID:
471. Gallagher SJ, Gunatilake D, Beaumont KA, Sharp DM, Tiffen JC, Heinemann A, Weninger W, Haass NK, Wilmott JS, Madore J, Ferguson PM, Rizos H, Hersey P. *HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma*. **Int J Cancer**, 2018. 142(9): p. 1926-1937. PMID: 29210065 PMCID:
472. Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L, Yu L, Sun SQ, Fusion Analysis Working G, Cancer Genome Atlas Research N, Chen K, Lazar AJ, Fields RC, Wendl MC, Van Tine BA, Vij R, Chen F, Nykter M, Shmulevich I, Ding L. *Driver Fusions and Their Implications in the Development and Treatment of Human Cancers*. **Cell Rep**, 2018. 23(1): p. 227-238 e223. PMID: 29617662 PMCID: PMC5916809
473. Garcia-Escudero R, Segrelles C, Duenas M, Pombo M, Ballestin C, Alonso-Riano M, Nenclares P, Alvarez-Rodriguez R, Sanchez-Aniceto G, Ruiz-Alonso A, Lopez-Cedrun JL, Paramio JM, Lorz C. *Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway*. **Oral Oncol**, 2018. 79: p. 55-63. PMID: 29598951 PMCID:
474. Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, Sun Y, Yao F, Li J, Zhang H, Liu J, Shriver CD, Hu H, Cancer Genome Atlas Research N, Piwnicka-Worms H, Ma L, Liang H. *Integrated Genomic Analysis of the*

- Ubiquitin Pathway across Cancer Types.* **Cell Rep**, 2018. 23(1): p. 213-226 e213. PMID: 29617661 PMID: PMC5916807
475. Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, L SE, Sood AK. *FABP4 as a key determinant of metastatic potential of ovarian cancer.* **Nat Commun**, 2018. 9(1): p. 2923. PMID: 30050129 PMID: PMC6062524
476. Gomez DR, Byers LA, Nilsson M, Diao L, Wang J, Li L, Tong P, Hofstad M, Saigal B, Wistuba I, Kalhor N, Swisher S, Fan Y, Hong WK, Suraokar M, Behrens C, Moran C, Heymach JV. *Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer.* **Oncotarget**, 2018. 9(18): p. 14268-14284. PMID: 29581842 PMID: PMC5865668
477. Grigsby P, Elhammali A, Ruiz F, Markovina S, McLellan MD, Miller CA, Chundury A, Ta NL, Rashmi R, Pfeifer JD, Fulton RS, DeWees T, Schwarz JK. *Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer.* **Oncotarget**, 2018. 9(3): p. 4061-4073. PMID: 29423104 PMID: PMC5790521
478. Grindel BJ, Martinez JR, Tellman TV, Harrington DA, Zafar H, Nakhleh L, Chung LW, Farach-Carson MC. *Matrilysin/MMP-7 Cleavage of Perlecan/HSPG2 Complexed with Semaphorin 3A Supports FAK-Mediated Stromal Invasion by Prostate Cancer Cells.* **Sci Rep**, 2018. 8(1): p. 7262. PMID: 29740048 PMID: PMC5940808
479. Gu S, Ngamcherdtrakul W, Reda M, Hu Z, Gray JW, Yantasee W. *Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment.* **PLoS One**, 2018. 13(6): p. e0198141. PMID: 29879129 PMID: PMC5991725 interests: Oregon Health & Science University, W.N., W.Y., and J.W.G. have a significant financial interest in PDX Pharmaceuticals, LLC, a company that may have a commercial interest in the results of this research and technology. This potential personal and institutional conflict of interest has been reviewed and managed by Oregon Health & Science University. This commercial affiliation does not alter our adherence to PLOS ONE policies on sharing data and materials.
480. Hartsough EJ, Kugel CH, 3rd, Vido MJ, Berger AC, Purwin TJ, Goldberg A, Davies MA, Schiewer MJ, Knudsen KE, Bollag G, Aplin AE. *Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo.* **Mol Cancer Ther**, 2018. 17(1): p. 84-95. PMID: 29133617 PMID: PMC5752590
481. Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM, Cancer Genome Atlas N, Stuart JM, Benz CC, Laird PW. *Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.* **Cell**, 2018. 173(2): p. 291-304 e296. PMID: 29625048 PMID: PMC5957518
482. Hsieh HJ, Zhang W, Lin SH, Yang WH, Wang JZ, Shen J, Zhang Y, Lu Y, Wang H, Yu J, Mills GB, Peng G. *Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery.* **Nat Commun**, 2018. 9(1): p. 3982. PMID: 30266942 PMID: PMC6162282
483. Hsu PY, Wu VS, Kanaya N, Petrossian K, Hsu HK, Nguyen D, Schmolze D, Kai M, Liu CY, Lu H, Chu P, Vito CA, Kruper L, Mortimer J, Chen S. *Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR(+)/HER2(+) Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant.* **Clin Cancer Res**, 2018. 24(2): p. 395-406. PMID: 29079660 PMID:
484. Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, Scott AD, Krassowski M, Cherniack AD, Houlahan KE, Jayasinghe R, Wang LB, Zhou DC, Liu D, Cao S, Kim YW, Koire A, McMichael JF, Huchtagowder V, Kim TB, Hahn A, Wang C, McLellan MD, Al-Mulla F, Johnson KJ, Cancer Genome Atlas Research N, Lichtarge O, Boutros PC, Raphael B, Lazar AJ, Zhang W, Wendl MC, Govindan R, Jain S, Wheeler D, Kulkarni S, Dipersio JF, Reimand J, Meric-Bernstam F, Chen K, Shmulevich I, Plon SE, Chen F, Ding L. *Pathogenic Germline Variants in 10,389 Adult Cancers.* **Cell**, 2018. 173(2): p. 355-370 e314. PMID: 29625052 PMID: PMC5949147
485. Hwang KT, Kim K, Chang JH, Oh S, Kim YA, Lee JY, Jung SH, Choi IS. *BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database.* **Cancer Res Treat**, 2018. 50(3): p. 658-669. PMID: 28701032 PMID: PMC6056973
486. Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, Zhao Y, Climente-Gonzalez H, Chai S, Wang F, Varghese R, Huang M, Liang WW, Wyczalkowski MA, Sengupta S, Li Z, Payne SH, Fenyo D, Miner JH, Walter MJ, Cancer Genome Atlas Research N, Vincent B, Eyraas E, Chen K, Shmulevich I, Chen F, Ding L. *Systematic*



- Analysis of Splice-Site-Creating Mutations in Cancer.* **Cell Rep**, 2018. 23(1): p. 270-281 e273. PMID: 29617666 PMID:
487. Jiang X, Mak PY, Mu H, Tao W, Mak D, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes JE, Liu Q, Andreeff M, Carter BZ. *Disruption of Wnt/beta-catenin exerts anti-leukemia activity and synergizes with FLT3 inhibition in FLT3-mutant acute myeloid leukemia.* **Clin Cancer Res**, 2018. PMID: 29463558 PMID:
488. Kahles A, Lehmann KV, Toussaint NC, Huser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C, Cancer Genome Atlas Research N, Ratsch G. *Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.* **Cancer Cell**, 2018. 34(2): p. 211-224 e216. PMID: 30078747 PMID:
489. Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatzka ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. *Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.* **EBioMedicine**, 2018. 38: p. 100-112. PMID: 30487062 PMID: PMC6306310
490. Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Shmulevich I, Cancer Genome Atlas Research N, Monnat RJ, Jr., Xiao Y, Wang C. *Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.* **Cell Rep**, 2018. 23(1): p. 239-254 e236. PMID: 29617664 PMID: PMC5961503
491. Koplev S, Lin K, Dohlman AB, Ma'ayan A. *Integration of pan-cancer transcriptomics with RPPA proteomics reveals mechanisms of epithelial-mesenchymal transition.* **PLoS Comput Biol**, 2018. 14(1): p. e1005911. PMID: 29293502 PMID: PMC5766255
492. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L, Cancer Genome Atlas Research N, Weinstein JN, Mishra L, Akbani R. *A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-beta Superfamily.* **Cell Syst**, 2018. 7(4): p. 422-437 e427. PMID: 30268436 PMID:
493. Lechner M, Chakravarthy AR, Walter V, Masterson L, Feber A, Jay A, Weinberger PM, McIndoe RA, Forde CT, Chester K, Kalavrezos N, O'Flynn P, Forster M, Jones TM, Vaz FM, Hayes DN, Fenton TR. *Frequent HPV-independent p16/INK4A overexpression in head and neck cancer.* **Oral Oncol**, 2018. 83: p. 32-37. PMID: 30098776 PMID:
494. Lee J, Geiss GK, Demirkan G, Vellano CP, Filanoski B, Lu Y, Ju Z, Yu S, Guo H, Bogatzki LY, Carter W, Meredith RK, Krishnamurthy S, Ding Z, Beechem JM, Mills GB. *Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies.* **Mol Cell Proteomics**, 2018. 17(6): p. 1245-1258. PMID: 29531020 PMID: PMC5986246
495. Lehrer M, Bhadra A, Aithala S, Ravikumar V, Zheng Y, Dogan B, Bonaccio E, Burnside ES, Morris E, Sutton E, Whitman GJ, Net J, Brandt K, Ganott M, Zuley M, Rao A, Group TBPR. *High-dimensional regression analysis links magnetic resonance imaging features and protein expression and signaling pathway alterations in breast invasive carcinoma.* **Oncoscience**, 2018. 5(1-2): p. 39-48. PMID: 29556516 PMID: PMC5854291
496. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, Cancer Genome Atlas Research N, Hu H. *An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.* **Cell**, 2018. 173(2): p. 400-416 e411. PMID: 29625055 PMID:
497. Liu W, Chen J, Tamayo AT, Ruan C, Li L, Zhou S, Shen C, Young KH, Westin J, Davis RE, Hu S, Medeiros LJ, Ford RJ, Pham LV. *Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.* **Oncotarget**, 2018. 9(1): p. 346-360. PMID: 29416618 PMID: PMC5787470
498. Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidfar F, Bowlby R, Islam M, Kim J, Chatila W, Akbani R, Kanchi RS, Rabkin CS, Willis JE, Wang KK, McCall SJ, Mishra L, Ojesina AI, Bullman S, Pedamallu CS, Lazar AJ, Sakai R, Cancer Genome Atlas Research N, Thorsson V, Bass AJ, Laird PW. *Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.* **Cancer Cell**, 2018. 33(4): p. 721-735 e728. PMID: 29622466 PMID: PMC5966039

499. Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kaminska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwinska P, Mazurek S, Mishra L, Heyn H, Krasnitz A, Godwin AK, Lazar AJ, Cancer Genome Atlas Research N, Stuart JM, Hoadley KA, Laird PW, Noushmehr H, Wiznerowicz M. *Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation*. **Cell**, 2018. 173(2): p. 338-354 e315. PMID: 29625051 PMCID: PMC5902191
500. Maust JD, Frankowski-McGregor CL, Bankhead A, 3rd, Simeone DM, Sebolt-Leopold JS. *Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers*. **Mol Cancer Ther**, 2018. 17(12): p. 2495-2506. PMID: 30254182 PMCID: PMC6279520
501. McGrail DJ, Federico L, Li Y, Dai H, Lu Y, Mills GB, Yi S, Lin SY, Sahni N. *Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers*. **Nat Commun**, 2018. 9(1): p. 1317. PMID: 29615613 PMCID: PMC5882811
502. Nagle AM, Levine KM, Tasdemir N, Scott JA, Burlbaugh K, Kehm J, Katz TA, Boone DN, Jacobsen BM, Atkinson JM, Oesterreich S, Lee AV. *Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors*. **Clin Cancer Res**, 2018. 24(20): p. 5165-5177. PMID: 29941485 PMCID:
503. Ng PK, Li J, Jeong KJ, Shao S, Chen H, Tsang YH, Sengupta S, Wang Z, Bhavana VH, Tran R, Soewito S, Minussi DC, Moreno D, Kong K, Dogruluk T, Lu H, Gao J, Tokheim C, Zhou DC, Johnson AM, Zeng J, Ip CKM, Ju Z, Wester M, Yu S, Li Y, Vellano CP, Schultz N, Karchin R, Ding L, Lu Y, Cheung LWT, Chen K, Shaw KR, Meric-Bernstam F, Scott KL, Yi S, Sahni N, Liang H, Mills GB. *Systematic Functional Annotation of Somatic Mutations in Cancer*. **Cancer Cell**, 2018. 33(3): p. 450-462 e410. PMID: 29533785 PMCID: PMC5926201
504. Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, Ajani JA, Lee JS. *Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype*. **Nat Commun**, 2018. 9(1): p. 1777. PMID: 29725014 PMCID: PMC5934392
505. Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, Ivan C, Morse J, Nelson M, Keating MJ, Wierda WG, Marszalek JR, Gandhi V. *Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy*. **Leukemia**, 2018. 32(4): p. 920-930. PMID: 29099493 PMCID: PMC5871548
506. Patil V, Mahalingam K. *A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma*. **Gene**, 2018. 679: p. 57-64. PMID: 30077762 PMCID:
507. Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, Wang Y, Cheng F, Tan L, Mojumdar K, Du D, Ge Z, Li J, Thomas GV, Birsoy K, Liu L, Zhang H, Zhao Z, Marchand C, Weinstein JN, Cancer Genome Atlas Research N, Bathe OF, Liang H. *Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers*. **Cell Rep**, 2018. 23(1): p. 255-269 e254. PMID: 29617665 PMCID: PMC5916795
508. Peng X, Xu X, Wang Y, Hawke DH, Yu S, Han L, Zhou Z, Mojumdar K, Jeong KJ, Labrie M, Tsang YH, Zhang M, Lu Y, Hwu P, Scott KL, Liang H, Mills GB. *A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer*. **Cancer Cell**, 2018. 33(5): p. 817-828 e817. PMID: 29706454 PMCID: PMC5953833
509. Petrossian K, Nguyen D, Lo C, Kanaya N, Somlo G, Cui YX, Huang CS, Chen S. *Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer*. **Breast Cancer Res Treat**, 2018. 170(3): p. 499-506. PMID: 29623577 PMCID: PMC6026053
510. Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, Leiserson MDM, Sethi G, Lu C, Ryan M, Su X, Cherniack AD, Robertson G, Akbani R, Spellman P, Weinstein JN, Hayes DN, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC, Cancer Genome Atlas N, Fujimoto J, Scapulatempo-Neto C, Moreira AL, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Gokmen-Polar Y, Badve S, Rajan A, Strobel P, Girard N, Tsao MS, Marx A, Tsao AS, Loehrer PJ. *The Integrated Genomic Landscape of Thymic Epithelial Tumors*. **Cancer Cell**, 2018. 33(2): p. 244-258 e210. PMID: 29438696 PMCID: PMC5994906
511. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhir R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG, Cancer Genome Atlas Research N, Spellman PT, Rathmell WK, Linehan

- WM. *The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma*. **Cell Rep**, 2018. 23(1): p. 313-326 e315. PMID: 29617669 PMCID:
512. Rockfield S, Guergues J, Rehman N, Smith A, Bauckman KA, Stevens SM, Jr., Nanjundan M. *Proteomic Profiling of Iron-Treated Ovarian Cells Identifies AKT Activation that Modulates the CLEAR Network*. **Proteomics**, 2018. 18(23): p. e1800244. PMID: 30267477 PMCID:
513. Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, Samaras D, Shroyer KR, Zhao T, Batiste R, Van Arnam J, Cancer Genome Atlas Research N, Shmulevich I, Rao AUK, Lazar AJ, Sharma A, Thorsson V. *Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images*. **Cell Rep**, 2018. 23(1): p. 181-193 e187. PMID: 29617659 PMCID: PMC5943714
514. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafeinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandath C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M, Cancer Genome Atlas Research N, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. *Oncogenic Signaling Pathways in The Cancer Genome Atlas*. **Cell**, 2018. 173(2): p. 321-337 e310. PMID: 29625050 PMCID:
515. Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Bernard B, Grandori C, Cancer Genome Atlas N. *Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas*. **Cell Syst**, 2018. 6(3): p. 282-300 e282. PMID: 29596783 PMCID: PMC5892207
516. Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, Smith PG, Cancer Genome Atlas Research N, Buonamici S, Yu L. *Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types*. **Cell Rep**, 2018. 23(1): p. 282-296 e284. PMID: 29617667 PMCID: PMC5933844
517. Shaw LC, Li Calzi S, Li N, Moldovan L, Sengupta-Caballero N, Quigley JL, Ivan M, Jun B, Bazan NG, Boulton ME, Busik J, Neu J, Grant MB. *Enteral Arg-Gln Dipeptide Administration Increases Retinal Docosahexaenoic Acid and Neuroprotectin D1 in a Murine Model of Retinopathy of Prematurity*. **Invest Ophthalmol Vis Sci**, 2018. 59(2): p. 858-869. PMID: 29490339 PMCID: PMC5815421
518. Shen H, Shih J, Hollern DP, Wang L, Bowlby R, Tickoo SK, Thorsson V, Mungall AJ, Newton Y, Hegde AM, Armenia J, Sanchez-Vega F, Pluta J, Pyle LC, Mehra R, Reuter VE, Godoy G, Jones J, Shelley CS, Feldman DR, Vidal DO, Lessel D, Kulis T, Carcano FM, Leraas KM, Lichtenberg TM, Brooks D, Cherniack AD, Cho J, Heiman DI, Kasaian K, Liu M, Noble MS, Xi L, Zhang H, Zhou W, Zenklusen JC, Hutter CM, Felau I, Zhang J, Schultz N, Getz G, Meyerson M, Stuart JM, Cancer Genome Atlas Research N, Akbani R, Wheeler DA, Laird PW, Nathanson KL, Cortessis VK, Hoadley KA. *Integrated Molecular Characterization of Testicular Germ Cell Tumors*. **Cell Rep**, 2018. 23(11): p. 3392-3406. PMID: 29898407 PMCID: PMC6075738
519. Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB. *BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency*. **Cancer Cell**, 2018. 33(3): p. 401-416 e408. PMID: 29533782 PMCID: PMC5944839
520. Tang W, Zhou M, Dorsey TH, Prieto DA, Wang XW, Ruppin E, Veenstra TD, Ambros S. *Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival*. **Genome Med**, 2018. 10(1): p. 94. PMID: 30501643 PMCID: PMC6276229
521. Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ, Cancer Genome Atlas Research N, Cherniack AD, Beroukhi R, Meyerson M. *Genomic and Functional Approaches to Understanding Cancer Aneuploidy*. **Cancer Cell**, 2018. 33(4): p. 676-689 e673. PMID: 29622463 PMCID:
522. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Peadarallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CE, Cancer Genome Atlas Research N, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich L. *The Immune Landscape of Cancer*. **Immunity**, 2018. 48(4): p. 812-830 e814. PMID: 29628290 PMCID: PMC5982584

523. Toraskar J, Magnussen SN, Chawla K, Svineng G, Steigedal TS. *Nephronectin mediates p38 MAPK-induced cell viability via its integrin-binding enhancer motif*. **FEBS Open Bio**, 2018. 8(12): p. 1992-2001. PMID: 30524949 PMCID: PMC6275265
524. Vangapandu HV, Chen H, Wierda WG, Keating MJ, Korkut A, Gandhi V. *Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells*. **Leuk Lymphoma**, 2018. 59(6): p. 1427-1438. PMID: 28971726 PMCID: PMC5882591
525. Wang J, Zhao W, Guo H, Fang Y, Stockman SE, Bai S, Ng PK, Li Y, Yu Q, Lu Y, Jeong KJ, Chen X, Gao M, Liang J, Li W, Tian X, Jonasch E, Mills GB, Ding Z. *AKT isoform-specific expression and activation across cancer lineages*. **BMC Cancer**, 2018. 18(1): p. 742. PMID: 30012111 PMCID: PMC6048698
526. Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB, Cancer Genome Atlas Research N, Camargo F, Liang H. *Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer*. **Cell Rep**, 2018. 25(5): p. 1304-1317 e1305. PMID: 30380420 PMCID:
527. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S, Cancer Genome Atlas Research N, Xie W, Yang D. *lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer*. **Cancer Cell**, 2018. 33(4): p. 706-720 e709. PMID: 29622465 PMCID:
528. Watson SS, Dane M, Chin K, Tatarova Z, Liu M, Liby T, Thompson W, Smith R, Nederlof M, Bucher E, Kilburn D, Whitman M, Sudar D, Mills GB, Heiser LM, Jonas O, Gray JW, Korkola JE. *Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes*. **Cell Syst**, 2018. 6(3): p. 329-342 e326. PMID: 29550255 PMCID: PMC5927625
529. Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N, Cancer Genome Atlas Research N, Sanchez Y, Greene CS. *Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas*. **Cell Rep**, 2018. 23(1): p. 172-180 e173. PMID: 29617658 PMCID: PMC5918694
530. Xu H, Lee MS, Tsai PY, Adler AS, Curry NL, Challa S, Freinkman E, Hitchcock DS, Copps KD, White MF, Bronson RT, Marcotrigiano M, Wu Y, Clish CB, Kalaany NY. *Ablation of insulin receptor substrates 1 and 2 suppresses Kras-driven lung tumorigenesis*. **Proc Natl Acad Sci U S A**, 2018. 115(16): p. 4228-4233. PMID: 29610318 PMCID: PMC5910837
531. Yam C, Xu X, Davies MA, Gimotty PA, Morrisette JJD, Tetzlaff MT, Wani KM, Liu S, Deng W, Buckley M, Zhao J, Amaravadi RK, Haas NB, Kudchadkar RR, Pavlick AC, Sosman JA, Tawbi H, Walker L, Schuchter LM, Karakousis GC, Gangadhar TC. *A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors*. **Clin Cancer Res**, 2018. 24(1): p. 22-32. PMID: 29051322 PMCID: PMC5754240
532. Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Vasilopoulos T, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, Krepler C, Brafford PA, Sproesser K, Murugan S, Somasundaram R, Garman B, Wubbenhorst B, Woo J, Yin X, Liu Q, Frederick DT, Miao B, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Kwong LN, Amaravadi RK, Lu Y, Boland G, Wei Z, Nathanson KL, Herbig U, Mills GB, Flaherty KT, Herlyn M, Shay JW. *Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma*. **Clin Cancer Res**, 2018. PMID: 29563139 PMCID:
533. Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Levine R, Tasian SK, Mullighan CG, Weinstock DM, Fruman DA, Konopleva M. *Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia*. **Oncotarget**, 2018. 9(8): p. 8027-8041. PMID: 29487712 PMCID: PMC5814279
534. Zhao W, Li J, Akbani R, Liang H, Mills GB. *Credentialing Individual Samples for Proteogenomic Analysis*. **Mol Cell Proteomics**, 2018. 17(8): p. 1515-1530. PMID: 29716986 PMCID: PMC6072548
535. Akbani R, Ling S, Lu Y. *Generation of Raw RPPA Data and Their Conversion to Analysis-Ready Data*. **Adv Exp Med Biol**, 2019. 1188: p. 165-180. PMID: 31820388 PMCID:
536. Bader DA, Hartig SM, Putluri V, Foley C, Hamilton MP, Smith EA, Saha PK, Panigrahi A, Walker C, Zong L, Martini-Stoica H, Chen R, Rajapakshe K, Coarfa C, Sreekumar A, Mitsiades N, Bankson JA, Ittmann MM, O'Malley BW, Putluri N, McGuire SE. *Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer*. **Nat Metab**, 2019. 1(1): p. 70-85. PMID: 31198906 PMCID: PMC6563330

537. Baffi TR, Van AN, Zhao W, Mills GB, Newton AC. *Protein Kinase C Quality Control by Phosphatase PHLPP1 Unveils Loss-of-Function Mechanism in Cancer*. **Mol Cell**, 2019. 74(2): p. 378-392 e375. PMID: 30904392 PMCID: PMC6504549
538. Barkovskaya A, Seip K, Hilmarsdottir B, Maelandsmo GM, Moestue SA, Itkonen HM. *O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes*. **Sci Rep**, 2019. 9(1): p. 5670. PMID: 30952976 PMCID: PMC6450885
539. Buj R, Chen CW, Dahl ES, Leon KE, Kuskovsky R, Maglakelidze N, Navaratnarajah M, Zhang G, Doan MT, Jiang H, Zaleski M, Kutzler L, Lacko H, Lu Y, Mills GB, Gowda R, Robertson GP, Warrick JI, Herlyn M, Imamura Y, Kimball SR, DeGraff DJ, Snyder NW, Aird KM. *Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming*. **Cell Rep**, 2019. 28(8): p. 1971-1980 e1978. PMID: 31433975 PMCID: PMC6716532
540. Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, Crews CM. *Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation*. **Cancer Res**, 2019. 79(18): p. 4744-4753. PMID: 31311809 PMCID: PMC6893872
541. Cardnell RJ, Byers LA, Wang J. *Integrated Approaches for the Use of Large Datasets to Identify Rational Therapies for the Treatment of Lung Cancers*. **Cancers (Basel)**, 2019. 11(2). PMID: 30791396 PMCID: PMC6406670
542. Carroll MJ, Parent CR, Page D, Kreeger PK. *Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting*. **BMC Cancer**, 2019. 19(1): p. 1025. PMID: 31672130 PMCID: PMC6822426
543. Chen MM, Li J, Wang Y, Akbani R, Lu Y, Mills GB, Liang H. *TCPA v3.0: An Integrative Platform to Explore the Pan-Cancer Analysis of Functional Proteomic Data*. **Mol Cell Proteomics**, 2019. 18(8 suppl 1): p. S15-S25. PMID: 31201206 PMCID: PMC6692772
544. Chung RH, Kang CY. *A multi-omics data simulator for complex disease studies and its application to evaluate multi-omics data analysis methods for disease classification*. **Gigascience**, 2019. 8(5). PMID: 31029063 PMCID: PMC6486474
545. Crook OM, Gatto L, Kirk PDW. *Fast approximate inference for variable selection in Dirichlet process mixtures, with an application to pan-cancer proteomics*. **Stat Appl Genet Mol Biol**, 2019. 18(6). PMID: 31829970 PMCID:
546. Fan P, Siwak DR, Abderrahman B, Agboke FA, Yerrum S, Jordan VC. *Suppression of Nuclear Factor-kappaB by Glucocorticoid Receptor Blocks Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells*. **Mol Cancer Ther**, 2019. 18(10): p. 1684-1695. PMID: 31511352 PMCID: PMC6774891
547. Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Urbe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB. *Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy*. **Cancer Cell**, 2019. 35(6): p. 851-867 e857. PMID: 31185210 PMCID: PMC6642675
548. Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. *Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells*. **Blood Cancer J**, 2019. 9(2): p. 4. PMID: 30647404 PMCID: PMC6333829
549. Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER, 3rd, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, Aguet F, Weir BA, Rothberg MV, Paoletta BR, Lawrence MS, Akbani R, Lu Y, Tiv HL, Gokhale PC, de Weck A, Mansour AA, Oh C, Shih J, Hadi K, Rosen Y, Bistline J, Venkatesan K, Reddy A, Sonkin D, Liu M, Lehar J, Korn JM, Porter DA, Jones MD, Golji J, Caponigro G, Taylor JE, Dunning CM, Creech AL, Warren AC, McFarland JM, Zamanighomi M, Kauffmann A, Stransky N, Imielinski M, Maruvka YE, Cherniack AD, Tsherniak A, Vazquez F, Jaffe JD, Lane AA, Weinstock DM, Johannessen CM, Morrissey MP, Stegmeier F, Schlegel R, Hahn WC, Getz G, Mills GB, Boehm JS, Golub TR, Garraway LA, Sellers WR. *Next-generation characterization of the Cancer Cell Line Encyclopedia*. **Nature**, 2019. 569(7757): p. 503-508. PMID: 31068700 PMCID: PMC6697103
550. Goodspeed A, Jean A, Costello JC. *A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer*. **Eur Urol**, 2019. 75(2): p. 242-250. PMID: 30414698 PMCID: PMC6339584
551. Hoff FW, Lu Y, Kornblau SM. *Antibody Screening*. **Adv Exp Med Biol**, 2019. 1188: p. 149-163. PMID: 31820387 PMCID:

552. Indarte M, Puentes R, Maruggi M, Ihle NT, Grandjean G, Scott M, Ahmed Z, Meuillet EJ, Zang S, Lemos R, Jr., Du-Cuny L, Layng F, Correa RG, Bankston LA, Liddington RC, Kirkpatrick L, Powis G. *An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors*. **Cancer Res**, 2019. 79(12): p. 3100-3111. PMID: 31040156 PMCID: PMC6571060
553. Itkonen HM, Urbanucci A, Martin SE, Khan A, Mathelier A, Thiede B, Walker S, Mills IG. *High OGT activity is essential for MYC-driven proliferation of prostate cancer cells*. **Theranostics**, 2019. 9(8): p. 2183-2197. PMID: 31149037 PMCID: PMC6531294
554. Kim TR, Jeong HH, Sohn KA. *Topological integration of RPPA proteomic data with multi-omics data for survival prediction in breast cancer via pathway activity inference*. **BMC Med Genomics**, 2019. 12(Suppl 5): p. 94. PMID: 31296204 PMCID: PMC6624183
555. Labrie M, Fang Y, Kendsersky ND, Li J, Liang H, Westin SN, Mitri Z, Mills GB. *Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance*. **Adv Exp Med Biol**, 2019. 1188: p. 251-266. PMID: 31820393 PMCID:
556. Labrie M, Kendsersky ND, Ma H, Campbell L, Eng J, Chin K, Mills GB. *Proteomics advances for precision therapy in ovarian cancer*. **Expert Rev Proteomics**, 2019. 16(10): p. 841-850. PMID: 31512530 PMCID: PMC6814571
557. Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. *Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options*. **Oncotarget**, 2019. 10(37): p. 3533-3546. PMID: 31191824 PMCID: PMC6544405
558. Li CJ, Jiang C, Liu Y, Bell T, Ma W, Ye Y, Huang S, Guo H, Zhang H, Wang L, Wang J, Nomie K, Zhang L, Wang M. *Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma*. **Mol Cancer Ther**, 2019. 18(2): p. 267-277. PMID: 30413649 PMCID: PMC6363842
559. Li X, Mak VCY, Zhou Y, Wang C, Wong ESY, Sharma R, Lu Y, Cheung ANY, Mills GB, Cheung LWT. *Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer*. **Nat Commun**, 2019. 10(1): p. 716. PMID: 30755611 PMCID: PMC6372715
560. Lin X, Spindler TJ, de Souza Fonseca MA, Corona RI, Seo JH, Dezem FS, Li L, Lee JM, Long HW, Sellers TA, Karlan BY, Noushmehr H, Freedman ML, Gayther SA, Lawrenson K. *Super-Enhancer-Associated LncRNA UCA1 Interacts Directly with AMOT to Activate YAP Target Genes in Epithelial Ovarian Cancer*. **iScience**, 2019. 17: p. 242-255. PMID: 31307004 PMCID: PMC6629722
561. Lindemann A, Patel AA, Silver NL, Tang L, Liu Z, Wang L, Tanaka N, Rao X, Takahashi H, Maduka NK, Zhao M, Chen TC, Liu W, Gao M, Wang J, Frank SJ, Hittelman WN, Mills GB, Myers JN, Osman AA. *COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms*. **Clin Cancer Res**, 2019. 25(18): p. 5650-5662. PMID: 31308060 PMCID: PMC6759991
562. Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK. *GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition*. **Mol Cancer Ther**, 2019. 18(5): p. 969-979. PMID: 30926640 PMCID: PMC6497555
563. Maric G, Annis MG, MacDonald PA, Russo C, Perkins D, Siwak DR, Mills GB, Siegel PM. *GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and beta-catenin activity*. **Oncogene**, 2019. 38(26): p. 5294-5307. PMID: 30914799 PMCID:
564. Mokhlis HA, Bayraktar R, Kabil NN, Caner A, Kahraman N, Rodriguez-Aguayo C, Zambalde EP, Sheng J, Karagoz K, Kanlikilicer P, Abdel Aziz AAH, Abdelghany TM, Ashour AA, Wong S, Gatza ML, Calin GA, Lopez-Berestein G, Ozpolat B. *The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers*. **Mol Ther Nucleic Acids**, 2019. 14: p. 301-317. PMID: 30654191 PMCID: PMC6348737
565. Patil SL, Palat A, Pan Y, Rajapakshe K, Mirchandani R, Bondesson M, Yustein JT, Coarfa C, Gunaratne PH. *MicroRNA-509-3p inhibits cellular migration, invasion, and proliferation, and sensitizes osteosarcoma to cisplatin*. **Sci Rep**, 2019. 9(1): p. 19089. PMID: 31836741 PMCID: PMC6911094
566. Patil V, Mahalingam K. *Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes*. **Gene**, 2019. 685: p. 85-95. PMID: 30401645 PMCID:
567. Polireddy K, Singh K, Pruski M, Jones NC, Manisundaram NV, Ponnala P, Ouellette M, Van Buren G, Younes M, Bynon JS, Dar WA, Bailey JM. *Mutant p53(R175H) promotes cancer initiation in the pancreas by stabilizing HSP70*. **Cancer Lett**, 2019. 453: p. 122-130. PMID: 30946870 PMCID:

568. Rader JS, Pan A, Corbin B, Iden M, Lu Y, Vellano CP, Akbani R, Mills GB, Simpson P. *Identification and validation of a prognostic proteomic signature for cervical cancer*. **Gynecol Oncol**, 2019. 155(2): p. 324-330. PMID: 31477280 PMCID: PMC6825895
569. Raglan O, Assi N, Nautiyal J, Lu H, Gabra H, Gunter MJ, Kyrgiou M. *Proteomic analysis of malignant and benign endometrium according to obesity and insulin-resistance status using Reverse Phase Protein Array*. **Transl Res**, 2019. PMID: 31954096 PMCID:
570. Ragon BK, Odenike O, Baer MR, Stock W, Borthakur G, Patel K, Han L, Chen H, Ma H, Joseph L, Zhao Y, Baggerly K, Konopleva M, Jain N. *Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study*. **Clin Lymphoma Myeloma Leuk**, 2019. 19(7): p. 431-440 e413. PMID: 31056348 PMCID: PMC6626580
571. Ruvolo PP, Hu CW, Qiu Y, Ruvolo VR, Go RL, Hubner SE, Coombes KR, Andreeff M, Qutub AA, Kornblau SM. *LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML*. **EBioMedicine**, 2019. 44: p. 126-137. PMID: 31105032 PMCID: PMC6604360
572. Sambandam V, Frederick MJ, Shen L, Tong P, Rao X, Peng S, Singh R, Mazumdar T, Huang C, Li Q, Pickering CR, Myers JN, Wang J, Johnson FM. *PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition*. **Clin Cancer Res**, 2019. 25(11): p. 3329-3340. PMID: 30770351 PMCID: PMC6548600
573. Singh PK, Deorukhkar AA, Venkatesulu BP, Li X, Tailor R, Bomalaski JS, Krishnan S. *Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation*. **Mol Cancer Ther**, 2019. 18(12): p. 2381-2393. PMID: 31395686 PMCID: PMC6891156
574. Sitte M, Menck K, Wachter A, Reinz E, Korf U, Wiemann S, Bleckmann A, Beissbarth T. *Reconstruction of Different Modes of WNT Dependent Protein Networks from Time Series Protein Quantification*. **Stud Health Technol Inform**, 2019. 267: p. 175-180. PMID: 31483270 PMCID:
575. Siwak DR, Li J, Akbani R, Liang H, Lu Y. *Analytical Platforms 3: Processing Samples via the RPPA Pipeline to Generate Large-Scale Data for Clinical Studies*. **Adv Exp Med Biol**, 2019. 1188: p. 113-147. PMID: 31820386 PMCID:
576. Thangavel H, De Angelis C, Vasaikar S, Bhat R, Jolly MK, Nagi C, Creighton CJ, Chen F, Dobrolecki LE, George JT, Kumar T, Abdulkareem NM, Mao S, Nardone A, Rimawi M, Osborne CK, Lewis MT, Levine H, Zhang B, Schiff R, Giuliano M, Trivedi MV. *A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer*. **J Clin Med**, 2019. 8(11). PMID: 31652963 PMCID: PMC6912280
577. Tong Z, Mejia A, Veeranki O, Verma A, Correa AM, Dokey R, Patel V, Solis LM, Mino B, Kathkuda R, Rodriguez-Canales J, Lin SH, Krishnan S, Kopetz S, Blum M, Ajani JA, Hofstetter WL, Maru DM. *Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma*. **Ther Adv Med Oncol**, 2019. 11: p. 1758835919864850. PMID: 31384313 PMCID: PMC6659187
578. Veeranki OL, Tong Z, Dokey R, Mejia A, Zhang J, Qiao Y, Singh PK, Katkhuda R, Mino B, Tailor R, Canales JR, Bassett R, Ajani J, Wu JY, Kopetz S, Blum M, Hofstetter W, Tetzlaff M, Krishnan S, Lin SH, Maru D. *Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma*. **Oncotarget**, 2019. 10(45): p. 4703-4718. PMID: 31384397 PMCID: PMC6659793
579. Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK. *Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4*. **Mol Cancer Ther**, 2019. 18(2): p. 421-436. PMID: 30420565 PMCID: PMC6363833
580. Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. *Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation*. **Breast Cancer Res**, 2019. 21(1): p. 78. PMID: 31277699 PMCID: PMC6612080

581. Yang P, Jiang Y, Pan Y, Ding X, Rhea P, Ding J, Hawke DH, Felsher D, Narla G, Lu Z, Lee RT. *Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression*. **Sci Rep**, 2019. 9(1): p. 6428. PMID: 31015523 PMCID: PMC6478697
582. Yang P, Jiang Y, Rhea PR, Coway T, Chen D, Gagea M, Harribance SL, Cohen L. *Human Biofield Therapy and the Growth of Mouse Lung Carcinoma*. **Integr Cancer Ther**, 2019. 18: p. 1534735419840797. PMID: 30947564 PMCID: PMC6475842
583. Yim SY, Hae NJ, Shin JH, Jeong YS, Kang SH, Park YN, Um SH, Lee JS. *Identification of prognostic biomarker in predicting hepatocarcinogenesis from cirrhotic liver using protein and gene signatures*. **Exp Mol Pathol**, 2019. 111: p. 104319. PMID: 31676327 PMCID:
584. Zhang L, Liu G, Kong M, Li T, Wu D, Zhou X, Yang C, Xia L, Yang Z, Chen L. *Revealing dynamic regulations and the related key proteins of myeloma-initiating cells by integrating experimental data into a systems biological model*. **Bioinformatics**, 2019. PMID: 31350562 PMCID:
585. Zheng L, Chen Z, Kawakami M, Chen Y, Roszik J, Mustachio LM, Kurie JM, Villalobos P, Lu W, Behrens C, Mino B, Solis LM, Silvester J, Thu KL, Cescon DW, Rodriguez-Canales J, Wistuba II, Mak TW, Liu X, Dmitrovsky E. *Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy*. **Mol Cancer Ther**, 2019. 18(10): p. 1775-1786. PMID: 31358662 PMCID:
586. Zhou J, Du Y, Lu Y, Luan B, Xu C, Yu Y, Zhao H. *CD44 Expression Predicts Prognosis of Ovarian Cancer Patients Through Promoting Epithelial-Mesenchymal Transition (EMT) by Regulating Snail, ZEB1, and Caveolin-1*. **Front Oncol**, 2019. 9: p. 802. PMID: 31497537 PMCID: PMC6712994
587. Zhuang J, Shirazi F, Singh RK, Kuitatse I, Wang H, Lee HC, Berkova Z, Berger A, Hyer M, Chattopadhyay N, Syed S, Shi JQ, Yu J, Shinde V, Tirrell S, Jones RJ, Wang Z, Davis RE, Orlowski RZ. *Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma*. **Blood**, 2019. 133(14): p. 1572-1584. PMID: 30737236 PMCID: PMC6450433
588. Akula SM, Ruvolo PP, McCubrey JA. *TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer*. **Aging (Albany NY)**, 2020. 12. PMID: 31986125 PMCID:
589. Andey T, Attah MM, Akwaaba-Reynolds NA, Cheema S, Parvin-Nejad S, Acquah-Mensah GK. *Enhanced immortalization, HUWE1 mutations and other biological drivers of breast invasive carcinoma in Black/African American patients*. **Gene X**, 2020. 5: p. 100030. PMID: 32550556 PMCID: PMC7286073
590. Berg HF, Ju Z, Myrvold M, Fasmer KE, Halle MK, Hoivik EA, Westin SN, Trovik J, Haldorsen IS, Mills GB, Krakstad C, Werner HMJ. *Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma*. **Br J Cancer**, 2020. PMID: 32037399 PMCID:
591. Blucher AS, Mills GB, Tsang YH. *Which path to follow? Utilizing proteomics to improve therapy choices for breast cancer patients*. **Expert Rev Proteomics**, 2020. 17(3): p. 187-190. PMID: 32306787 PMCID:
592. Buccarelli M, Lulli V, Giuliani A, Signore M, Martini M, D'Alessandris QG, Giannetti S, Novelli A, Ilari R, Giurato G, Boe A, Castellani G, Spartano S, Marangi G, Biffoni M, Genuardi M, Pallini R, Marziali G, Ricci-Vitiani L. *Deregulated expression of the imprinted DLK1-DIO3 region in glioblastoma stemlike cells: tumor suppressor role of lncRNA MEG3*. **Neuro Oncol**, 2020. 22(12): p. 1771-1784. PMID: 32459347 PMCID: PMC7746944
593. Das I, Chen H, Maddalo G, Tuominen R, Rebecca VW, Herlyn M, Hansson J, Davies MA, Egyhazi Brage S. *Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma*. **Cell Death Dis**, 2020. 11(10): p. 882. PMID: 33082316 PMCID: PMC7576205
594. Demirkol Canli S, Seza EG, Sheraj I, Gomceli I, Turhan N, Carberry S, Prehn JHM, Gure AO, Banerjee S. *Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway*. **Carcinogenesis**, 2020. 41(9): p. 1219-1228. PMID: 32628753 PMCID:
595. Dodhiawala PB, Khurana N, Zhang D, Cheng Y, Li L, Wei Q, Seehra K, Jiang H, Grierson PM, Wang-Gillam A, Lim KH. *TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations*. **J Clin Invest**, 2020. 130(9): p. 4771-4790. PMID: 32573499 PMCID: PMC7456254
596. Elesela S, Morris SB, Narayanan S, Kumar S, Lombard DB, Lukacs NW. *Sirtuin 1 regulates mitochondrial function and immune homeostasis in respiratory syncytial virus infected dendritic cells*. **PLoS Pathog**, 2020. 16(2): p. e1008319. PMID: 32106265 PMCID: PMC7046194
597. Fan D, Liu Q, Wu F, Liu N, Qu H, Yuan Y, Li Y, Gao H, Ge J, Xu Y, Wang H, Liu Q, Zhao Z. *Prognostic significance of PI3K/AKT/ mTOR signaling pathway members in clear cell renal cell carcinoma*. **PeerJ**, 2020. 8: p. e9261. PMID: 32547875 PMCID: PMC7271881



598. Fang X, Liu X, Weng C, Wu Y, Li B, Mao H, Guan M, Lu L, Liu G. *Construction and Validation of a Protein Prognostic Model for Lung Squamous Cell Carcinoma*. **Int J Med Sci**, 2020. 17(17): p. 2718-2727. PMID: 33162799 PMCID: PMC7645351
599. Fisher MM, SenthilKumar G, Hu R, Goldstein S, Ong IM, Miller MC, Brennan SR, Kaushik S, Abel L, Nickel KP, Iyer G, Harari PM, Kimple RJ, Baschnagel AM. *Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas*. **Int J Radiat Oncol Biol Phys**, 2020. PMID: 32298810 PMCID:
600. Garrido-Castro AC, Saura C, Barroso-Sousa R, Guo H, Ciruelos E, Bermejo B, Gavila J, Serra V, Prat A, Pare L, Celiz P, Villagrasa P, Li Y, Savoie J, Xu Z, Arteaga CL, Krop IE, Solit DB, Mills GB, Cantley LC, Winer EP, Lin NU, Rodon J. *Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer*. **Breast Cancer Res**, 2020. 22(1): p. 120. PMID: 33138866 PMCID: PMC7607628
601. He G, Xie X, Siddik ZH. *Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents*. **Cancer Chemother Pharmacol**, 2020. 85(6): p. 1129-1140. PMID: 32468080 PMCID: PMC7402587
602. Jaiprasart P, Dogra S, Neelakantan D, Devapatla B, Woo S. *Identification of signature genes associated with therapeutic resistance to anti-VEGF therapy*. **Oncotarget**, 2020. 11(1): p. 99-114. PMID: 32002127 PMCID: PMC6967771
603. Jordan KR, Sikora MJ, Slansky JE, Minic A, Richer JK, Moroney MR, Hu J, Wolsky RJ, Watson ZL, Yamamoto TM, Costello JC, Clauset A, Behbakht K, Kumar TR, Bitler BG. *The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval*. **Clin Cancer Res**, 2020. 26(23): p. 6362-6373. PMID: 32928797 PMCID: PMC7923250
604. Khoury JD, Tashakori M, Yang H, Loghavi S, Wang Y, Wang J, Piya S, Borthakur G. *Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation*. **Cancers (Basel)**, 2020. 12(12). PMID: 33255818 PMCID: PMC7761301
605. Kun EHS, Tsang YTM, Lin S, Pan S, Medapalli T, Malpica A, Richards JS, Gershenson DM, Wong KK. *Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations*. **Sci Rep**, 2020. 10(1): p. 20678. PMID: 33244099 PMCID: PMC7693266
606. Kwon J, Helfman DM, Kim MY. *AKT drives sustained motility following MEK inhibition via promoting SNAIL and AXL in MDA-MB-231 LM2*. **Biochem Biophys Res Commun**, 2020. 528(1): p. 92-98. PMID: 32456793 PMCID:
607. Lara OD, Bayraktar E, Amero P, Ma S, Ivan C, Hu W, Wang Y, Mangala LS, Dutta P, Bhattacharya P, Ashizawa AT, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AK. *Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer*. **Oncotarget**, 2020. 11(29): p. 2819-2833. PMID: 32754300 PMCID: PMC7381098
608. Li F, Guo E, Huang J, Lu F, Yang B, Xiao R, Liu C, Wu X, Fu Y, Wang Z, Peng S, Lei Y, Guo Z, Li L, Xi L, Sun C, Liu S, Chen G. *mTOR inhibition overcomes primary and acquired resistance to Wee1 inhibition by augmenting replication stress in epithelial ovarian cancers*. **Am J Cancer Res**, 2020. 10(3): p. 908-924. PMID: 32266099 PMCID: PMC7136919
609. Lin Z, Meng X, Wen J, Corral JM, Andreev D, Kachler K, Schett G, Chen X, Bozec A. *Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients*. **Front Oncol**, 2020. 10: p. 596493. PMID: 33344244 PMCID: PMC7747763
610. Liu G, Jin Z, Lu X. *Differential Targeting of Gr-MDSCs, T Cells and Prostate Cancer Cells by Dactolisib and Dasatinib*. **Int J Mol Sci**, 2020. 21(7). PMID: 32230980 PMCID: PMC7178187
611. Luo Q, Zhang X. *Construction of Protein-related Risk Score Model in Bladder Urothelial Carcinoma*. **Biomed Res Int**, 2020. 2020: p. 7147824. PMID: 32802870 PMCID: PMC7421160
612. Marusak C, Thakur V, Li Y, Freitas JT, Zmina PM, Thakur VS, Chang M, Gao M, Tan J, Xiao M, Lu Y, Mills GB, Flaherty K, Frederick DT, Miao B, Sullivan RJ, Moll T, Boland GM, Herlyn M, Zhang G, Bedogni B. *Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma*. **Clin Cancer Res**, 2020. 26(22): p. 6039-6050. PMID: 32820016 PMCID: PMC7669662
613. McDaniel NK, Iida M, Nickel KP, Longhurst CA, Fischbach SR, Rodems TS, Kranjac CA, Bo AY, Luo Q, Gallagher MM, Welke NB, Mitchell KR, Schulz AE, Eckers JC, Hu R, Salgia R, Hong S, Bruce JY, Kimple RJ, Wheeler DL. *AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer*. **Clin Cancer Res**, 2020. 26(16): p. 4349-4359. PMID: 32439698 PMCID: PMC7442604

614. Moon SJ, Kim JH, Kong SH, Shin CS. *Protein Expression of Cyclin B1, Transferrin Receptor, and Fibronectin Is Correlated with the Prognosis of Adrenal Cortical Carcinoma*. **Endocrinol Metab (Seoul)**, 2020. 35(1): p. 132-141. PMID: 32207273 PMCID: PMC7090291
615. O'Brien NA, McDermott MSJ, Conklin D, Luo T, Ayala R, Salgar S, Chau K, DiTomaso E, Babbar N, Su F, Gaither A, Hurvitz SA, Linnartz R, Rose K, Hirawat S, Slamon DJ. *Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer*. **Breast Cancer Res**, 2020. 22(1): p. 89. PMID: 32795346 PMCID: PMC7427086
616. Otani Y, Yoo JY, Chao S, Liu J, Jaime-Ramirez AC, Lee TJ, Hurwitz B, Yan Y, Dai H, Glorioso JC, Caligiuri MA, Yu J, Kaur B. *Oncolytic HSV-Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition*. **Clin Cancer Res**, 2020. 26(10): p. 2381-2392. PMID: 32139403 PMCID: PMC7325527
617. Petersen S, Wilson AJ, Hirst J, Roby KF, Fadare O, Crispens MA, Beeghly-Fadiel A, Khabele D. *CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes*. **Gynecol Oncol**, 2020. 157(2): p. 405-410. PMID: 32044108 PMCID: PMC7217738
618. Raglan O, Assi N, Nautiyal J, Lu H, Gabra H, Gunter MJ, Kyrgiou M. *Proteomic analysis of malignant and benign endometrium according to obesity and insulin-resistance status using Reverse Phase Protein Array*. **Transl Res**, 2020. 218: p. 57-72. PMID: 31954096 PMCID:
619. Sasaki N, Iwaya T, Chiba T, Fujita M, Ju Z, Endo F, Yaegashi M, Hachiya T, Sugimoto R, Sugai T, Siwak DR, Liotta LA, Lu Y, Mills GB, Nakagawa H, Nishizuka SS. *Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA*. **PLoS One**, 2020. 15(10): p. e0239966. PMID: 33027286 PMCID: PMC7540850 Daiichi Sankyo. T. Hachiya is an employee and a Board Member of Genome Analytics Japan, Inc. G. B. Mills receives research grants from AstraZeneca, Karus Therapeutics, Nanostring, Pfizer, Tesaro, Adelson Medical Research Foundation, Breast Cancer Research Foundation, Komen Research Foundation, Ovarian Cancer Research Foundation, and Prospect Creek Foundation; serves as a consultant/scientific advisory board of AstraZeneca, Chrysalis(\*), ImmunoMET, Ionis, Lilly USA, Mills Institute for Personalized Care(\*), Nuevolution(\*), PDX Pharma, Signalchem Lifesciences, Symphogen, and Tarveda (\*, travel reimbursement only); is a stockowner of Catena Pharmaceuticals, ImmunoMet, SignalChem, Spindletop Ventures, and Tarveda; and has a relationship in licensed technology to HRD assay to Myriad Genetics, and DSP to Nanostring. S. S. Nishizuka receives research grants from Array Jet, Geninus, Taiho Pharmaceuticals, and Boelinger-Ingelheim, Geninus; serves as a consultant of CLEA Japan; receives travel expense reimbursement from Mills Institute for Personalized Care, Nomura Jimusyo; and receives honoraria from Chugai Pharmaceutical. These do not alter our adherence to PLOS ONE policies on sharing data and materials.
620. Shackelford MT, Rao DM, Bordeaux EK, Hicks HM, Towers CG, Sottnik JL, Oesterreich S, Sikora MJ. *Estrogen Regulation of mTOR Signaling and Mitochondrial Function in Invasive Lobular Carcinoma Cell Lines Requires WNT4*. **Cancers (Basel)**, 2020. 12(10). PMID: 33053661 PMCID: PMC7650584
621. Shenoy N. *HIF1alpha is not a target of 14q deletion in clear cell renal cancer*. **Sci Rep**, 2020. 10(1): p. 17642. PMID: 33077781 PMCID: PMC7573601
622. Sun C, Fang Y, Labrie M, Li X, Mills GB. *Systems approach to rational combination therapy: PARP inhibitors*. **Biochem Soc Trans**, 2020. 48(3): p. 1101-1108. PMID: 32379297 PMCID: PMC7329579
623. Takahashi S, Asada K, Takasawa K, Shimoyama R, Sakai A, Bolatkan A, Shinkai N, Kobayashi K, Komatsu M, Kaneko S, Sese J, Hamamoto R. *Predicting Deep Learning Based Multi-Omics Parallel Integration Survival Subtypes in Lung Cancer Using Reverse Phase Protein Array Data*. **Biomolecules**, 2020. 10(10). PMID: 33086649 PMCID: PMC7603376
624. Tiago M, Capparelli C, Erkes DA, Purwin TJ, Heilman SA, Berger AC, Davies MA, Aplin AE. *Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma*. **Br J Cancer**, 2020. PMID: 31932756 PMCID:
625. Vinik Y, Ortega FG, Mills GB, Lu Y, Jurkowicz M, Halperin S, Aharoni M, Gutman M, Lev S. *Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response*. **Sci Adv**, 2020. 6(40). PMID: 33008904 PMCID: PMC7852393
626. Wang B, Shao W, Shi Y, Liao J, Chen X, Wang C. *Verteporfin induced SUMOylation of YAP1 in endometrial cancer*. **Am J Cancer Res**, 2020. 10(4): p. 1207-1217. PMID: 32368396 PMCID: PMC7191103

627. Wang Y, Tzeng YT, Chang G, Wang X, Chen S. *Amphiregulin retains ERalpha expression in acquired aromatase inhibitor resistant breast cancer cells*. **Endocr Relat Cancer**, 2020. 27(12): p. 671-683. PMID: 33112819 PMCID: PMC7665895
628. Wei M, Haney MG, Rivas DR, Blackburn JS. *Protein tyrosine phosphatase 4A3 (PTP4A3/PRL-3) drives migration and progression of T-cell acute lymphoblastic leukemia in vitro and in vivo*. **Oncogenesis**, 2020. 9(1): p. 6. PMID: 32001668 PMCID: PMC6992623
629. Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, Reuben A, Ingram D, Wang WL, Ju Z, Hong Leung C, Lin H, Zheng Y, Roszik J, Wang W, Patel S, Benjamin RS, Somaiah N, Conley AP, Mills GB, Hwu P, Gorlick R, Lazar A, Daw NC, Lewis V, Futreal PA. *Immuno-genomic landscape of osteosarcoma*. **Nat Commun**, 2020. 11(1): p. 1008. PMID: 32081846 PMCID: PMC7035358
630. Wu D, Gong P, Zeng Q, Zhang W, Xie F, Zhou X. *Prognostic implication of proteomic profiles in head and neck squamous cell carcinoma*. **Clin Chim Acta**, 2020. 509: p. 304-309. PMID: 32569632 PMCID:
631. Wu ZH, Yang DL. *Identification of a protein signature for predicting overall survival of hepatocellular carcinoma: a study based on data mining*. **BMC Cancer**, 2020. 20(1): p. 720. PMID: 32746792 PMCID: PMC7398333
632. Xie X, He G, Siddik ZH. *Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill*. **Mol Pharmacol**, 2020. 97(4): p. 237-249. PMID: 32063580 PMCID: PMC7045891
633. Yang X, Wen Y, Song X, He S, Bo X. *Exploring the classification of cancer cell lines from multiple omic views*. **PeerJ**, 2020. 8: p. e9440. PMID: 32874774 PMCID: PMC7441922
634. Yeh CH, Bellon M, Wang F, Zhang H, Fu L, Nicot C. *Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells*. **Mol Cancer**, 2020. 19(1): p. 139. PMID: 32907612 PMCID: PMC7487643
635. Yuan Y, Yang X, Li Y, Liu Q, Wu F, Qu H, Gao H, Ge J, Xu Y, Wang H, Wang Y, Zhao Z. *Expression and prognostic significance of fatty acid synthase in clear cell renal cell carcinoma*. **Pathol Res Pract**, 2020. 216(11): p. 153227. PMID: 33027752 PMCID:
636. Yue T, Liu C, Zhu J, Huang Z, Guo S, Zhang Y, Xu H, Liu Y, Wang P, Chen S. *Identification of 6 Hub Proteins and Protein Risk Signature of Colorectal Cancer*. **Biomed Res Int**, 2020. 2020: p. 6135060. PMID: 33376727 PMCID: PMC7744197
637. Zhao W, Li J, Chen MM, Luo Y, Ju Z, Nesser NK, Johnson-Camacho K, Boniface CT, Lawrence Y, Pande NT, Davies MA, Herlyn M, Muranen T, Zervantonakis IK, von Euw E, Schultz A, Kumar SV, Korkut A, Spellman PT, Akbani R, Slamon DJ, Gray JW, Brugge JS, Lu Y, Mills GB, Liang H. *Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines*. **Cancer Cell**, 2020. 38(6): p. 829-843 e824. PMID: 33157050 PMCID: PMC7738392
638. Zhao X, Liu X, Cui L. *Development of a five-protein signature for predicting the prognosis of head and neck squamous cell carcinoma*. **Aging (Albany NY)**, 2020. 12(19): p. 19740-19755. PMID: 33049713 PMCID: PMC7732293
639. Zhao Y, Zhang M, Pu H, Guo S, Zhang S, Wang Y. *Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment*. **Front Oncol**, 2020. 10: p. 585961. PMID: 33552963 PMCID: PMC7855963
640. Zong X, Wang W, Ozes A, Fang F, Sandusky GE, Nephew KP. *EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells*. **Cancer Res**, 2020. 80(20): p. 4371-4385. PMID: 32816909 PMCID: PMC7572866
641. Abbas HA, Mohanty V, Wang R, Huang Y, Liang S, Wang F, Zhang J, Qiu Y, Hu CW, Qutub AA, Dail M, Bolen CR, Daver N, Konopleva M, Futreal A, Chen K, Wang L, Kornblau SM. *Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes*. **Front Oncol**, 2021. 11: p. 705627. PMID: 34422660 PMCID: PMC8372368
642. Al-Hassan JM, Wei D, Chakraborty S, Conway T, Rhea P, Wei B, Tran M, Gagea M, Afzal M, Oommen S, Nair D, Paul BM, Yang P. *Fraction B From Catfish Epidermal Secretions Kills Pancreatic Cancer Cells, Inhibits CD44 Expression and Stemness, and Alters Cancer Cell Metabolism*. **Front Pharmacol**, 2021. 12: p. 659590. PMID: 34349642 PMCID: PMC8326461
643. Aslan B, Kismali G, Chen LS, Iles LR, Mahendra M, Peoples M, Gagea M, Fowlkes NW, Zheng X, Wang J, Vellano CP, Marszalek JR, Bertilaccio MTS, Gandhi V. *Development and characterization of prototypes for in*

- vitro and in vivo mouse models of ibrutinib-resistant CLL. Blood Adv*, 2021. 5(16): p. 3134-3146. PMID: 34424317 PMCID: PMC8405195
644. Bouhaddou M, Lee RH, Li H, Bhola NE, O'Keefe RA, Naser M, Zhu TR, Nwachuku K, Duvvuri U, Olshen AB, Roy R, Hechmer A, Bolen J, Keysar SB, Jimeno A, Mills GB, Vandenberg S, Swaney DL, Johnson DE, Krogan NJ, Grandis JR. *Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. JCI Insight*, 2021. 6(20). PMID: 34546978 PMCID: PMC8564908
645. Castellonet O, Ahmad F, Vinik Y, Mills GB, Habermann B, Borg JP, Lev S, Lamballe F, Maina F. *BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators. Theranostics*, 2021. 11(19): p. 9180-9197. PMID: 34646365 PMCID: PMC8490507
646. Coleman RL, Hu W, Soliman P, Nick A, Ramirez PT, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, Meyer LA, Sood AK. *Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol*, 2021. 161(1): p. 104-112. PMID: 33551196 PMCID:
647. Dwyer AR, Kerkvliet CP, Krutilina RI, Playa HC, Parke DN, Thomas WA, Smeester BA, Moriarity BS, Seagroves TN, Lange CA. *Breast Tumor Kinase (Brk/PTK6) Mediates Advanced Cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) Signaling. Mol Cancer Res*, 2021. 19(2): p. 329-345. PMID: 33172975 PMCID:
648. Fukumura K, Malgulwar PB, Fischer GM, Hu X, Mao X, Song X, Hernandez SD, Zhang XH, Zhang J, Parra ER, Yu D, Debeb BG, Davies MA, Huse JT. *Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. Acta Neuropathol*, 2021. 141(2): p. 303-321. PMID: 33394124 PMCID: PMC7852029
649. Garcia-Soto AE, McKenzie ND, Whicker ME, Pearson JM, Jimenez EA, Portelance L, Hu JJ, Lucci JA, 3rd, Qureshi R, Kossenkov A, Schwartz L, Mills GB, Maity A, Lin LL, Simpkins F. *Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer. Cancer*, 2021. 127(13): p. 2279-2293. PMID: 33932031 PMCID: PMC8252376
650. George J, Li Y, Kadamberi IP, Parashar D, Tsaih SW, Gupta P, Geethadevi A, Chen C, Ghosh C, Sun Y, Mittal S, Ramchandran R, Rui H, Lopez-Berestein G, Rodriguez-Aguayo C, Leone G, Rader JS, Sood AK, Dey M, Pradeep S, Chaluvaly-Raghavan P. *RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. Cell Rep*, 2021. 37(5): p. 109934. PMID: 34731628 PMCID: PMC8675433
651. Gheysen L, Soumoy L, Trelcat A, Verset L, Journe F, Saussez S. *New Treatment Strategy Targeting Galectin-1 against Thyroid Cancer. Cells*, 2021. 10(5). PMID: 34063063 PMCID: PMC8147933
652. Githaka JM, Tripathi N, Kirschenman R, Patel N, Pandya V, Kramer DA, Montpetit R, Zhu LF, Sonenberg N, Fahlman RP, Danial NN, Underhill DA, Goping IS. *BAD regulates mammary gland morphogenesis by 4E-BP1-mediated control of localized translation in mouse and human models. Nat Commun*, 2021. 12(1): p. 2939. PMID: 34011960 PMCID: PMC8134504
653. Guzman EA, Pitts TP, Winder PL, Wright AE. *The Marine Natural Product Furospinulosin 1 Induces Apoptosis in MDA-MB-231 Triple Negative Breast Cancer Cell Spheroids, But Not in Cells Grown Traditionally with Longer Treatment. Mar Drugs*, 2021. 19(5). PMID: 33924764 PMCID: PMC8145321
654. Handley KF, Rodriguez-Aguayo C, Ma S, Stur E, Joseph R, Bayraktar E, Dasari SK, Nguyen N, Powell RT, Sobieski M, Ivan C, Kim M, Umamaheswaran S, Glassman D, Wen Y, Amero P, Stephan C, Coleman RL, Landesman Y, Westin SN, Ram PT, Sood AK. *Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Mol Cancer Ther*, 2021. 20(12): p. 2352-2361. PMID: 34583979 PMCID: PMC8643313
655. Haugen MH, Lingjaerde OC, Hedenfalk I, Garred O, Borgen E, Loman N, Hatschek T, Borresen-Dale AL, Naume B, Mills GB, Maelandsmo GM, Engebraaten O. *Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers. JCO Precis Oncol*, 2021. 5. PMID: 34036235 PMCID: PMC8140811
- manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/cci/author-center](http://ascopubs.org/cci/author-center). Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Mads H. Haugen Patents, Royalties, Other Intellectual Property: Patent application 62/969770 to USPTO; Christian Lingjaerde Consulting or Advisory Role: Novartis; Thomas Hatschek Consulting or Advisory Role: Roche, Pfizer, Pierre Fabre; Research Funding: Roche, Pfizer; Travel,

- Accommodations, Expenses: RocheAnne-Lise Borresen-DaleEmployment: Arctic Pharma AS, PubGene Stock and Other Ownership Interests: Arctic Pharma ASGordon B. MillsStock and Other Ownership Interests: Catena, SignalChem, Tarveda Therapeutics, ImmunoMET Honoraria: Nuevolution: AstraZeneca, Tarveda Therapeutics, Tesaro, Symphogen, PDX Pharmacy, ImmunoMET, Lilly Consulting or Advisory Role: AstraZeneca, SignalChem, Tarveda Therapeutics, Symphogen, Takeda/Millennium, PDX Pharmacy, ImmunoMET, Lilly, Turbine, ION Pharma, Zentalis Research Funding: Adelson Medical Research Foundation, AstraZeneca, NanoString Technologies, Breast Cancer Research Foundation, Karus Therapeutics, Pfizer, Prospect Creek Foundation, Tarveda Therapeutics, Ions Pharmaceuticals, ImmunoMET Patents, Royalties, Other Intellectual Property: HRD assay to Myriad Genetics, DSP technology patent with Nanostring Travel, Accommodations, Expenses: AstraZeneca, Pfizer, Symphogen, Chrysalis Biomedical Advisors, ImmunoMET, Michigan Primary Care ConsortiumGunhild M. MaelandsmoPatents, Royalties, Other Intellectual Property: Patent application submitted for a nine-protein/gene panel predicting response to anti VEGF therapies in combination with chemotherapyOlav EngebraatenPatents, Royalties, Other Intellectual Property: Patent application pending for a biomarker for antibody drug conjugates, Patent application submitted for a nine-protein/gene panel predicting response to anti VEGF therapies in combination with chemotherapy No other potential conflicts of interest were reported.
656. Kim HAJ, Shaikh MH, Lee M, Zeng PYF, Sorgini A, Akintola T, Deng X, Jarycki L, Khan H, MacNeil D, Khan MI, Mendez A, Yoo J, Fung K, Lang P, Palma DA, Patel K, Mymryk JS, Barrett JW, Boutros PC, Morris LGT, Nichols AC. *3p Arm Loss and Survival in Head and Neck Cancer: An Analysis of TCGA Dataset*. **Cancers (Basel)**, 2021. 13(21). PMID: 34771477 PMCID: PMC8582539
657. Lee DW, Lee W, Kwon M, Lee HN. *Dual inhibition of FOXM1 and its compensatory signaling pathway decreased the survival of ovarian cancer cells*. **Oncol Rep**, 2021. 45(1): p. 390-400. PMID: 33200225 PMCID:
658. Li T, Guan L, Tang G, He B, Huang L, Wang J, Li M, Bai Y, Li X, Zhang H. *Downregulation of TMEM220 promotes tumor progression in Hepatocellular Carcinoma*. **Cancer Gene Ther**, 2021. PMID: 34321624 PMCID:
659. Lim B, Peterson CB, Davis A, Cho E, Pearson T, Liu H, Hwang M, Ueno NT, Lee J. *ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells*. **Biomedicines**, 2021. 9(10). PMID: 34680527 PMCID: PMC8533320
660. Longworth J, Dittmar G. *An antigen microarray protocol for COVID-19 serological analysis*. **STAR Protoc**, 2021. 2(3): p. 100815. PMID: 34462737 PMCID: PMC8387221
661. Makhov P, Bychkov I, Faezov B, Deneka A, Kudinov A, Nicolas E, Brebion R, Avril E, Cai KQ, Kharin LV, Voloshin M, Frantsiyants E, Karnaukhov N, Kit OI, Topchu I, Fazliyeva R, Nikonova AS, Serebriiskii IG, Borghaei H, Edelman M, Dulaimi E, Golemis EA, Bumber Y. *Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC)*. **Oncogenesis**, 2021. 10(3): p. 29. PMID: 33723247 PMCID: PMC7961039
662. Nahm JH, Lee HS, Kim H, Yim SY, Shin JH, Yoo JE, Ahn SH, Choi JS, Lee JS, Park YN. *Pathological predictive factors for late recurrence of hepatocellular carcinoma in chronic liver disease*. **Liver Int**, 2021. 41(7): p. 1662-1674. PMID: 33638929 PMCID: PMC8774293
663. Osz A, Lanczky A, Gyorffy B. *Survival analysis in breast cancer using proteomic data from four independent datasets*. **Sci Rep**, 2021. 11(1): p. 16787. PMID: 34408238 PMCID: PMC8373859
664. Pairawan S, Zhao M, Yuca E, Annis A, Evans K, Sutton D, Carvajal L, Ren JG, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Yang F, Bose PSC, Zheng X, Dumbrava EI, Aivado M, Meric-Bernstam F. *First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models*. **Breast Cancer Res**, 2021. 23(1): p. 29. PMID: 33663585 PMCID: PMC7934277
665. Phadke MS, Chen Z, Li J, Mohamed E, Davies MA, Smalley I, Duckett DR, Palve V, Czerniecki BJ, Forsyth PA, Noyes D, Adeegbe DO, Eroglu Z, Nguyen KT, Tsai KY, Rix U, Burd CE, Chen YA, Rodriguez PC, Smalley KSM. *Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity*. **Cancer Immunol Res**, 2021. 9(5): p. 554-567. PMID: 33653716 PMCID: PMC8102376
666. Polewko-Klim A, Mnich K, Rudnicki WR. *Robust Data Integration Method for Classification of Biomedical Data*. **J Med Syst**, 2021. 45(4): p. 45. PMID: 33624190 PMCID: PMC7902598
667. Shen C, Shyu DL, Xu M, Yang L, Webb A, Duan W, Williams TM. *Deregulation of AKT-mTOR Signaling Contributes to Chemoradiation Resistance in Lung Squamous Cell Carcinoma*. **Mol Cancer Res**, 2021. PMID: 34810212 PMCID:

668. Suntravat M, Sanchez O, Reyes A, Cirilo A, Ocheltree JS, Galan JA, Salazar E, Davies P, Sanchez EE. *Evaluation of Signaling Pathways Profiling in Human Dermal Endothelial Cells Treated by Snake Venom Cysteine-Rich Secretary Proteins (svCRiSPs) from North American Snakes Using Reverse Phase Protein Array (RPPA)*. **Toxins (Basel)**, 2021. 13(9). PMID: 34564617 PMCID: PMC8473428
669. Suzuki H, Mitsunaga S, Ikeda M, Aoyama T, Yoshizawa K, Yoshimatsu H, Kawai N, Masuda M, Miura T, Ochiai A. *Clinical and Tumor Characteristics of Patients with High Serum Levels of Growth Differentiation Factor 15 in Advanced Pancreatic Cancer*. **Cancers (Basel)**, 2021. 13(19). PMID: 34638326 PMCID: PMC8507697
670. Tian X, Xu WH, Anwaier A, Wang HK, Wan FN, Cao DL, Luo WJ, Shi GH, Qu YY, Zhang HL, Ye DW. *Construction of a robust prognostic model for adult adrenocortical carcinoma: Results from bioinformatics and real-world data*. **J Cell Mol Med**, 2021. 25(8): p. 3898-3911. PMID: 33626208 PMCID: PMC8051734
671. Wagner MJ, Lyons YA, Siedel JH, Dood R, Nagaraja AS, Haemmerle M, Mangala LS, Chanana P, Lazar AJ, Wang WL, Ravi V, Holland EC, Sood AK. *Combined VEGFR and MAPK pathway inhibition in angiosarcoma*. **Sci Rep**, 2021. 11(1): p. 9362. PMID: 33931674 PMCID: PMC8087824
672. Wang B, Zhang W, Zhang G, Kwong L, Lu H, Tan J, Sadek N, Xiao M, Zhang J, Labrie M, Randell S, Beroard A, Sugarman E, Rebecca VW, Wei Z, Lu Y, Mills GB, Field J, Villanueva J, Xu X, Herlyn M, Guo W. *Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma*. **Oncogene**, 2021. 40(37): p. 5590-5599. PMID: 34304249 PMCID: PMC8445818
673. Wang H, Chen H, Liu S, Zhang J, Lu H, Somasundaram R, Choi R, Zhang G, Ou L, Scholler J, Tian S, Dong L, Yeye G, Huang L, Connelly T, Li L, Huang A, Mitchell TC, Fan Y, June CH, Mills GB, Guo W, Herlyn M, Xu X. *Costimulation of gammadeltaTCR and TLR7/8 promotes Vdelta2 T-cell antitumor activity by modulating mTOR pathway and APC function*. **J Immunother Cancer**, 2021. 9(12). PMID: 34937742 PMCID: PMC8705233
674. Wang J, Guo X. *Magnetic Resonance Features of Lower-grade Gliomas in Prediction of the Reverse Phase Protein A*. **J Comput Assist Tomogr**, 2021. 45(2): p. 300-307. PMID: 33512852 PMCID:
675. Wicker CA, Hunt BG, Krishnan S, Aziz K, Parajuli S, Palackdharry S, Elaban WR, Wise-Draper TM, Mills GB, Waltz SE, Takiar V. *Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models*. **Cancer Lett**, 2021. 502: p. 180-188. PMID: 33450358 PMCID: PMC7897292
676. Yu S, Wei S, Savani M, Lin X, Du K, Mender I, Siteni S, Vasilopoulos T, Reitman ZJ, Ku Y, Wu D, Liu H, Tian M, Chen Y, Labrie M, Charbonneau CM, Sugarman E, Bowie M, Hariharan S, Waitkus M, Jiang W, McLendon RE, Pan E, Khasraw M, Walsh KM, Lu Y, Herlyn M, Mills G, Herbig U, Wei Z, Keir ST, Flaherty K, Liu L, Wu K, Shay JW, Abdullah K, Zhang G, Ashley DM. *A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas*. **Clin Cancer Res**, 2021. 27(24): p. 6800-6814. PMID: 34593527 PMCID: PMC8678347
677. Zapala P, Fus L, Lewandowski Z, Garbas K, Zapala L, Gornicka B, Radziszewski P. *E-Cadherin, Integrin Alpha2 (Cd49b), and Transferrin Receptor-1 (Tfr1) Are Promising Immunohistochemical Markers of Selected Adverse Pathological Features in Patients Treated with Radical Prostatectomy*. **J Clin Med**, 2021. 10(23). PMID: 34884287 PMCID: PMC8658679
678. Zeng Z, Ly C, Daver N, Cortes J, Kantarjian HM, Andreeff M, Konopleva M. *High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells*. **Ann Hematol**, 2021. 100(6): p. 1485-1496. PMID: 33787984 PMCID:
679. Kim K, Hwangbo S, Kim H, Kim YB, No JH, Suh DH, Park T. *Clinicopathologic and protein markers distinguishing the "polymerase epsilon exonuclease" from the "copy number low" subtype of endometrial cancer*. **J Gynecol Oncol**, 2022. PMID: 35128857 PMCID:
680. Omokehinde T, Jotte A, Johnson RW. *gp130 Cytokines Activate Novel Signaling Pathways and Alter Bone Dissemination in ER+ Breast Cancer Cells*. **J Bone Miner Res**, 2022. 37(2): p. 185-201. PMID: 34477239 PMCID: PMC8828687
681. Owens AE, Iannotti MJ, Sanchez TW, Voss T, Kapoor A, Hall MD, Marugan JJ, Michael S, Southall N, Henderson MJ. *High-Throughput Cellular Thermal Shift Assay Using Acoustic Transfer of Protein Lysates*. **ACS Chem Biol**, 2022. 17(2): p. 322-330. PMID: 35119255 PMCID:
682. Pairawan S, Akcakanat A, Kopetz S, Tapia C, Zheng X, Chen H, Ha MJ, Rizvi Y, Holla V, Wang J, Evans KW, Zhao M, Busaidy N, Fang B, Roth JA, Dumbrava EI, Meric-Bernstam F. *Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations*. **Sci Rep**, 2022. 12(1): p. 1248. PMID: 35075200 PMCID: PMC8786858